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 Introduction 
1.1 N-Heterocyclic carbene (NHC) 
1.1.1 Historical perspective 
Since the pioneering work of Doering in 1954, carbenes have been recognised as a unique 
type of intermediate with characteristics distinct from radicals already known in the organic 
chemistry community.1 Since then, research on carbenes has rapidly expanded, but almost no 
attempts were made to stabilise carbenes until the 1980s when Tomioka started to study 
persistent triplet diarylcarbenes.2 
The first isolable carbenes were reported in 1988 by Bertrand3 (1) and 1991 by Arduengo4 (2). 
Phosphinocarbene 1 can be distilled at 80-85°C/10-2 Torr and N-heterocyclic carbene (NHC) 
2 is a crystalline solid that melts at above 240-241°C (Figure 1.1). 
P
NiPr2
NiPr2
Me3Si
1 2
N N
 
Figure 1.1 The first isolated carbenes. 
Although NHCs have been known since the pioneering work of Wanzlick, who observed their 
dimerisation5 and was able to trap them to form mercury-salt carbene complexes,6 thirty years 
went by before the first NHC was isolated. The particular stability of the NHCs made them 
very popular and during the following years further analogues were synthesised (Figure 1.2). 
In 1995, Arduengo proved7 using NHC 3 that aromaticity was not needed for stabilisation, 
and in 1996 Alder isolated acyclic NHC 4.8 This research area has been continually expanded 
with the isolation of four-membered carbene9 5 by Grubbs and alkyl carbene10 6 by Bertrand 
in 2004. 
N Nmes mes iPr
N N
iPr iPr
iPr
P
N N
N
iPriPr
iPr
iPr
iPr
iPr
N
iPr
iPr
3 4 5 6  
Figure 1.2 Stable NHCs and their derivatives. 
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1.1.2 Nomenclature 
For the sake of homogeneity, the following nomenclature will be used throughout this work.11 
NHCs 7 which are related to an imidazoline structure will be called 1,3-di-R-imidazolin-2-
ylidenes and NHCs 8 with a saturated C-C double bond will be described as 1,3-di-R-
imidazolidin-2-ylidenes (Figure 1.3). 
N N
7 8
N NR R R R
 
Figure 1.3 Nomenclature of the various NHCs. 
1.1.3 General characteristics 
Carbenes are neutral divalent carbon with only six electrons in its valence shell. With two 
nitrogen substituents next to the Ccarbene atom, the NHCs are predicted to stabilise their singlet 
state (two paired electrons in the σ orbital) by a push-pull effect (Figure 1.4).12 Firstly, the σ-
electronwithdrawing nitrogen inductively stabilises the σ-nonbonding orbital by increasing its 
s-character. Secondly, the energy of the vacant pπ-orbital is increased by interaction with the 
symmetric combination of the nitrogen lone pairs. Combination of the two effects increases 
the σ-pπ gap and favours therefore the singlet state. Moreover, the pseudo sp2 hybridisation 
adopted by the Ccarbene atom in its singlet state matches the bent geometry of the NHC five-
membered ring. 
N
N
N
N
-I inductive effect +M mesomer effect
pπ
σ
 
Figure 1.4 Electronic stabilisation of NHCs. 
The interaction of the nitrogen lone pair with the pπ-orbital of the carbene is reflected by a 
N-Ccarbene bond length of 1.365 Å, which is consistent with double bond character. An 
accurate assessment of the π backbonding was found by analysing dynamic 1H-NMR 
behaviour of bis(diisopropylamine)carbene 4.8 As the major part of this process involves 
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rotation about the N-Ccarbene bonds, the measured barrier to rotation of 53 kJ/mol was mostly 
attributed to the substantial π-component of these bonds. 
Dimerisation of NHCs has been known since the first attempts to isolate them.5 Alder recently 
showed that dimerisation is thermodynamically unfavorable for imidazolin-2-ylidenes 7 
(singlet/triplet gap of 354 kJ/mol), but very likely to happen for imidazolidin-2-ylidenes 8 due 
to lack of aromaticity and acyclic NHCs due to loss of conjugation through twisting around 
the N-Ccarbene bond.13 The reaction is likely to be proton catalysed. 
The 13C-NMR chemical shifts14 range from 210-220 ppm downfield from TMS for aromatic 
imidazolin-2-ylidenes 7, to 235-245 ppm for imidazolidin-2-ylidenes 8 and acyclic NHCs. 
1.1.4 Generation of diaminocarbene / pKa 
Three principal methods were successfully used for the generation of diaminocarbenes: i) 
deprotonation of imidazolium salts 9 or formamidinium salts 10, ii) desulfurisation of 
thioureas 11 and iii) thermolysis of methanol adducts of type 12 (Figure 1.5). 
NN N N NN N Nor or
Base
NNR2 R2 NNR2 R2
S
K,THF
N
NNPh Ph
OMe
80°C, 0.1 mbar
9 10
11
xx
12
N
NNPh Ph
Ph Ph
R1 R1 R1 R1
R1, R2 = alkyl
 
Figure 1.5 Three principal methods for the generation of NHCs. 
The pKa value was measured for diisopropyl-imidazolin-2-ylidene on the DMSO scale and 
found to be 24 by Alder.15,16 For di-tert-butyl-imidazolin-2-ylidene Streitwieser found a pKa 
of 20 on the THF scale.17 Therefore, it is not surprising that the principal method used to 
synthesise NHCs is deprotonation of the corresponding imidazolium or formamidinium salts. 
For the isolation of the first NHC, Arduengo's group used NaH/KH in THF in the presence of 
KOtBu and DMSO (to generate the dimsyl ion).4 Herrmann showed that milder conditions 
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such as sodium amide in liquid ammonia and THF at -40°C, were also efficient.18 With a pKa 
increased by 2 to 6 units, formamidinium salts underwent nucleophilic addition of the base 
rather than deprotonation.16 This problem was solved by the use of hindered alkali amide 
bases such as lithium diispropylamide or potassium hexamethyldisilazide. 
In 1993, Kuhn and Kratz reported another pathway to imidazolin-2-ylidene by reduction of 
the corresponding thiourea using metallic potassium.19 This heterogeneous reaction, which 
has proved difficult to reproduce,16 is attractive because the only other product is potassium 
sulfide which is insoluble in THF. 
Finally, another successful method was established by Enders who synthesised in a good yield 
a triazol-2-ylidene by thermolysis of its methanol adduct.20 One drawback of this 
methodology is the extreme sensitivity of the methanol adduct. 
1.2 N-Heterocyclic carbene metal complexes 
1.2.1 Historical perspective 
Carbenes were introduced to inorganic chemistry by Fisher and Maasböl who reported that 
reaction of phenyl lithium with W(CO)6, followed by addition of acid and then diazomethane, 
gave complex 13 (Figure 1.6).21 A few years later Wanzlick and Öfele's first syntheses of 
NHC metal complexes respectively 14 and 15, extended the Fischer type carbene family.22,23 
In 1974, Schrock developed24 a new type of carbene, the so-called Schrock carbene, with a 
totally different reactivity (16). 
W
OMe
Ph
CO
COOC
OC
CO
(Me3CCH2)3Ta
tBu
H
NN
Hg
NNPh Ph
Ph Ph
2 ClO4
2
N
N
Cr(CO)5
13 14 15 16
 
Figure 1.6 Fischer, Wanzlick, Öfele and Schrock carbenes. 
1.2.2 NHC ligand properties 
Although the metal carbene bond in Schrock and Fischer carbene complexes are both 
described as double bond, they differ by the polarity of the electron density. This difference 
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arises from the difference in energy between the dπ orbital of the metal and the pπ orbital of 
the carbene (Figure 1.7). If the dπ orbital is lower in energy than the pπ orbital, the metal 
carbon bond is polarised δ- on the metal and δ+ on the carbene and it is a Fischer carbene 
complex. Contrary, if the dπ orbital is higher in energy than the pπ orbital, the metal carbon 
bond is polarised δ+ on the metal and δ- on the carbene and it is a Schrock carbene complex. 
A particular example of Fisher carbenes are NHCs which have a pπ orbital of very high 
energy since their multiple bonding between the carbene atom and the two nitrogen atoms. As 
a result, the pπ orbital does not interact well with the dπ, thus preventing almost any 
π-backbonding from the metal to the carbene. In the NHC complexes, the metal carbon bond 
is therefore best represented by a single bond. 
CM
dπ
σ
pπ M
C
dπ
pπ
M
dπ
M
dπ
C
pπ C
pπ
δ+ δ− δ− δ+
Schrock
nucleophilic carbene
Fischer
electrophilic carbene NHC carbene
dz2
 
Figure 1.7 Partial molecular diagram for Schrock, Fischer and NHC carbene complexes. 
The fundamental difference between a typical Schrock alkylidene moiety and an NHC as a 
ligand is underlined in the crystal structure of [RuCl2(NHC)2(=CHC6H4Cl)] (NHC =  1,3-
diisopropylimidazolin-2-ylidene) where the two types of carbenes are linked to the same 
metal centre.25 The ruthenium-carbon bond of the Schrock carbene, generally written as a 
double bond, has a bond length of 1.821(3) Å, whereas the Ru-C bond length to the NHC 
(2.107(3) Å and 2.115 (3)Å) justifies its representation as a single bond (σ-donor and virtually 
no π-acceptor). 
Measurement of IR carbonyl absorption frequencies of NHC carbonyl metal (Fe, Cr, Rh, Mo 
and Ir) and their phosphine analogues showed the significantly increased donor capacity of 
NHC relative to phosphines, even to trialkylphosphines.26-28 Experimental investigations,29 
calorimetric studies30,31 and experimental calculations32 agree that the ligand dissociation 
energy of NHCs from Ru complexes is higher than for phosphines. Further calculations with 
other metals such as Au, Cu, Ag, Pd and Pt led to similar conclusions.33,34 
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By analogy to the cone angle defined for phosphines by Tolman,35 a method to quantify the 
steric parameters of NHCs has been proposed by Nolan31 who described NHCs as "fences" 
with "length" and "height". 
The structural differences for free NHCs and metal complexed NHCs are very small. In 
13C-NMR spectra, the signals for the free carbene carbon are usually shifted upfield by about 
20-30 ppm upon complexation of the free NHC to a transition metal. 
1.2.3 Complexation 
Four synthetic methodologies have been most commonly applied in the literature for the 
preparation of NHC metal complexes: i) proton abstraction with bases prior to metalation, ii) 
in situ deprotonation of the imidazolium by basic metalates or basic counter-ions, iii) use of 
an external base in a one pot reaction with the metal, and iv) transmetallation via silver 
complexes. 
NHCs are very strong σ donors and show dissociation energies higher than phosphines for a 
large range of metals (vide supra). Therefore, when their free form can be isolated, their 
complexation is achieved in high yield. It has been shown that free NHCs are able to cleave 
dimeric metallic species such as [(η4-cod)RhCl]236 and exchange phosphine25 or pyridine37 
ligands.  
In his original work,23 Öfele formed NHCs by in situ deprotonation of the corresponding 
imidazolium salts using the metal itself (Scheme 1.1). The basic metalate ion [HCr(CO)5]- 
serves as base and ligand acceptors at the same time. One drawback of this method is the 
limited availability of the metal precursor. 
N
N
HCr(CO)5
120°C
N
N
-H2
Cr(CO)5
 
Scheme 1.1 In situ deprotonation by a basic metalate ion 
Basic counter-ions of the metal precursors can also act as deprotonating agents. For example, 
a convenient method to synthesise NHC-Pd(II) complexes is by mixing Pd(OAc)2 with the 
corresponding imidazolium salt. In a similar way, μ-alkoxo complexes of (η4-cod) rhodium(I) 
and iridium(I), formed in situ by adding μ-chloro bridged analogues to a solution of sodium 
alkoxide in the corresponding alcohol, will deprotonate an imidazolium salt and deliver the 
corresponding NHC complex.26 
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The use of an external base to generate NHCs in the presence of a metal precursor is also an 
efficient method. Potassium tert-butoxylate and sodium hydride in THF at room temperature 
can be used to co-ordinate NHCs to Cr(CO)6 and to W(CO)6 in situ.38 A large variety of bases 
ranging from triethylamine,39 lithium diisopropylamide40 to phosphazene bases41 have been 
successfully used over the past years. 
Recently, a method for preparing NHC metal complex via silver complex has been developed 
by Wang.42 Silver NHC complexes are readily prepared upon mixing the corresponding 
imidazolium salt with Ag2O in CH2Cl2 at room temperature. Subsequent reaction with a 
chloro-metal precursor gives the desired NHC metal complex that can be easily separated 
from AgCl, the latter being insoluble in THF. 
1.2.4 Abnormal binding modes for NHC ligands 
In 2001, Crabtree discovered an unexpected binding mode of NHCs. Instead of having co-
ordination at the C(2) position of the NHC, the metal was linked at C(4) or C(5) 
(Figure 1.8).43 Since this publication, there have been an increasing number of reports of NHC 
with abnormal binding mode.44-46 
N
N
M
R
R
N
N
R
R
M
Binding at C(2) Binding at C(4) or C(5) 
Figure 1.8 C(2) and C(4) or C(5) binding mode of the NHCs. 
Non-classical carbene formation was initially observed by mixing pyridine-substituted 
imidazolium salts with [IrH5(PPh3)2] in refluxing C6H6. Since theoretical calculation 
predicts47 that binding at the C(4) or C(5) position is less favoured, it was reasoned that steric 
effects of the bidentate pyridine-NHC around the metal centre controlled the reaction. 
However, the isolation of monodentate NHC complexes with a C(4) or C(5) binding mode 
proved that the chemistry involved is more complicated than previously thought. Abnormal 
co-ordination of NHCs is still intensively studied. 
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1.3 Catalysis involving NHCs 
1.3.1 Ruthenium metathesis 
Due to their σ-donor ability and their strong metal-carbon bond, NHC ligands have been 
applied as directing ligands in various catalytic transformations.48 It is however in ruthenium-
catalysed olefin metathesis type reactions that NHC ligands have proved their efficiency, 
giving access to unprecedented successful catalytic systems. 
A breakthrough in catalytic metathesis reactions was achieved when NHC ligands were used 
to replace one of the phosphines of complex 17 (Figure 1.9). Herrmann showed that having 
one imidazolin-2-ylidene in place of a phosphine (18) favours the dissociative substitution of 
the phosphine ligand with an olefinic substrate, giving rise to a more active species.29,49 
Catalysts 18 showed excellent activities in the ring opening metathesis of 1,5-cyclooctadiene. 
In the same year, Grubbs introduced50 a new generation of ring closing metathesis catalysts 
containing an even more basic NHC. Catalyst 19, which contains an imidazolidin-2-ylidene 
ligand, showed outstanding activities combined with a large functional group tolerance. 
Moreover, the use of imidazolidin-2-ylidene allowed access to more chiral catalysts, by 
introduction of chirality at the C(4) and C(5) positions of the NHC. The application of 
complexes 20 in the desymmetrisation of triolefins yielded the ring closing metathesis 
products in high enantioselectivities.51 
PR3
Ru
PR3
CHPh
Cl
Cl
Ru
PR3
CHPh
Cl
Cl
NN RR
Ru
PR3
CHPh
Cl
Cl
NN RR
Ru
PR3
CHPh
Cl
Cl
NN
Ph Ph
R
R
17 18 19 20  
Figure 1.9 NHCs in ruthenium metathesis. 
1.3.2 Asymmetric catalysis 
The first example of chiral carbenes used in asymmetric catalysis appeared in 1996/1997 with 
the pioneering work of Enders52 and Herrmann.53 Since then, the field has largely expanded 
and now there are many reports on the use of NHCs for asymmetric homogeneous catalysis.54 
Enders successfully applied the NHC and their derivatives in carbene catalysed asymmetric 
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nucleophilic acylation processes. High asymmetric induction in enantioselective benzoin 
condensation and enantioselective Stetter reactions were obtained by the use of simple chiral 
triazolium and thiazolium salt. 
Chiral NHC ligands have been used in a large variety of metal asymmetric catalysed 
reactions. Applications to the following reactions were investigated: Rh-hydrosilylation of 
ketones,53,55,56 olefin metathesis,51,57 Pd-oxindole reaction,58-60 Pd-allylic alkylation,59 Rh(I)- 
and Ir(I)-transfer hydrogenation of ketones,61 Cu-catalysed addition of diethylzinc to 
cyclohexenones,62-64 Ni-hydroamination of acrylonitrile derivatives65 and hydrogenation. 
1.3.3 Hydrogenation 
When our work was initiated in 2001, two reports on iridium-catalysed hydrogenation with 
NHC ligands were already published by Nolan and Burgess. Nolan initiated investigations 
into the field using achiral monodentate NHC iridium complex 21 for the hydrogenation of 
cyclohexene and 1-methylcyclohexene (Figure 1.10).66 It was shown that catalyst 21 and 
Crabtree's catalyst 22 had comparable activity at room temperature. However, complex 21, 
which was proven to be more robust than complex 22, was more efficient at higher 
temperature. 
NN
Ir
N
PF6 PF6
21 22
N
Ir
PCy3
 
Figure 1.10 Achiral monodentate NHC ligand and Crabtree's catalyst 
A few months later, Burgess reported the first use of a bidentate oxazoline-NHC ligand 23 for 
asymmetric iridium-catalysed hydrogenation of unsubstituted alkenes (Figure 1.11).67 
N
N
O
N
R2R1
PR2 N
O
R1
N PR2
O
O
R2
R2
R1
23 24 25  
Figure 1.11 Burgess's bidentate oxazoline-NHC ligands, PHOX ligands and its derivatives. 
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His remarkable system gave high enantioselectivities for a range of olefins approaching the 
best results obtained with the phosphino-oxazoline (PHOX) ligands 24 and its derivatives 
25.68,69 
In 2002, Buriak showed that combining NHC with phosphine ligands led to efficient systems 
for the hydrogenation of simple olefins.70 The comparison of complex 26 with its analogue 
27, for the hydrogenation of 1-methylcyclohexene and 2,3-dimethyl-2-butene, proved the 
superiority of catalyst 26 in term of activity (Figure 1.12). While complex 26 fully 
hydrogenated 2,3-dimethyl-2-butene in less than an hour at 1 bar H2 and room temperature, 
complex 27 gave 19% conversion in four hours under the same conditions. 
PF6
26
PF6
27
N
Ir
N
N
Ir
PCy3
N
N
 
Figure 1.12 Achiral monodentate NHC phosphine and NHC pyridine iridium complexes. 
Bolm took advantages of the planar chirality of paracyclophane to synthesise enantiopure 
bidentate ligands 28 and 29 (Figure 1.13).71,72 In comparison with the Ir-PHOX complexes, 
both systems are less active and therefore require higher temperature and longer reaction time 
to go to completion. Although iridium catalysts containing NHC 29 gave higher asymmetric 
induction than iridium catalysts containing NHC 28, the enantioselectivities were still low. 
PPh2
N
N
Ar
N
O
N
N
R
R1
28 29  
Figure 1.13 Bolm's paracyclophane based NHC bidentate ligands. 
It is worth noticing that little work has been done on chiral NHC ligands for rhodium-
catalysed asymmetric hydrogenation. To date, only two ligands have been reported (Figure 
1.14). The first one, which was published in 2003 by Chung, is a bidentate NHC-phosphine 
ligand built on a ferrocene backbone (30).73 Controlling the binding mode of ligand 30 to 
 24 
 Introduction 
rhodium proved to be difficult. Nevertheless, the rhodium complexes studied showed very 
little activity and low enantioselectivities. The second report published by Helmchen also 
concerns a phosphine-NHC ligand (31), which possesses an chiral axis in addition to two 
centres of chirality.74 Contrary to the previous system, Rh-catalyst containing NHC 31 
performed very well, especially in terms of asymmetric induction. With Rh-catalysed 
asymmetric hydrogenation standard substrates such as dimethyl itaconate and N-
acetyldehydroamino acid derivatives, almost perfect enantioselectivities were obtained after 
optimisation of reaction conditions. 
Fe PPh2
N N R N N
iPr
PPh2
Ph Ph
30 31  
Figure 1.14 Phosphine-NHC ligands tested in Rh-asymmetric hydrogenation. 
1.4 Objectives of this work 
The success encountered by monodentate achiral NHCs in iridium-catalysed hydrogenation of 
olefins66,70 prompted us to start our work with the design of direct analogues of Crabtree’s 
catalyst 32 and 33. In these analogues, either the pyridine (32) or the phosphine (33) would be 
replaced by a monodentate chiral C2-symmetric NHC (Figure 1.15). 
N
Ir
PCy3
PF6
PPh3Ir
N
∗
N or N Ir
N
∗
N
X X
32 33
R
R R
R
R1
R1
R1
R1
 
Figure 1.15 Derivation of Crabtree's analogues containing chiral C2-symmetric NHC. 
Another objective was to develop NHC chelating ligands, incorporating an oxazoline moiety. 
As a first investigation, a library of iridium complexes 34 could be synthesized starting from 
previously published imidazolium salt 35 (Figure 1.16).75 One could expect these catalysts to 
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give higher asymmetric induction than their direct analogues derived from ligand 23, since the 
six-membered chelating ring around the iridium centre would increase their conformational 
rigidity. 
However, the R1 substituent of catalysts 34 are synthetically restricted to those found in 
readily available amino-alcohols. We therefore planned to synthesise a second generation 
catalysts library 36, where the R1 substituent can be formed from derivatives of any 
carboxylic acid, thus allowing more variations in direct proximity to the iridium. 
Cl
N
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N
R1 R2
N
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N
R1 R2
X
NH2
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N
N
O
N
R1 R2
X
Ir
N
X
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R1
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COOH
HO
34 35
36
Ir
 
Figure 1.16 NHC chelating ligands incorporating an oxazoline moiety. 
Based on Buriak's and Bolm's reports,70,72 which showed that iridium complexes bearing a 
phosphine and NHC are active in hydrogenation of unsubstituted olefins, we decided to 
synthesise new phosphine-NHC 38. The synthesis of these ligands, which are closely related 
to the successful ligands 37 developed in our laboratory,76 was devised starting from amino-
phosphine 39 (Figure 1.17). 
N PR2
O
∗
R1
N
PR2
R2
N
R1
H2N
PR2
R2
37 38 39  
Figure 1.17 Phosphine-NHC bidentate ligands. 
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During the course of this work, it has been shown that phosphinite containing ligands are 
almost always superior to their phosphine analogues in terms of enantioselectivity. Therefore, 
it was decided to devise a short convenient synthesis of phosphinite-NHC ligands starting 
from chiral epoxides (Figure 1.18). 
O
R1
N
PR2
O
N
R1
R2  
Figure 1.18 Phosphinite-NHC ligands synthesised from chiral epoxides. 
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 Analogues of Crabtree's catalyst bearing chiral C2-symmetric NHC 
2.1 Introduction 
In his pioneering work, Crabtree showed that iridium complex 40 was able to hydrogenate 
normally unreactive tri- and tetrasubstituted alkenes, lacking a coordinating group (Figure 
2.1).1-3 At that time, the enantioselective hydrogenation of prochiral functionalised alkenes, 
using chiral rhodium-phosphine complexes as catalysts, was well established: high activity 
and asymmetric induction were already observed in the case of aromatic dehydroamino 
acids.4 In rhodium-catalysed hydrogenation, the functionality on the olefin is crucial for high 
enantiomeric excess since it becomes an additional coordination site for the metal and hold 
the substrate in a defined position leading to high stereoselectivity. In contrast to the latter, 
development of enantioselective catalysts for the hydrogenation of unfunctionalised olefins is 
difficult, since stereodifferentiation of the prochiral faces must be achieved, mainly via non-
bonding, sterically-based interactions. A major breakthrough was achieved in the field when 
Pfaltz showed that good turnover numbers (TON) and high enantioselectivities were obtained 
for the hydrogenation of several imines and unfunctionalised alkenes using chiral bidentate 
phosphinooxazoline-iridium complexes 41.5,6 
X
43
X
42
N
Ir
N
N
R
R
Ir
PR3
N
N
R
R
PF6
40
Ir
PCy3N
R2P Ir
N
O
R1
BArF
41
R1
R1
R1
R1
Pfaltz
Nolan
Buriak
achiral
achiral
Crabtree
 
Figure 2.1 Crabtree's catalyst 40 and its derivatives 41-43. 
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As discussed in the introduction chapter, it was recently shown that cationic achiral analogues 
of Crabtree's catalyst 42 and 43, where the pyridine or the phosphine were replaced by NHCs, 
are active catalysts for hydrogenation of simple olefins such as methyl-cyclohexene (Figure 
2.1).7,8 
Based on these reports, we were interested in synthesising iridium complexes bearing one 
chiral C2-symmetric NHC in combination with a phosphine or a pyridine unit and to test them 
in the enantioselective hydrogenation of unfunctionalised olefins. 
In this project, two major issues were anticipated: i) activity of Crabtree's catalyst analogues 
with tri-substituted olefins and ii) asymmetric induction of chiral monodentate NHCs 
compared to bidentate ligands such as phosphinooxazolines 41. 
Crabtree's catalyst is known to be very effective in the hydrogenation of simple olefins. 
Although high TOFs (up to 8000 h-1) are obtained for terminal and vicinal disubstituted 
olefins, catalyst deactivation prevents full hydrogenation of tri- and tetrasubstituted alkenes.3 
With their ability to bind metals strongly, NHCs are expected to give rise to robust catalysts 
(see chapter 1). We thought therefore that analogues of Crabtree's catalyst bearing C2-
symmetric NHCs would be less prone to catalyst deactivation and would allow the use of 
harsher reaction conditions. 
Up to now, the best catalytic systems for iridium-catalysed hydrogenation are based on 
bidentate ligands such as 41. One generally assumes that bidentate ligands lead to more 
effective chiral induction due to the rigidity they impose to the catalyst.9 However, in some 
examples, monodentate ligands proved to be as enantioselective as the best bidentate ligands. 
Recently, Feringa and Reetz showed that monodentate phosphoramidites and phosphites give 
almost perfect asymmetric induction in rhodium-catalysed hydrogenation of dehydroamino 
acids (Figure 2.2).10,11 
O
O
P N
O
O
P OR
 
Figure 2.2 Monodentate phosphoramidites and phosphites used in enantioselective rhodium-
catalysed hydrogenation. 
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Three different class of chiral C2-symmetric NHC were chosen for this project (Figure 2.3). 
N N RR N N
R R
R1
R1
N N
O O
R R
44 45 46  
Figure 2.3 The three different class of NHCs used. 
In the first structure (44), chirality is incorporated in the N-substituents of the NHCs. The 
chirality of the second class of NHCs (45), which was developed by Grubbs,12 is located at 
the C(4) and C(5) positions of the NHCs. For these NHCs, steric repulsions between the 
backbone R groups and the o-aryl R1 groups are believed to stabilise an anti-conformation of 
the N-substituents, thus allowing efficient transmission of the chiral information to the active 
site of the catalyst. The third class of NHCs (46) developed by Glorius is derived from 
bioxazoline ligands.13 With the N-substituents linked to the C(4) and C(5) positions of the 
backbone, these NHCs are the most rigid of the series. 
2.2 Synthesis of imidazolium salts 
Four different imidazolium salts were synthesised according to literature procedures. 
Imidazolium salt 49 was synthesised in two steps starting from commercially available chiral 
amine 47 (Scheme 2.1). Condensation of chiral amine 47 with 1,2-dichlorethane followed by 
vacuum distillation yielded secondary amine 48 in good yield.14 Imidazolium salt 49 was 
obtained in high yield after ring closure using triethylorthoformate and ammonium 
tetrafluoroborate salt. 
NH2
Cl
Cl NH HN N N
(i) (ii)
BF4
(R)-47 (R,R)-48 (R,R)-49  
Reagents and conditions: (i) neat, 100°C, 16h, (74%); (ii) HC(OEt)3 excess, NH4BF4, neat, 120°C, 
14h, (95%). 
Scheme 2.1 Synthesis of imidazolium salt 49. 
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Imidazolium salts 53a and 53b were prepared according Grubbs' procedure (Scheme 2.2). 
Chiral diamine 50, which was synthesised in five steps,15 underwent Buchwald-Hartwig 
coupling reaction with bromoaryl 51a and 51b to yield diamine 52a and 52b. Ring closure 
with triethylorthoformate and tetrafluoroborate salt gave the desired imidazolium salts 53a 
and 53b in high yield. 
(i) (ii)
BF4
(S,S)-50
H2N NH2
Ph Ph
NH HN
Ph Ph
N N
Ph Ph
R
RR R
R
Br
51a R = Me 
51b R = iPr
(S,S)-52a R = Me (82%) 
(S,S)-52b R = iPr (88%)
(S,S)-53a R = Me (99%) 
(S,S)-53b R = iPr (97%)  
Reagents and conditions: (i) Pd(OAc)2 (5 mol %), (±)-BINAP (10 mol %), NaOtBu (3 eq.), toluene, 
reflux, 14h; (ii) HC(OEt)3 excess, NH4BF4, neat, 120°C, 14h. 
Scheme 2.2 Synthesis of imidazolium salts 53a and 53b. 
Imidazolium salt 55 was also included in this project as part of a collaboration with Frank 
Glorius. Its synthesis was achieved in one step starting from bioxazoline ligand 54 via 
cyclisation using chloromethylpivalate and silver triflate (Scheme 2.3).13 
(i)
OTf
N N
OO
N N
OO
(S,S)-54 (S,S)-55
Cl O
O
 
Reagents and conditions: (i) AgOTf, CH2Cl2, 40°C, 24h, (80%). 
Scheme 2.3 Synthesis of imidazolium salt 55. 
2.3 Preparation of the iridium complexes 
As already discussed in the introduction chapter, Crabtree's analogues, in which NHCs are 
combined with phosphines, are slightly more efficient in the hydrogenation of simple olefin 
than catalysts bearing NHCs and a pyridine unit. Since the difference in activity between the 
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two types of catalyst is not pronounced, we decided to synthesise two families of Crabtree's 
catalyst analogues 56 and 57 with pyridine and phosphine as co-ligand (Figure 2.4). 
X
56
N
Ir
∗
N
N
R
R
∗
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PR3
N
N
R
R
R1 R1
R1R1
chiral
X
chiral
57  
Figure 2.4 The two families of Crabtree's analogues 56 and 57. 
2.3.1 Analogues of Crabtree's catalyst bearing pyridine as co-ligand 
Crabtree’s analogues 56a and 56b containing two different counter-ions were synthesised, 
since the counter-ion of the Ir-PHOX catalysts has been shown to strongly influence the 
kinetic profile of asymmetric hydrogenation.17,18 Previous work showed that reaction rates of 
Ir-PHOX catalysts were much higher with BArF- counter-ion than with PF6- counter-ion. 
Enantiopure complexes 56a and 56b, were synthesised by ligand exchange of one pyridine 
unit of iridium precursors 58a and 58b (Scheme 2.4). 
X
Ir
N N
Ir Ir
Cl
Cl
N
N
Ir
∗
N
N
R
R
R1
R1
X
(i) (ii)
58a X = BArF- (97%)
58b X = PF6- (95%)
56a X = BArF- (31-41%)
56b X = PF6- (52-86%)
BArF- = tetrakis[3,5-bis(trifluoromethyl)phenyl]borate  
Reagents and conditions: (i) NaBArF, CH2Cl2, RT, 8h for 58a; NH4PF6, acetone/water (1:1), RT, 8h 
for 58b (ii) imidazolium salt, BEMP, toluene, RT, 8h. 
Scheme 2.4 Iridium precursors for NHC-pyridine iridium-complexes. 
Iridium precursor 58a was prepared according to a literature procedure.16 Slight modifications 
of the procedure allowed synthesis of 58b. 
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In order to replace one of the pyridine units of complexes 58a and 58b by NHCs, 
imidazolium salts must be deprotonated either before complexation or in situ. Since isolation 
of the free carbene from imidazolium salts 49, 53a, 53b and 55 proved to be difficult, 
deprotonation of the imidazolium salts in presence of the metal precursor 56a was chosen. A 
careful screen of the bases and reaction conditions was undertaken with imidazolium salt 53a 
(Table 2.1). The purity of the products was confirmed by FAB-MS and 1H-NMR. 
 
entry solvent base NHC/metal 
ratio 
reaction 
condition 
analyses 
1 THF NaH (in oil) 1:1 RT s. m.. 
2 NH3/THF (10/1) NaH (in oil) 1:1 -78°C→RT s.m. and prod. 
3 THF nBuLi 1:1 -78°C→RT s.m. and prod. 
4 THF nBuLi 2:1 -78°C→RT s.m. and prod. 
5 THF NaOtBu 1:1 RT s.m. and prod. 
6 Toluene BEMP 1:1 RT prod. 
Table 2.1 Base screen for in situ generation of NHCs. 
The choice of the base appeared to be crucial. None of the anionic bases generally used for in 
situ deprotonation of imidazolium salts were satisfactory (Table 2.1, Entry 1 to 5). The 
reactions failed to go to completion, even when using strong base as nBuli. The lack of 
reactivity of NaH, nBuLi and NaOtBu was attributed to their ability to react with the metal 
precursor instead of deprotonating the salt. Finally, non-anionic phosphazene base BEMP 
(Figure 2.5), which is 2000 times more basic and also much more sterically hindered than 
DBU,19 proved to be suitable for in situ deprotonation of imidazolium salt 53a (Table 2.1, 
Entry 6). 
N
P
N
N
N
BEMP  
Figure 2.5 Non anionic phosphazene BEMP base. 
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One drawback of in situ deprotonation of imidazolium salts is counter-ion scrambling 
(Scheme 2.5). Since two salts with different counter-ions are mixed in the reaction, the 
desired complex is likely to bear different anions. However, the minor undesired complex 60 
was easily separated by chromatography on silica gel in every case. 
N
Ir
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N
R
R
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Ir
N
R1
R1
N N * NR R
R1 R1
Base
Xb
Xa
N
Ir
*
N
N
R
R
R1
R1
Xb
major minor
59 60  
Scheme 2.5 Counter-ion scrambling during synthesis of NHC-pyridine iridium complexes. 
2.3.2 Analogues of Crabtree's catalyst bearing phosphine as co-ligand 
Complexes 57, in which the pyridine is replaced by a chiral NHC, were synthesised in two 
steps (Scheme 2.6). Starting from [(η4-cod)IrCl]2, complexes 61 were prepared by in situ 
deprotonation of the imidazolium salts using BEMP. Abstraction of the chloride counter-ion 
from complexes 61 followed by addition of the triphenylphosphine gave the desired 
complexes 57 in good yield. 
Ir Ir
Cl
Cl
N ∗ NR R
R1 R1
X
X
*
Ir
Cl
N
N
R
R
R1
R1
X
*
Ir
PPh3
N
N
R
R
R1
R1(i) (ii)
(iii)
61 57  
Reagents and conditions: (i) BEMP, CH2Cl2, RT, 2h; (ii) AgPF6, CH2Cl2 / THF (1:1), RT, 15 min. (iii) 
PPh3, THF, RT, 1h, (50-72 % overall yield). 
Scheme 2.6 General procedure for the synthesis of NHC-phosphine iridium complexes 57. 
This procedure allows easy variation of the phosphine, since it is introduced in the last step of 
the synthesis. In the studies of monodentate achiral NHC phosphine iridium complexes for 
hydrogenation, Buriak combined a range of phosphines with 1,3-dimethylimidazolin-2-
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ylidene.8 Triphenylphosphine appeared to be the phosphine of choice and was therefore 
selected for our project. 
An overview of all the complexes synthesised by the two methods described above is depicted 
in Figure 2.6. Four complexes 62, 63, 64 and 67 bear a pyridine unit as co-ligand. In this 
family, complexes 62 and 63 differ by their ortho-substituents on the aryl ring and their 
counter-ions (PF6- and BArF-). Two complexes 66 and 69 have triphenylphosphine as co-
ligand. They were both prepared with the PF6- counter-ion, which allowed efficient 
purification by crystallisation. 
N N
N N
O O
Ir N
Ir
N N
O O
Ir PPh3
N N
Ir PPh3
N
N N
Ir N
N N
Ir N
PF6
PF6
PF6PF6
BArF
BArF
(S,S)-62 (S,S)-63
(S,S)-69
(R,R)-66
(S,S)-67
N N
O O
Ir Cl
(S,S)-68
N N
Ir Cl
(R,R)-65(R,R)-64
 
Figure 2.6 Analogues of Crabtree's catalyst bearing chiral C2-symmetric NHC. 
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2.4 Structural analysis of the iridium complexes 
All complexes were characterised by standard 2D NMR analysis. Complexation of the 
C2-symmetric imidazolium salts lowers the ligand symmetry from C2 for the imidazolium 
salts to C1 for the complexes. As a result, splitting of all the signals, except the NCN signal, is 
observed in the 1H-NMR and 13C-NMR spectra of the complexes. Complexation was 
monitored by the shift of the 13C-NMR NCN signals from δ = 155(±2) ppm for imidazolium 
salts 49, 53a and 53b to δ = 202(±2) ppm for the corresponding complexes. For NHC 46, 
which has an unsaturated bond between C(4) and C(5), the 13C-NMR NCN chemical shift is 
displaced from 116 ppm for imidazolium salt 55 to 155(±3) for complexes 67-69. 
Dynamic behaviour at room temperature was observed by NMR for complexes 62 and 63. 
Complex 62 has two conformers in solution with a 100:7 ratio. NOESY experiments proved 
that the two conformers interchange at room temperature. In contrast to complex 62, complex 
63 has a complicated 1H-NMR spectrum, thus making structural assignment difficult. At least, 
two interchangeable conformers are present at room temperature. The geometrical 
arrangement of the different conformers could not be established; neither for complex 62 nor 
complex 63. The probable origin of the conformers is the position of the ortho-substituents, 
which can be orientated anti or syn relative to the phenyl substituents of the imidazole. 
 
 
Figure 2.7 Crystal structures of (S,S)-62 (left) and (S,S)-67 (right). Counter-ion omitted for 
clarity. 
Single crystals suitable for X-ray diffraction studies were obtained for complexes 62, 65 and 
complex 67. Unfortunately, the data for both complexes 62 and 67 were impossible to refine 
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satisfactorily. Despite acceptable R-values (6.4% for complex 62 and 6.9% for complex 67), 
the structures can only be used to show the connectivity and the coordination geometry of the 
complexes (Figure 2.7). 
As expected, the N-substituents of complex 62 are in an anti-anti arrangement relative to the 
phenyls of the imidazole ring. The X-ray structure analysis proves that in the solid state, the 
chiral information at the C(4) and C(5) positions of the imidazole is well transmitted to the 
active site of the catalyst. The crystal structure of complex 67 emphasises the rigidity of the 
NHC ligand, with the two isopropyl substituents pointing towards the iridium. 
X-ray data of complex 65 were solved without any problems (Figure 2.8). In the same way as 
in the previous crystal structures, the iridium atom lies in an almost square planar 
arrangement, with the cyclooctadiene double bonds perpendicular to the plane of co-
ordination. Although complex 65 is only the precursor of catalyst 66, its crystal structure 
gives us an insight into the geometry adopted by the ligand for catalysts 64 and 66. In the 
solid state, a C2-symmetric arrangement of the NHC is the most stable structure. The methyl 
and phenyl substituents are pointing away from the iridium atom, leaving an empty cavity 
around the reaction centre. Therefore, despite the fact that the chirality centres are in 
proximity to the iridium, asymmetric induction of catalysts 64 and 66 is expected to be less 
efficient than for the other catalysts. 
 
Figure 2.8 Crystal structures of (R,R)-65. Counter-ion and disorder of the N1-phenyl ring 
omitted for clarity. 
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2.5 Hydrogenation 
Analogues of Crabtree's catalyst 62-69 bearing C2-symmetric chiral NHCs were tested in the 
asymmetric hydrogenation of a range of unfunctionalised olefins 70-73 (Figure 2.9). These 
substrates were chosen as they are difficult to hydrogenate with high enantiocontrol. 
MeO MeO MeO
70 71 72 73  
Figure 2.9 Substrates used for the screen of catalysts. 
Since the activity of monodentate iridium catalysts with substrates 70-73 is not documented in 
the literature, a screen was undertaken with Crabtree's catalyst (Table 2.2) and with Nolan's 
achiral monodentate NHC-pyridine-iridium complex 74 (Table 2.3). 
The performance of Crabtree's catalyst 40 with substrates 70-73 was tested using conditions 
generally applied for Ir-PHOX 41 and its derivatives (0.1 mmol substrate, 1 mol% catalyst, 50 
bar H2, 0.5 ml CH2Cl2, RT, 2h).20 Trisubstituted alkenes (Table 2.2, Entry 1-3) showed very 
low conversion especially with trans-α-methylstilbene 70 (Table 2.2, Entry 1). Disubstituted 
olefin 73 performed reasonably well with 90% conversion. 
 
entry substrate H2 pression (bar) temperature (°C) time (h) conversion (%) 
1 70 50 25 2 8 
2 71 50 25 2 12 
3 72 50 25 2 30 
4 73 50 25 2 90 
Table 2.2 Hydrogenation of substrates 70-73 using Crabtree's catalyst 40. 
In order to define the reaction conditions and achieve full conversion for trans-α-
methylstilbene with monodentate NHC iridium complexes, temperature and pressure screen 
was performed with Nolan's achiral NHC-pyridine-iridium complex 74 (Table 2.3). 
Despite a reaction time of 16 hours, almost no conversion was observed at 50 bar H2 and 
room temperature (Table 2.3, Entry 1). Increasing the hydrogen pressure to 100 bar did not 
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improve efficiency of the catalytic system (Table 2.3, Entry 2). However, the activity of 
catalyst 74 was found to increase with temperature, and full conversion of trans-α-
methylstilbene was obtained at 100°C (Table 2.3, Entry 3 and 4). 
NN
Ir
N
PF6
74
1 mol % cat. 74
H2, CH2Cl2, 16h
 
entry H2 pression (bar) temperature (°C) time (h) conversion (%) 
1 50 25 16 1 
2 100 25 16 1 
3 50 60 16 18 
4 50 100 16 >99 
Table 2.3 Hydrogenation of trans-α-methylstilbene with Nolan's catalyst 74. 
Analogues of Crabtree's catalyst bearing a C2-symmetrical NHC 62-69 were tested for 
enantioselective hydrogenation of trans-α-methylstilbene under the conditions established in 
the preceding screen: 0.1 mmol substrate, 1 mol% catalyst, 50 bar H2, 0.5 ml CH2Cl2, 100°C, 
16h. 
Only catalysts 63, 64 and 67 gave full conversion. Catalysts 62 and 63 (Table 2.4, Entry 1 
and 2) were the only catalysts that induced enantioselectivity. These quite remarkable results 
gave good evidence that these catalysts resisted the strong conditions applied. For catalysts 64 
and 67, which showed full conversion without asymmetric induction, it is not clear if the 
active species in the hydrogenation is the real catalyst, or another achiral catalytic species 
formed after complex degradation (Table 2.4, Entry 3 and 4). A considerable counter-ion 
effect was observed for complexes 62 and 63 (Table 2.4, Entry 1 and 2). Trans-α-
methylstilbene was fully hydrogenated using catalyst 62 bearing BArF- counter-ion, whereas 
its analogue 63 only reached 36% ee. Moreover, the small difference in enantioselectivity 
between 62 and 63 indicates that the ortho-substituents of the aryl rings have almost no 
influence on the stereochemical outcome of the hydrogenation. Very low activities were 
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observed for complexes 66 and 69 which proved to be non-stereoselective (Table 2.4, Entry 5 
and 6). 
∗
1 mol % cat.
50 bar H2, 100°C
CH2Cl2, 16h  
entry catalyst counter-ion co-ligand conversiona (%) eeb (%) 
1 62 PF6- pyridine 36 34 (S) 
2 63 BArF- pyridine >99 30 (S) 
3 64 BArF- pyridine >99 0 
4 67 PF6- pyridine >99 0 
5 66 PF6- PPh3 7 0 
6 69 PF6- PPh3 12 - 
a Determined by GC. b Determined by HPLC. 
Table 2.4 Hydrogenation of trans-α-methylstilbene with catalysts 62-69. 
The very low activities observed and strong reaction conditions required for the 
hydrogenation of trans-α-methylstilbene, prompted us to investigate hydrogenation of 
disubstituted olefin 73. Disubstituted olefin 73 is known to be more easily hydrogenated than 
trisusbstituted olefins. Pfaltz showed that a strong hydrogen pressure dependence was 
observed for this substrate, which reacts with higher enantioselectivity at low pressure. 20 We 
therefore tested our catalysts with substrate 73 using two sets of condition: i) 50 bar H2, RT, 
2h (Table 2.5) and ii)1 bar H2, RT, 2h (Table 2.6). 
At 50 bar H2, almost all catalysts were able to fully hydrogenate alkene 73. However, the 
enantioselectivities measured are rather low. Catalysts bearing NHC type 45 showed almost 
no asymmetric induction (Table 2.5, Entry 1 and 2). The highest enantioselectivity (20% ee) 
was obtained with catalyst 66 (Table 2.5, Entry 5). The effect of triphenylphosphine or 
pyridine as co-ligand seems to be NHC dependent. While NHC of type 44 induces higher 
enantiomeric excess in combination with triphenylphosphine (Table 2.5, Entry 3 and 5), NHC 
type 46 is more enantioselective when combined with pyridine (Table 2.5, Entry 4 and 6). 
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∗
1 mol % cat.
50 bar H2, 25°C
CH2Cl2, 2hMeO MeO  
entry catalyst counter-ion co-ligand conversiona (%) eeb (%) 
1 62 PF6- pyridine >99 5 (R) 
2 63 BArF- pyridine >99 5 (R) 
3 64 BArF- pyridine >99 11 (S) 
4 67 PF6- pyridine 96 13 (R) 
5 66 PF6- PPh3 >99 20 (S) 
6 69 PF6- PPh3 >99 0 
a Determined by GC. b Determined by HPLC. 
Table 2.5 Hydrogenation of 2-(4-methoxyphenyl)-1-butene with catalysts 62-69 at 50 bar H2. 
At 1 bar H2, all the catalysts were less active than at 50 bar H2. The TONs were still 
acceptable, with the exception of 62 (Table 2.6, Entry 1), which required 3 mol% catalyst to 
achieve 30% conversion in 2 hours. As already observed during hydrogenation of trans-α-
methylstilbene, catalysts 62 and 63 show a counter-ion effect. With BArF- counter-ion the 
activity is higher than with PF6- (Table 2.6, Entry 1 and 2). No significant difference in 
activity was observed between NHC iridium catalysts bearing pyridine and those bearing 
triphenylphosphine. As expected, lowering the pressure to 1 bar H2 had a positive effect on 
the asymmetric induction. The enantioselectivities measured at 1 bar H2 were all largely 
superior to those measured at 50 bar H2. Astonishingly, reduction of the pressure to 1 bar H2 
for catalyst 66 resulted in inversion of enantioselectivity (Table 2.6, Entry 5 and Table 2.6, 
Entry 5). As already observed for hydrogenation of trans-α-methylstilbene, changing the 
methyl ortho-substituent of catalyst 62 to an isopropyl substituent (catalyst 63) did not lead to 
higher enanatioselectivities (Table 2.6, Entry 1 and 2). For catalysts bearing pyridine as co-
ligand, the rigidity of the N-substituent of the imidazole seems to be an important factor for 
asymmetric induction: the more rigid the N-substituents (64 < 63 < 67), the higher the 
enantioselectivities (Table 2.6, Entry 2-4). No improvement in activity was noted when 
triphenylphosphine was used instead of pyridine. As already observed at 50 bar H2, the choice 
of triphenylphosphine or pyridine as co-ligand does not affect significantly the asymmetric 
induction (Table 2.6, Entry 3 versus 5 and Entry 4 versus 6). 
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∗
1 mol % cat.
1 bar H2, 25°C
CH2Cl2, 2hMeO MeO  
entry catalyst counter-ion co-ligand conversiona (%) eeb (%) 
1 62 PF6- pyridine 30c 21 (R) 
2 63 BArF- pyridine 40 25 (R) 
3 64 BArF- pyridine 61 14 (S) 
4 67 PF6- pyridine 88 44 (R) 
5 66 PF6- PPh3 50 22 (R) 
6 69 PF6- PPh3 72 35 (R) 
a Determined by GC. b Determined by HPLC. c 3 mol % catalyst. 
Table 2.6 Hydrogenation of 2-(4-methoxyphenyl)-1-butene with catalysts 62-69 at 1 bar H2. 
2.6 Conclusion 
A family of six iridium complexes bearing monodentate NHC ligands, and pyridine or 
triphenylphosphine as co-ligand, were synthesised starting from readily available 
C2-symmetric imidazolium salts.  
Full characterisation by standard 2D NMR techniques and X-ray diffraction studies were 
undertaken to investigate the dynamic behaviour and geometry of the NHC ligands. 
Complexes 62 and 63, bearing NHC 45 developed by Grubbs, showed a dynamic behaviour 
as observed by NMR. X-ray data analysis strongly suggests that the geometry of the ortho-
substituents of the N-aryl groups in solution is anti-anti relative to the phenyls of the 
imidazole. 
In terms of both activity and enantioselectivity, analogues of Crabtree’s catalyst bearing 
C2-symmetric chiral NHC are not suitable for trisubstituted olefins. Full conversions were 
only obtained under harsh conditions (50 bar H2, 100 °C, 16h). However, these experiments 
highlight the remarkable robustness of catalysts 62 and 63, which gave enantiomeric excesses 
up to 34% ee. 
With terminal olefin 73, a reasonable activity was observed. Full conversions were obtained at 
50 bar H2, 25°C, 2h. The low asymmetric induction obtained at 50 bar H2 was improved by 
lowering the pressure to 1 bar. At 1 bar H2, the activities were still acceptable with low to 
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moderate enantiomeric excesses (up to 44% with complex 67). The choice of pyridine or 
triphenylphosphine as co-ligand does not significantly affect the activity of the catalysts. In 
terms of asymmetric induction, no clear trend was observed. 
Analogues of Crabtree's catalyst bearing a C2-symmetrical NHC may find applications in 
other iridium-catalysed reactions. In particular, NHC ligands combined with triphenyl 
phosphite could give rise to interesting systems for iridium-catalysed allylic alkylation 
(Scheme 2.7). 
R
OAc
R
OO
MeO OMe
NaCH(CO2Me)2 
cat. 75
PF6
Ir
N
N
O
O
(PhO)3P
75  
Scheme 2.7 Possible application of C2-symmetric NHCs in combination with P(OPh)3 for 
iridium-catalysed allylic alkylation. 
It has been recently shown that iridium-phosphoramidite complexes prepared in situ can 
achieve enantioselectivities up to 86% ee.21 By combining the strong σ-donor NHC with 
P(OPh)3, the large electronic difference of the ligands should allow effective regiocontrol in 
the iridium-catalysed allylic alkylation of monosubstituted allylic substrates, thus leading to 
high enantioselectivities. 
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Oxazoline-imidazolin- 
2-ylidene ligands 

Oxazoline-imidazolin-2-ylidene ligands 
3.1 Introduction 
Chiral phosphino-oxazolines A (PHOX ligands) and related compounds such as B are highly 
versatile and efficient ligands for the enantioselective iridium-catalysed hydrogenation of 
imines and a wide range of functionalised and unfunctionalised olefins (Figure 3.1).1-4 In 
order to improve the enantioselectivity and widen the application range, many variants of 
ligands A and B have been synthesised, giving rise to a large library of P,N-ligands.5 In 
addition, a series of pyridyl-phosphinites C and related pyridine- and quinoline-derived 
ligands, which were devised to mimic the co-ordination sphere of Crabtree's catalyst 
([Ir(PCy3)(pyridine)(cod)]PF6)6 were developed in our group. These ligands also showed high 
asymmetric induction in iridium-catalysed hydrogenations.7 Other groups as well have 
reported efficient P,N-ligands containing a pyridine or oxazole as co-ordinating units.8,9 
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Figure 3.1 P,N-ligands for the enantioselective iridium-catalysed hydrogenation and their 
oxazoline-carbene analogues. 
Recently, Burgess et al. synthesised chiral iridium complexes from ligands E containing a 
seven-membered chelate ring, in which phosphorus was replaced by a N-heterocyclic carbene 
(NHC).10,11 Among the various derivatives tested, one particular structure E1, with 
R1 = 1-adamantyl and R2 = 2,6-diisopropylphenyl clearly gave the best enantioselectivities 
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with 98% ee for trans-α-methylstilbene. Although high enantioselectivities were observed for 
a range of substrates with this ligand, the overall performance was still inferior to the most 
efficient P,N-ligands. Because the most efficient P,N-ligands for iridium-catalysed 
hydrogenation all form six-membered chelate rings, we became interested in evaluating NHC-
oxazoline ligands, forming a six-membered chelate ring. (Oxazoline-imidazolin-2-ylidene 
ligands forming five-membered rings were developed and studied by Gade et al.12,13) 
Previously reported ligands D were thought to be good candidates for this study.14 However, 
the R1 group in ligands D is restricted to substituents found in readily available amino 
alcohols. In addition, in view of the good results obtained with ligands B, we devised a 
second generation of oxazoline-carbenes (structure F), in which the R1 substituents are 
formed from derivatives of almost any carboxylic acid, thus giving more scope for diversity. 
3.2 Synthesis of chiral imidazolium salts 
The syntheses of imidazolium salts 80a-g and 89a-p, which are precursors of ligands D and F 
are summarised in Schemes 3.1 and 3.2. Imidazolium salts 80a-g were synthesised using a 
divergent pathway, in which the imidazolium salt moiety is introduced in the last step, thus 
allowing easy variation of the imidazolin-2-ylidene substituents. This route differs from the 
previously published synthesis14 that starts from an imidazole and introduces the oxazoline 
ring at the end. The key intermediates, chloromethyloxazolines 79,15 were prepared by 
condensation of chloroacetyl chloride 77 with (S)-tert-leucinol or (S)-valinol, followed by 
ring closure using Burgess reagent.16,17 After purification by distillation, 
chloromethyloxazolines 79 were reacted with a range of imidazoles, which were either 
commercially available or prepared according to literature procedures.18-20 The resulting 
imidazolium chlorides were treated with NaBArF (BArF- = tetrakis[3,5-
bis(trifluoromethyl)phenyl]borate) to give the corresponding BArF- salts 80a-g in moderate to 
high yield. 
The weakly co-ordinating BArF- counter-ion was used for two reasons. Firstly, it allowed 
simple purification of imidazolium salts 80a-g by standard chromatography on silica gel, 
which was not possible with the corresponding chloride salts. Secondly, the BArF- anion is 
known to improve the performance of iridium complexes as hydrogenation catalysts 
compared to other weakly co-ordinating anions such as hexafluorophosphate, 
tetrafluoroborate or triflate.21,22 
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R1 = tBu, R2 = tBu
BArF
 
Reagents and conditions: (i) NEt3, CH2Cl2, RT, 10h, (83-89%); (ii) Burgess reagent, THF, reflux, 4h 
(50-66%); (iii) Imidazole, DMF, 80°C, 8h; (iv) NaBArF (BArF- = tetrakis[3,5-
bis(trifluoromethyl)phenyl]borate), CH2Cl2, RT, 15 min, (58-78% over two steps); (v) [(η4-cod)IrCl]2, 
NaOtBu, THF, RT, 3h, (44-65%). 
Scheme 3.1 Synthesis of iridium complexes D. 
In the synthesis of ligands F, the imidazolium moiety was again introduced in the last step 
(Scheme 3.2). Oxazolines 86 were obtained by reacting (S)-serine methyl ester hydrochloride 
83, either with commercially available benzimidate hydrochloride 83, or with acyl chlorides 
84 followed by ring closure using Burgess reagent. Reduction of the ester group using DIBAL 
in THF gave oxazoline alcohols 87 in moderate to good yields. Tosylation and subsequent 
nucleophilic substitution with a range of imidazoles yielded the corresponding imidazolium 
tosylates, which were converted into BArF- salts 89a-p by anion exchange with NaBArF, 
followed by flash chromatography on silica gel. By this method, four different sets of ligands 
(R1 = tert-butyl, adamantyl, 2,6-dimethylphenyl and phenyl) with various R2 groups were 
prepared. 
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Reagents and conditions: (i) (S)-serine methyl ester hydrochloride, NEt3, CH2Cl2, RT, 10h, (80-93%); 
(ii) Burgess reagent, THF, reflux, 4h (65-72%); (iii) 1,2-dichlorethane, reflux, 20h, (91%); (iv) DIBAL, 
THF, RT, 12h, (52-78%); (v) NEt3, TsCl, CH2Cl2, RT, (50-83%); (vi) Imidazole, DMF, 80°C, 8h; (vii) 
NaBArF (BArF- = tetrakis[3,5-bis(trifluoromethyl)phenyl]borate), acetone, RT, 15 min (50-78% over two 
steps); (viii) [(η4-cod)IrCl]2, NaOtBu, THF, RT, 3h, (48-83%). 
Scheme 3.2 Synthesis of iridium complexes F. 
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Iodide derivates 88bis, synthesised from tosylate 88p (Scheme 3.3), were also prepared in 
order to determine if iodide would be a better leaving group than tosylate for nucleophilic 
substitution by imidazoles. However, racemisation occurred during synthesis of iodides 88bis 
and their reactivity with the imidazoles was not investigated. 
N
O
OTs
88p
(i) N
O
I
88bis
 
Reagents and conditions: (i) NaI, acetone, 50°C, 16h, (94%). 
Scheme 3.3 Synthesis of iodide 88bis. 
3.3 Preparation of the iridium complexes 
Cationic iridium(I) complexes 81a-f and 90a-o were synthesised in a one-step procedure, 
starting from the corresponding imidazolium salts 80a-g and 89a-o (Schemes 3.1 and 3.2). 
Deprotonation at the imidazolium ring23,24 using sodium tert-butoxide in the presence of 
[(η4-cod)IrCl]2 allowed simultaneous generation and complexation of the N-heterocyclic 
carbene.25 The chloride anions were removed from the reaction mixture by precipitation of 
NaCl. The resulting yellow to orange crystalline BArF- salts were purified by flash 
chromatography on silica gel. 
Whereas complexation of imidazolium salts 80a-f was successful, no complex formation was 
observed with imidazolium salt 80g, even when more forcing conditions with a strong base 
such as nBuLi were applied. In this particular case, steric hindrance by the two tert-butyl 
substituents seems to prevent complexation of imidazolium salt 80g to iridium. However, the 
analogous imidazolium salt 89e, which also contains two tert-butyl groups, was metalated in 
respectable yield (59%). 
Under the reaction conditions described above, complexation of imidazolium salt 89p gave an 
unexpected product 90p as a colorless powder in 84% yield (Scheme 3.3). Full 
characterisation, including single crystal X-ray diffraction analysis, allowed the assignment of 
structure 90p. Apparently, complexation of ligand 89p was accompanied by insertion of the 
Ir(I) centre into one of the ortho C-H bonds of the phenyl substituents at the oxazoline ring. 
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90p89p
(i)
BArF
 
Reagents and conditions: (i) i) [(η4-cod)IrCl]2, NaOtBu, THF, 3h, (84%). 
Scheme 3.3 Synthesis of complex 90p. 
The presence of an Ir-bound hydride, resulting from C-H activation, was proved by the 
observation of a hydride signal at δ = -14.6 ppm in the 1H-NMR spectrum. The crystal 
structure of 90p shows the iridium atom in a pseudo-octahedral co-ordination environment 
with the iridium atom lying within 0.02 Å in the best plane fitted through the carbene atom 
C(13), the phenyl C(1) atom and the midpoints of the cyclooctadiene double bonds (Figure 
3.2). This geometry implies that the hydride is located trans to the oxazoline ring. Since 
complex 90p proved to be catalytically unreactive in hydrogenation, no other complexes of 
this type were synthesised. 
 
Figure 3.2 Structure of the cation of 90p. Selected bond lengths (Å) and angles (°): Ir(1)-C(1) 
2.029(4), Ir(1)-N(1) 2.159(3), Ir(1)-C(13) 2.054(4), Ir(1)-C(23) 2.281(4), Ir(1)-C(24) 
2.300(4), Ir(1)-C(27) 2.226(4), Ir(1)-C(28) 2.248(4), C(23)-C(24) 1.380(7), C(27)-C(28) 
1.373(7); N(2)-C(13)-N(3) 104.3(3), N(1)-Ir(1)-C(1) 78.27(15), C(13)-Ir(1)-N(1) 78.34(14). 
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3.4 Structural analysis of the iridium complexes 
All 13C and 1H resonances of complexes 81a-f and 90a-o were assigned by standard 2D NMR 
techniques. In the 13C-NMR spectra, a shift of the NCN signal from δ = 134(±3) ppm for the 
imidazolium salts to δ = 173(±4) ppm for the carbene complexes was observed upon NHC 
complexation. 
Single crystals, suitable for X-ray analysis were obtained for complexes 81b and 90q, the 
latter being an analogue of complex 90b with PF6- instead of BArF- as counter-ion (Figures 
3.3 and 3.4). Synthesis of 90q was achieved by reacting [(η4-cod)IrCl]2 and NaOtBu in THF 
at room temperature with the corresponding imidazolium salt bearing a chloride counter-ion, 
followed by addition of TlPF6 in CH2Cl2 at room temperature. 
In both crystal structures, the iridium atom adopts a nearly square planar co-ordination 
geometry with the cod double bonds perpendicular to the co-ordination planes. The bond 
angles observed at the carbene centres, N(2)-C(14)-N(3) = 104.8° for 81b and N(2)-C(1)-
N(1) = 104.3° for 90q, are in good agreement with the value expected for a singlet 
N-heterocyclic carbene.26 
 
Figure 3.3 Structure of the cation of 81b. Selected bond lengths (Å) and angles (°): Ir(1)-
C(14) 2.034(4), Ir(1)-N(1) 2.089(4) Ir(1)-C(15) 2.175(3), Ir(1)-C(16) 2.193(4), Ir(1)-C(19) 
2.105(5), Ir(1)-C(20) 2.136(3), C(15)-C(16) 1.388(6), C(19)-C(20) 1.418(7); N(2)-C(14)-N(3) 
104.8(3), N(1)-Ir(1)-C(14) 82.28(15). 
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Figure 3.4 Structure of the cation of 90q. Selected bond lengths (Å) and angles (°): Ir(1)-C(1) 
2.042(3), Ir(1)-N(3) 2.094(2), Ir(1)-C(15) 2.159(3), Ir(1)-C(16) 2.167(3), Ir(1)-C(19) 
2.115(3), Ir(1)-C(20) 2.124(3), C(15)-C(16) 1.383(6), C(19)-C(20) 1.403(5); N(2)-C(1)-N(1) 
104.3(3), N(3)-Ir(1)-C(1) 79.47(11). 
 
O 
C Ir N 
O 
Figure 3.5 Superposition of the crystal structures of complex 81b (purple) and 90q (grey). 
The structures are aligned on the plane defined by the Ccarbene-Ir-Noxazoline atoms. Counter-ion 
and cod omitted for clarity. 
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The 13C-NMR chemical shifts of the cyclooctadiene olefinic C-atoms and the Ir-(C=C) 
distances trans to the oxazoline and trans to the NHC moiety were compared with those of 
the most efficient P,N-ligands developed in our laboratory (Table 3.1). According to the 
observed values, the trans influence of the imidazolin-2-ylidene group lies between that of the 
phosphine and the oxazoline groups. This is reflected by the Ir-(C=C) distances trans to the 
co-ordinating units, which increase from 200-204 pm for the oxazoline to 205-207 pm for the 
imidazolin-2-ylidene and 211-212 pm for the phosphine group. 
 
 Ir-(C=C) distance to Ir (pm)[a] Ir-(C=C) 13C NMR chemical shift[b]
 trans to N trans to P/C trans to N trans to P/C 
P(oTol)2Ir
N
O
PF6
 
91 
204 211 
67.5 
67.4 
95.0 
90.0 
O
PCy2Ir
N
O
BnBn
Ph
BArF
 
92 
203 212 
69.2 
64.9 
102.8 
96.6 
O
PPh2Ir
N
O
BArF
 
93 
201 212 
64.5 
60.6 
99.8 
97.4 
N
Ir
N
O
BArF
N
 
81b 
200 207 
65.7 
60.1 
84.6 
82.9 
N
Ir
N
O
BArF
N
 
90b 
200[c] 205[c]
66.2 
56.0 
80.8 
79.9 
[a] distance from the midpoint of the cod double bond to Ir in pm. [b] chemical shift in ppm. 
[c] measured in complex 90q. 
Table 3.1 Structural data of complexes 81b and 90q in comparison with complexes 91,27 9228 
and 93.29 
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As shown by the superposition of the crystal structures of complexes 81b and 90q, the ligand 
arrangement around the iridium atoms in the two complexes is very similar (Figure 3.5). In 
both complexes, the six-membered chelate rings give rise to rigid structures with the R1 and 
R2 substituents pointing in the same direction. 
In comparison to Ir-P,N complexes, in which the two substituents of the phosphine occupy a 
large region in space, the co-ordination sphere of Ir-D and Ir-F complexes is less shielded 
since the NHC moiety bears only one substituent. This difference in spatial occupation is 
highlighted in the superposition of the crystal structures of complexes 81b and 93 (Figure 
3.6). 
 Ir 
C/P N 
Front view 
 
C/P 
Ir 
N 
Side view 
Figure 3.6 Superposition of the crystal structures of complex 81b (grey) and 93 (purple). The 
structures are aligned on the plane defined by the Noxazoline-Ir-Ccarbene (81b) and the Noxazoline-
Ir-P atoms (Ir-A) atoms. Counter-ion and cod omitted for clarity. 
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3.5 Enantioselective hydrogenation 
In order to investigate the potential of these complexes, we tested them in the asymmetric 
hydrogenation of four different unfunctionalised alkenes (94, 95, 96 and 97) and one α,β-
unsaturated carboxylic ester (98) (Figure 3.7). For each substrate, our complexes were 
compared with Burgess' best catalyst E1, with R1 = 1-adamantyl and 
R2 = 2,6-diisopropylphenyl, and one threonine-derived phosphinite-oxazoline iridium 
complex (92). All reactions were set up under inert atmosphere with 1 mol% catalyst and 
0.1 mmol of substrate in CH2Cl2 (0.5 ml). 
MeO MeO
MeO
COOEt
94 95 96
97 98  
Figure 3.7 Substrates used in the hydrogenation screen. 
In the hydrogenation of trans-α-methylstilbene 94, up to 90% ee was obtained with the best 
catalysts of type D and F (81a and 90b; Table 3.2). For type D catalysts (81a-f), the choice of 
R1 = tert-butyl is crucial for activity as well as enantioselectivity. A decrease from 90% to 
50% ee was observed when R1 = tert-butyl was replaced by an isopropyl group. The strong 
influence of the oxazoline substituent is consistent with the findings of Burgess et al. for 
ligands of type E, which were rationalised by computational studies that suggested a strong 
steric interaction between the R1 substituent and the substrate.30 Although the R2 substituent at 
the imidazolin-2-ylidene unit plays a less important role, the asymmetric induction increases 
when the size of R2 is reduced (cf. complexes 81a, 81c and 81d). 
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(R)
1 mol % cat.
50 bar H2, 25°C
CH2Cl2, 2h
94  
catalyst R1 R2 yield[a] ee[b]
81a tBu Me >99 90 (R) 
81b iPr Me 25[c] 55 (R) 
81c tBu iPr >99 87 (R) 
81d tBu 2,4,6-Me3C6H2 76 59 (R) 
81e tBu Neopentyl 96 84 (R) 
81f tBu Isobutyl 99 85 (R) 
90a tBu Me >99 89 (R) 
90b tBu iPr >99 90 (R) 
90c tBu 2,4,6-Me3C6H2 >99 79 (R) 
90d tBu Neopentyl >99 87 (R) 
90e tBu tBu 66 78 (R) 
90f 1-Ad Me 97 69 (R) 
90g 1-Ad iPr >99 72 (R) 
90h 1-Ad 2,4,6-Me3C6H2 >99 61 (R) 
90i 1-Ad Neopentyl >99 71 (R) 
90j 1-Ad tBu 70 66 (R) 
90k 2,6-Me2C6H3 Me 27 68 (R) 
90l 2,6-Me2C6H3 iPr 92 59 (R) 
90m 2,6-Me2C6H3 2,4,6-Me3C6H2 15 rac. 
90n 2,6-Me2C6H3 Neopentyl 58 50 (R) 
90o 2,6-Me2C6H3 tBu 7 32 (R) 
E1[11] 1-Ad 2,6-iPr2C6H3 >99 98 (S) 
92[4] - - >99 99 (R) 
[a] % Determined by GC. [b] % Determined by HPLC. [c] 5 mol% cat. 
Table 3.2 Hydrogenation of trans-α-methylstilbene 94. 
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Both activity and enantioselectivity of type F catalysts strongly depend on the oxazoline 
substituent. High conversion was obtained for R1 = tert-butyl and 1-adamantyl, with the 
exception of complexes 90e and 90j bearing a tert-butyl group at the NHC unit. In these two 
catalysts, the co-ordination sphere seems to be too congested to allow high catalytic activity. 
With R1 = 2,6-dimethylphenyl, activities were low to moderate (90k-o). As for the D series, 
the best enantioselectivities were recorded for catalysts with a tert-butyl group at the 
oxazoline ring (90a-e). Replacement of R1 = tert-butyl by 1-adamantyl reduced the 
enantioselectivities by about 20%. With R1 = 2,6-dimethylphenyl, the asymmetric induction 
was even lower. In combination with R1 = tert-butyl, only the catalysts bearing small R2 
substituents such as methyl and isopropyl reached 90% ee, a trend already observed in the D 
series. 
Hydrogenation of (E)-2-(4-methoxyphenyl)-2-butene 95 and (Z)-2-(4-methoxyphenyl)-2-
butene 96 showed similar trends (Table 3.3 and 3.4). Contrary to trans-α-methylstilbene, the 
highest enantioselectivity values, 87% ee for alkene 95 and 73% ee for alkene 96, were 
obtained with type F catalysts 90b and 90c, respectively. 
Among type D catalysts, complex 81a, which bears the least bulky substituent on the NHC 
ring, was again the most selective catalyst with 76% ee for substrate 95 and 56% ee for 
substrate 96. 
The results with type F catalysis confirmed the trend that the R1 substituent has a strong 
influence on both activity and enantioselectivity. Similar to the hydrogenation of trans-α-
methylstilbene, catalysts with R1 = tert-butyl gave by far the highest enantiomeric excesses 
followed by catalysts with R1 = 1-admantyl and R1 = 2,6-dimethylphenyl. The R2 substituent 
at the NHC unit allowed fine tuning of the enantioselectivity of substrates 95 and 96. While 
the highest enantiomeric excesses were obtained for substrate 95 with a small R2 group such 
as methyl (90a) and isopropyl (90b), the best enantioselectivities for substrate 96 were 
obtained with R2 = 2,4,6-trimethylphenyl (90c). 
Two further aspects of the hydrogenation of alkene 96 with Ir-F catalysts are remarkable. 
Firstly, three catalysts 90k, 90l and 90n produce the opposite enantiomer. The observed 
formation of (R)-products starting from both the (E)- and the (Z)-olefins is in contrast to the 
general trend that (E)- and (Z)-olefins give products of opposite configuration.5 A possible 
explanation could be that cis-trans isomerisation takes place during hydrogenation such that 
reactions of the less stable (Z)-isomer 96 proceed mainly via the (E)-isomer 95.31 
Secondly, catalysts 90e, 90j and 90o with a tert-butyl group on the NHC moiety not only gave 
low conversion but also no asymmetric induction. 
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(R)
1 mol % cat.
50 bar H2, 25°C
CH2Cl2, 2hMeO MeO
95  
catalyst R1 R2 yield[a] ee[b]
81a tBu Me >99 76 (R) 
81b iPr Me 5 - 
81c tBu iPr >99 69 (R) 
81d tBu 2,4,6-Me3C6H2 >99 9 (R) 
81e tBu Neopentyl >99 69 (R) 
81f tBu Isobutyl >99 69 (R) 
90a tBu Me >99 85 (R) 
90b tBu iPr >99 87 (R) 
90c tBu 2,4,6-Me3C6H2 >99 75 (R) 
90d tBu Neopentyl >99 84 (R) 
90e tBu tBu 50 80 (R) 
90f 1-Ad Me >99 69 (R) 
90g 1-Ad iPr >99 71 (R) 
90h 1-Ad 2,4,6-Me3C6H2 >99 61 (R) 
90i 1-Ad Neopentyl >99 73 (R) 
90j 1-Ad tBu 87 75 (R) 
90k 2,6-Me2C6H3 Me 83 74 (R) 
90l 2,6-Me2C6H3 iPr 89 59 (R) 
90m 2,6-Me2C6H3 2,4,6-Me3C6H2 20 11 (R) 
90n 2,6-Me2C6H3 Neopentyl 84 61 (R) 
90o 2,6-Me2C6H3 tBu 6 rac. 
E1[11] 1-Ad 2,6-iPr2C6H3 >99 91 (S) 
92[4] - - >99 99 (R) 
[a] % Determined by GC. [b] % Determined by HPLC. 
Table 3.3 Hydrogenation of (E)-2-(4-methoxyphenyl)-2-butene 95. 
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(S)
1 mol % cat.
50 bar H2, 25°C
CH2Cl2, 2hMeO MeO
96  
catalyst R1 R2 yield[a] ee[b]
81a tBu Me 97 56 (S) 
81b iPr Me 3 - (S) 
81c tBu iPr >99 41 (S) 
81d tBu 2,4,6-Me3C6H2 65 27 (S) 
81e tBu Neopentyl 91 30 (S) 
81f tBu Isobutyl 97 46 (S) 
90a tBu Me >99 56 (S) 
90b tBu iPr >99 66 (S) 
90c tBu 2,4,6-Me3C6H2 >99 73 (S) 
90d tBu Neopentyl >99 50 (S) 
90e tBu tBu 68 rac. 
90f 1-Ad Me >99 33 (S) 
90g 1-Ad iPr >99 43 (S) 
90h 1-Ad 2,4,6-Me3C6H2 >99 66 (S) 
90i 1-Ad Neopentyl >99 10 (S) 
90j 1-Ad tBu 79 rac. 
90k 2,6-Me2C6H3 Me 89 25 (R) 
90l 2,6-Me2C6H3 iPr >99 38 (R) 
90m 2,6-Me2C6H3 2,4,6-Me3C6H2 38 17 (S) 
90n 2,6-Me2C6H3 Neopentyl >99 41 (R) 
90o 2,6-Me2C6H3 tBu 18 rac. 
E1[11] 1-Ad 2,6-iPr2C6H3 95 78 (R) 
92[4] - - >99 72 (S) 
[a] % Determined by GC. [b] % Determined by HPLC. 
Table 3.4 Hydrogenation of (Z)-2-(4-methoxyphenyl)-2-butene 96. 
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The terminal olefin 2-(4-methoxyphenyl)-1-butene 97 is a much more reactive substrate than 
those discussed so far. Since previous work on substrate 97 showed that low hydrogen 
pressure increases the asymmetric induction,5,32 catalyst screen was performed at 1 bar H2 
(Table 3.5). 
For type D catalysts, R1 = tert-butyl is required for high activity. In this series, the importance 
of the R2 substituent is demonstrated by a remarkable inversion of enantioselectivity from 
15% ee (R) to 79% ee (S) when R2 = methyl is replaced by an isopropyl group. With a value 
of 79% ee, complex 81c was the most selective catalyst of both 81a-f and 90a-o libraries. 
Type F catalysts gave low to moderate enantioselectivities. The best enantiomeric excesses of 
substrate 97 were again observed with R1 = tert-butyl, even though the difference between the 
tert-butyl and the 1-adamantyl substituent is less pronounced than for substrates 94, 95 and 
96. Complexes 90e, 90j and 90o, bearing a tert-butyl substituent on the NHC moiety, showed 
no catalytic activity. 
 
Finally, our catalyst library was tested in the hydrogenation of (E)-2-methylcinnamic acid 
ethyl ester 98 (Table 3.6). Type D complexes gave moderate enantioselectivities of up to 
59% ee (81a). Complexes with less sterically hindered R2 substituents such as methyl (81a), 
isopropyl (81c) and isobutyl (81d) were again the most enantioselective catalysts. 
Higher enantioselectivities were obtained with catalysts of type F. Contrary to previous 
substrates 94-97, the R2 substituent in complexes 90a-j plays a more important role than the 
R1 substituent. The best enantiomeric excesses, 76% and 72% ee, were obtained with 
R2 = 2,4,6-trimethylphenyl (90c and 90h). 
Moreover, in contrast to the results obtained with unfunctionalised alkenes, catalysts with 
R1 = 1-adamantyl showed higher ee values than their analogues with R1 = tert-butyl. With 
R1 = 2,6-dimethylphenyl (90k-o), enantioselectivities were moderate. Contrary to catalysts 
90a-j, no positive effect on the asymmetric induction was observed with R2 = 2,4,6-
trimethylphenyl. 
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(S)
1 mol % cat.
1 bar H2, 25°C
CH2Cl2, 2hMeO MeO
97  
catalyst R1 R2 yield[a] ee[b]
81a tBu Me >99 15 (R) 
81b iPr Me 2 - 
81c tBu iPr >99 79 (S) 
81d tBu 2,4,6-Me3C6H2 >99 54 (S) 
81e tBu Neopentyl >99 70 (S) 
81f tBu Isobutyl >99 78 (S) 
90a tBu Me >99 69 (S) 
90b tBu iPr >99 66 (S) 
90c tBu 2,4,6-Me3C6H2 >99 55 (S) 
90d tBu Neopentyl >99 65 (S) 
90e tBu tBu 0 - 
90f 1-Ad Me >99 62 (S) 
90g 1-Ad iPr >99 56 (S) 
90h 1-Ad 2,4,6-Me3C6H2 >99 56 (S) 
90i 1-Ad Neopentyl >99 65 (S) 
90j 1-Ad tBu 0 - 
90k 2,6-Me2C6H3 Me >99 29 (S) 
90l 2,6-Me2C6H3 iPr 90 20 (S) 
90m 2,6-Me2C6H3 2,4,6-Me3C6H2 20 rac. 
90n 2,6-Me2C6H3 Neopentyl >99 27 (S) 
90o 2,6-Me2C6H3 tBu 0 - 
E1[11] 1-Ad 2,6-iPr2C6H3 >99 89 (R) 
92[4] - - >99 94 (S) 
[a] % Determined by GC. [b] % Determined by HPLC. 
Table 3.5 Hydrogenation of 2-(4-methoxyphenyl)-1-butene 97 at 1 bar H2. 
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(R)
COOEt
1 mol % cat.
50 bar H2, 25°C
CH2Cl2, 2h
98
COOEt
 
catalyst R1 R2 yield[a] ee[b]
81a tBu Me >99 59 (R) 
81b iPr Me 0 - 
81c tBu iPr >99 54 (R) 
81d tBu 2,4,6-Me3C6H2 93 13 (S) 
81e tBu Neopentyl >99 48 (R) 
81f tBu Isobutyl >99 55 (R) 
90a tBu Me >99 12 (R) 
90b tBu iPr >99 38 (R) 
90c tBu 2,4,6-Me3C6H2 >99 72 (R) 
90d tBu Neopentyl >99 30 (R) 
90e tBu tBu >99 rac. 
90f 1-Ad Me >99 16 (R) 
90g 1-Ad iPr >99 46 (R) 
90h 1-Ad 2,4,6-Me3C6H2 >99 76 (R) 
90i 1-Ad Neopentyl >99 44 (R) 
90j 1-Ad tBu 96 36 (R) 
90k 2,6-Me2C6H3 Me >99 50 (R) 
90l 2,6-Me2C6H3 iPr >99 41 (R) 
90m 2,6-Me2C6H3 2,4,6-Me3C6H2 >99 30 (R) 
90n 2,6-Me2C6H3 Neopentyl >99 27 (R) 
90o 2,6-Me2C6H3 tBu 70 rac. 
E1[11] 1-Ad 2,6-iPr2C6H3 - - 
92[4] - - >99 94 (R) 
[a] % Determined by GC. [b] % Determined by HPLC. 
Table 3.6 Hydrogenation of (E)-2-methylcinnamic acid ethyl ester 98. 
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3.6 Conclusion 
Simple and efficient syntheses for two families of chiral iridium(oxazoline-carbene) 
complexes D and F with a six-membered chelate ring have been developed. The modular 
nature of these ligands allowed the preparation of a wide range of derivatives. 
The complexes were tested in the iridium-catalysed asymmetric hydrogenation of olefins. 
Among type D complexes, catalyst 81a gave the highest enantiomeric excesses for all 
substrates except terminal olefin 97. Remarkably, catalyst 81a is the one bearing the least 
bulky R2 substituent at the NHC moiety. 
The most selective catalysts in the F series were found to be equivalent or superior to type D 
complexes. Good enantioselectivities were generally induced by catalysts with a bulky tert-
butyl- or adamantly-oxazoline unit in combination with a smaller group such as methyl or 
isopropyl at the NHC moiety. The functionalised substrate 98 is an exception. Here, the most 
efficient catalyst was complex 90h bearing two bulky groups, 1-adamantyl and 2,4,6-
trimethylphenyl. 
The six-membered chelate complexes strongly differ from the seven-membered analogues E 
developed by Burgess. Whereas only one particular complex of type E was found to give high 
enantioselectivities, Ir-E1 with R1 = 1-adamantyl and R2 = 2,6-diisopropylphenyl, several 
representatives of type D and F were identified, which induced similar ee levels. In contrast to 
Burgess' catalysts, which require large substituents at the NHC and oxazoline units for high 
enantioselectivity, the six-membered chelate analogues D and F in general give better results 
with less sterically demanding ligands. 
However, despite the wide range of D and F type catalysts investigated, the enantiomeric 
excesses are not as high as those obtained with Burgess best complex Ir-E1. Nevertheless, our 
results indicate that carbene-oxazoline ligands of this type have considerable potential. Their 
modular nature, which enables easy tuning of the ligand structure suggests that they could 
find applications in other areas of asymmetric catalysis. 
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 Phosphine/phosphinite-N-heterocyclic carbene ligands 
4.1 Introduction 
The disposition of the phosphine substituents in the Ir-P,N complexes is thought to be crucial 
for high asymmetric induction.1 In chapter three, a crystal structure comparison of iridium 
oxazoline-imidazolin-2-ylidene complexes with Ir-PHOX showed that the spatial occupation 
of the imidazolin-2-ylidene moiety (which has been considered by Nolan and co-workers as 
"fences" with a defined length and height)2 strongly differs from that of the phosphine moiety. 
Whereas NHC shields the co-ordination sphere with only one substituent, the phosphine with 
two substituents occupies a much larger region in space. Moreover, in comparison to NHCs, 
phosphines are versatile ligands, whose steric and electronic parameters can be easily 
modulated.3 
In order to take advantage of the properties that phosphines show in iridium-asymmetric 
hydrogenation, we decided to synthesise chiral ligands in which a NHC is tethered to a 
phosphine or a phosphinite moiety. 
Phosphine-NHC bidentate ligands have been already investigated by Herrmann, who 
published in 1996 the first achiral phosphine-NHC ligand 99, obtained by reduction of the 
corresponding phosphine oxide using methyldichlorosilane (Figure 4.1). Ruthenium 
complexes were prepared but no catalytic reaction was reported.4 A few years later, 
applications of achiral phosphine-NHC ligands to palladium cross-coupling reactions were 
investigated by Nolan5,6 and Lee.7 Recently, tridentate phosphine-NHC pincer ligand, PCNHCP 
100, was developed and successfully used in ruthenium-catalysed transfer hydrogenation.8,9 
N NN N
PPh2
99 100
Ph2P PPh2
 
Figure 4.1 First achiral phosphine-NHC 99 and tridentate PCNHCP ligands 100. 
The first chiral phosphine-NHC ligand was published in 2003 by Chung who took advantage 
of the ferrocene backbone to synthesise ligand 101 (Figure 4.2).10 A paracyclophane 
backbone was used by Bolm to prepare ligand 102, iridium complexes of which were tested in 
the asymmetric catalytic hydrogenation of olefins.11 The complexes showed low activities and 
low enantioselectivities. Ligand 103, developed by Helmchen, gave high asymmetric 
induction in the rhodium-catalysed hydrogenation of dimethyl itaconate and N-
acetyldehydroamino acid derivatives.12 More recently, Togni prepared chiral phosphine-NHC 
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pincer ligand 104 and undertook some preliminary studies in the palladium catalysed 
enantioselective addition of morpholine to methacrylonitrile.13,14 
PPh2
N
N
Ar
Fe PPh2
N N R
N N
iPr
PPh2
Ph Ph
Fe PPh2
N N
Fe
101 102
103 104
Ph2P
 
Figure 4.2 Chiral phosphine-NHC and tridentate PCNHCP ligands. 
The first phosphine-NHC ligand that we decided to synthesise was derived from pyridyl 
phosphinite ligands 105, recently developed in our group (Figure 4.3). Pyridyl-phosphinite 
ligands 105 are efficient ligands for the iridium-catalysed asymmetric hydrogenation of 
olefins. The success achieved with this simple structure, in which the stereogenic centre is 
situated at the bridge between the pyridine moiety and the phosphinite, prompted us to 
synthesise structural analogue phosphine-NHC ligands 106. Contrary to pyridyl-phosphinite 
ligands 105, phosphine-NHC ligands 106 have a R1 substituent which points towards the co-
ordination sphere of iridium, thus allowing fine-tuning of the steric hindrance in close 
proximity to the metal. 
N PR2
O
∗
R1
N
PR2
R2
N
R1
105 106  
Figure 4.3 Derivation of phosphine-NHC ligands with a stereogenic centre at the chelate ring. 
In a closely related project, we synthesised phosphinite-NHC ligands 107 (Figure 4.4). 
Phosphinite-NHC 107 should be readily available from commercially available chiral 
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epoxides 108. This synthesis allows easy variation of the chirality centre, the imidazolin-2-
ylidene substituents and the phosphinite moiety. 
O
R1
N
PR2
O
N
R1
R2
HN N R
2X
107 108  
Figure 4.4 Synthesis of phosphinite-NHC ligands 107 from chiral epoxides. 
4.2 Phosphine-N-heterocyclic carbene ligands 
4.2.1 Ligand design and synthesis 
Synthesis of phosphine-imidazolium salts 109, precursors to phosphine-NHC ligands 106, is 
not straightforward, since introduction of a phosphine group almost always requires basic 
conditions that might interfere with imidazolium salts. We therefore decided to build the 
imidazolium salt moiety after synthesis of the phosphine (Figure 4.5). Previously reported 
amino-phosphines 111,15,16 derived from amino-alcohols 112, were found to be a convenient 
building block for this synthesis, since the imidazolium salt moiety could be introduced via 
the primary amine functionality in a three step synthesis according to a procedure reported by 
Hoveyda.17 
N
PR2
R2
N
R1
109
H2N
PR2
R2
O
NBoc
R1
H2N
OH
R2
110 111 112  
Figure 4.5 Retrosynthesis of phosphine-imidazolium salt 109. 
The synthesis of amino-phosphine 111 (R2 = iPr), which was investigated by Björn Gschwend 
during his Wahlpraktikum work, is described in Scheme 4.1. Minor modifications were added 
to the reported procedure. 
Boc-protection of amino-alcohol 112 yielded alcohol 113, which was subsequently converted 
to tosylate 114 using tosyl chloride and triethylamine in CH2Cl2. Despite its tendency to 
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undergo intramolecular cyclisation, tosylate 114 was purified by chromatography on silica gel 
and was further reacted with a solution of KPPh2 in THF at -35°C. Finally, Boc-deprotection 
of phosphine 115 yielded the desired amino-phosphine 111 in 31% overall yield. 
H2N
OH
BocNH
OH
BocNH
OTs
BocNH
PPh2
H2N
PPh2
(i) (ii)
(iii) (iv)
112 113 114
115 111  
Reagents and conditions: (i) (Boc)2O, NEt3, CH2Cl2, 25°C, (95%), 15h; (ii) TsCl, NEt3, CH2Cl2, 
-10°C→25°C, RT, 8h, (55%); (iii) KPPh2, THF, -35°C, 15h, (58%); (iv) TFA, CH2Cl2, RT, 20h, (99%); 
Scheme 4.1 Synthesis of amino-phosphine 111. 
Following a procedure developed by Hoveyda, aldehydes 110 were prepared from primary 
amines 116a-c (Scheme 4.2). 
R1
NH2 R
1
N
H
O
O
N
H
NBoc
R1
PPh2
N
H
NH
R1
PPh2
N
N
R1
PPh2
BArF
116a-c
(i) (ii), (iii)
N
Boc
R1 O
N
Boc
R1
117a-c 118a-c 1 -c
119a-c 120a-c 109a-c
10a
(iv), (v)
(vi) (vii) (viii), (ix)
109a R1 = Me          109b R1 = iPr          109c R1 = 2,4,6-Me3C6H2  
Reagents and conditions: (i) (Boc)2O, DMAP (1 mol%), THF, RT, 19h, (55-74%); (ii) KH, DMF, 
0°C→25°C, 2h; (iii) 3,3-dimethylallylbromide, DMF, RT, 1h, (30-74% over two steps); (iv) O3/O2, 
MeOH and CH2Cl2 (1:3), -78°C, ½h; (v) Me2S, RT, 3h, (74-82% over two steps); (vi) amino-phosphine 
111, NaHB(OAc)3, CH2ClCH2Cl, RT, 4h, (74-82%); (vii) TFA, CH2Cl2, RT, 20h, (82-99%); (viii) 
HC(OEt)3, NH4BF4, 100°C, 1h; (ix) NaBArF, CH2Cl2, RT, 15 min, (48-80%). 
Scheme 4.2 Synthesis of phosphine-imidazolium salts 109a-c. 
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Boc-protection of amines 116 yielded carbamates 117, which were deprotonated using KH in 
DMF and then subjected to nucleophilic substitution with 3,3-dimethylallylbromide to give 
olefins 118. Since olefins 118 were not stable on silica gel, the crude products were directly 
converted into aldehydes 110 by ozonolysis using dimethyl sulfide. Reductive amination of 
aldehydes 110 with amino-phosphine 111, gave phosphine 119 in 74-82% yield. Boc-
deprotection followed by ring-closure using NH4BF4 and HC(OEt)3 yielded imidazolium salts 
bearing a tetrafluoroborate counter-ion. Similar to the procedure developed to purify 
oxazoline-imidazolium salts (see chapter three), BF4- counter-ion exchange with BArF- 
allowed purification of phosphine-imidazolium salts 109 by chromatography on silica gel. To 
prevent phosphine oxidation, reactions and purification procedures of compounds 119, 120 
and 109 were performed under inert atmosphere. Three different phosphine-imidazolium salts 
109a-c with R1 = Me, iPr and 2,4,6-Me3C6H2 were prepared by this method. 
4.2.2  Iridium complexes synthesis and structural analysis 
Iridium complexes 121a-c were obtained by deprotonation of the corresponding imidazolium 
salts with freshly sublimed NaOtBu in presence of the metal precursor, [(η4-cod)IrCl]2 (see 
chapter three). Upon addition of NaOtBu, a fast colour change from yellow to dark red was 
observed (Scheme 4.3). 
N
N
R1
PPh2
BArF
109a-c
(i)
N
N
R1
PPh2
BArF
121a-c
Ir69-75%
121a R1 = Me          121b R1 = iPr          121c R1 = 2,4,6-Me3C6H2 
Reagents and conditions: (i) [(η4-cod)IrCl]2, NaOtBu, THF, RT, 2h. 
Scheme 4.3 Synthesis of iridium complexes 121a-c. 
Complexes 121a-c were fully characterised by 2D NMR techniques. Single crystals suitable 
for X-ray analysis were obtained for complexes 122b and 122c, analogues of complexes 121b 
and 121c bearing BF4- as counter-ion. Complexes 122b and 122c were prepared by the same 
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procedure as previously described, but the reaction was performed with the crude BF4- 
imidazolium salts instead of BArF- imidazolium salts 109b and 109c. 
In order to give insight into the structural characteristics and the dynamic behaviour of 
complexes 121a-c, a detailed analysis of complex 121c will be presented here. At room 
temperature, complex 121c showed broad signals in the 1H-NMR spectrum and two peaks in 
the 31P-NMR spectrum at δ = 3.18 ppm (major) and δ = 6.35 ppm (minor) with a 2:1 ratio. 
Clearly, two species are present in solution. At -25°C, the signals were sharp enough and full 
NMR analyses allowed the assignment of structure 121c to both species. Particular care was 
taken to prove the co-ordination mode of the imidazol-2-ylidene at the NCN position of the 
ring for both species. At -25°C, the two conformers interconvert, as proved by the cross-peaks 
observed in the NOESY spectrum. Since no interconversion was observed for the two ortho-
methyl groups of the mesityl ring, rotation of the imidazol-2-ylidene substituent as origin of 
the conformers was ruled out. The geometry of the two conformers was difficult to assign 
unequivocally with NOESY spectrum. However, an important observation was made, when 
the isopropyl substituent on the chelate ring of the major conformer showed a NOE to one 
olefinic proton of the cod moiety. 
Further structural information about complex 121c was obtained by analysing the crystal 
structure of its analogue 122c, which is depicted in Figure 4.6. 
 
Figure 4.6 Crystal structure of complex 122c. Counter-ion and cod omitted for clarity. Ir(1)-
C(1) 2.0606(19), Ir(1)-P(1) 2.3034(4), N(1)-C(1)-N(2) 107.50(17). 
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The bond angle at the carbene centre N(1)-C(1)-N(2) = 107.5°C is in good agreement with 
that expected for a singlet N-heterocyclic carbene.18 The iridium atom lies in an almost square 
planar arrangement, with the cod double bonds perpendicular to the plane of coordination. 
The chelate ring around the iridium has a boat-like conformation. Such geometry is expected 
with this type of ligand, since the planarity of the NHC moiety forces the C(4), N(1), C(1) and 
Ir(1) atoms to lie in the same plane (measured torsion angle = 3.9°C). This geometry best fits 
with a boat conformation of the six-membered chelate ring (Figure 4.7). 
  
Side view Front view 
Figure 4.7 Boat-like conformation origin in complex 122c. 
From a structural point of view, a boat-like geometry of the chelate ring allows complex 121c 
to adopt two conformations (Figure 4.8). In the first conformation (a), which corresponds to 
the crystal structure of 122c, the isopropyl substituent is bent over the iridium and in the 
second conformation (b), it is pointing away from the metal. 
Ir
Ir
P
N
N
P
(a) (b)  
Figure 4.8 The two possible arrangements of complex 121c. Cyclooctadiene double bonds 
shown for clarity. 
This hypothesis is consistent with the two conformers observed by NMR. In solution, the 
major conformer, which shows a NOE between one olefinic proton of the cod and the 
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isopropyl group, would correspond to structure (a). Structure (b) would be therefore the 
minor conformer. 
Dicarbonyl derivative 123c was prepared from complex 121c in order to investigate the 
influence of cod on the conformers' equilibrium. Dicarbonyl complex 123c was obtained by 
dissolving complex 121c in CDCl3 and stirring under 1 bar of CO at room temperature for 30 
minutes (Scheme 4.4). A few seconds after pressurisation of the reaction vessel with CO, the 
colour changed from dark red to light yellow. 
(i)
N
N
R1
PPh2
BArF
121c
Ir
N
N
R1
PPh2
BArF
Ir
C C
O O
123c
IR (CDCl3):
νCO = 2084, 2029 cm-1
 
Reagents and conditions: (i) CO 1 bar, CDCl3, RT, 30 min. 
Scheme 4.4 Synthesis of dicarbonyl complex 123c. 
1H-NMR confirmed complete loss of cod. In the 31P-NMR spectrum, one signal at δ = 1.56 
ppm was observed at room temperature. Even though NMR measurements indicate the 
presence of one species in solution, one can not exclude the fact that, without cod, the 
equilibrium of the two conformers is too fast to be observed on the NMR-time scale. 
Therefore, one can not unequivocally conclude that complex 123c has one conformer in 
solution. 
Similar to complex 121c, complexes 121a and 121b have two conformers in solution at room 
temperature, as observed by NMR. However, the absence of cross-peaks in the NOESY 
spectrum proved that the conformers did not interconvert. The crystal structure of 122b 
(which is the analogue of 121b bearing BF4- as counter-ion) showed the same arrangement of 
the ligand around the iridium as that of complex 122c (Figure 4.9). 
Observation of conformers for complexes 121a, 121b and 121c highlights the lack of rigidity 
of phosphine-carbene ligand 106. Therefore, with such a ligand backbone, dynamic behaviour 
of the chelate ring is likely to affect the chirality transfer from the catalyst to the substrate 
during hydrogenation. 
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Figure 4.9 Crystal structure of complex 122b. Counter-ion and cod omitted for clarity. Ir(1)-
C(1) 2.0606(19), Ir(1)-P(1) 2.3034(4), N(1)-C(1)-N(2) 107.50(17). 
The electronic properties of complexes 121b and 121c were investigated by measuring the 
13C-NMR chemical shift of the cod olefinic C-atoms and the distance from the cod double 
bonds to iridium (Ir-(C=C) trans to the carbene and trans to the phosphine (Table 4.1). 
Complexes 121b and 121c were compared with oxazoline-imidazolin-2-ylidene complexes 
81b and 90b (see chapter three) and Ir-PHOX 91. 
There is a small difference between the imidazolin-2-ylidene unit of complexes 81b and 90b 
and the imidazol-2-ylidene unit of complexes 121b and 121c. In comparison to imidazolin-2-
ylidene, imidazol-2-ylidene has no aromaticity which can stabilise the carbene, and therefore 
induces a larger trans influence. This is illustrated by a longer Ir-C=C distance and a larger 
chemical shift of the cod olefinic C-atoms trans to C in complexes 121b and 121c. 
According to the data for complexes 91, 81b and 90b, the diphenylphosphine group has the 
strongest trans influence, followed by imidazolin-2-ylidene and then oxazoline. This order is 
unexpected, since NHC have been proven to be a better donor than phosphines (see 
introduction). In complexes 121b and 121c, a direct and therefore more accurate comparison 
of the phosphine and the imidazol-2-ylidene group can be made, since the two are present in 
the same complex. As shown in the crystal structure of complexes 122b and 122c, the Ir-C=C 
distances trans to the phosphine and the imidazol-ylidene are in the same range (207-209 
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ppm). Moreover, the 13C-NMR signals of the olefinic C-atoms of complexes 121b and 121c 
all resonate in the same region, between 79-90 ppm. 
 
 Ir-(C=C) distance to Ir[a] Ir-(C=C) 13C-NMR chemical shift[b]
 trans to N trans to P/C trans to N trans to P/C 
P(oTol)2Ir
N
O
PF6
 
91 
204 211 
67.5 
67.4 
95.0 
90.0 
N
Ir
N
O
BArF
N
 
81b 
200 207 
65.7 
60.1 
84.6 
82.9 
N
Ir
N
O
BArF
N
 
90b 
200[c] 205[c]
66.2 
56.0 
80.8 
79.9 
 trans to C trans to P trans to C trans to P 
PPh2Ir
N
N
BArF
 
121b 
208[d] 209[d]
88.9 / 81.9 major 
90.1 / 87.1 minor 
84.0 / 81.5 major 
79.2 / 79.3 minor 
PPh2Ir
N
N
BArF
 
121c 
209[e] 207[e]
88.8 / 87.2 major 
86.5 / 83.6 minor 
78.9 / 77.8 major 
81.5 / 82.5 minor 
[a] distance from the midpoint of the cod double bond to Ir in pm. [b] chemical shifts in ppm. 
[c] measured in complex 90q. [d] measured in complex 122b. [e] measured in complex 122c. 
 
Table 4.1 Structural comparison of iridium complex 121b and 121c with oxazoline-imidazol-
2-ylidene iridium complex 81b and 90b and Ir-PHOX 91. 
More important, in comparison to Ir-PHOX complex 91, which shows significant 
differentiation between the two cod double bonds, complexes 121b and 121c have almost no 
C=C electronic imbalance. 
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4.3 Phosphinite-N-heterocyclic carbene ligands 
4.3.1 Ligand design and synthesis 
As shown in the preceding section, the synthesis of phosphine-imidazolium salts is subject to 
functional group tolerance issues. Since the basic conditions generally needed to synthesise a 
phosphine are incompatible with imidazolium salts, the latter must be introduced at the end of 
the ligand synthesis. However, synthesising the phosphine first is not very attractive. Firstly, 
variation of the phosphine substituents requires much more synthetic work and secondly, 
precautions to avoid phosphine oxidation are required throughout the synthesis. 
A solution to this problem was found by synthesising phosphinite-imidazolium salt 124 
(Scheme 4.5). Synthesis of a phosphinite moiety, which can be achieved via the 
corresponding alcohol using mild phosphorylating reagents, should be possible in presence of 
imidazolium salts and, therefore, was the last step of the ligand synthesis. 
N NH
N NO
Ph
HO Ph
N N
HO Ph
N N
HO PhI
P N
N N
Ph2PO
Ph
BArFBArF
125 126 127 128
129 130 124
(i) (ii)
(iv)(iii)
 
Reagents and conditions: (i) neat, 50°C, 12h; (ii) iPrI, CH3CN, 80°C, 3h, (30% over two steps); (iii) 
NaBArF, CH2Cl2, 15 min, (83%); (iv) 4,5-dichloroimidazole, NEt3, CH2Cl2, RT, 48h, (60%). 
Scheme 4.5 Synthesis of phosphinite-imidazolium salt 124. 
Synthesis of alcohol-N-heterocyclic-imidazolium 128 was achieved in a one-pot procedure, as 
reported in the literature.19-22 Purification of imidazolium salt 128 by crystallisation from hot 
acetonitrile was tedious and accounted for the low yield of the procedure. Counter-ion 
exchange with NaBArF, gave BArF- imidazolium salt 129 in good yield. The BArF- counter-
ion was introduced at this stage of the synthesis to enhance the solubility of imidazolium salt 
129 in dichloromethane, which was crucial for the next step in the synthesis. Phosphorylation 
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of the alcohol was achieved using diphenylphosphamide 13023 in combination with NEt3 and 
4,5-dichloroimidazole as catalyst. The reaction required 1.5 equivalents of phosphamide to 
yield phosphinite 124 in 60% within 48 hours. Purification of phosphinite 124 by 
chromatography was only possible using alox (Fluka, adjusted to grade III). On silica gel, the 
phosphinite was hydrolysed back to alcohol 129. 
4.3.2 Iridium complex synthesis and structural analysis 
Complexation of phosphinite-imidazolium salt 124 was achieved by deprotonation with 
NaOtBu in the presence of [(η4-cod)IrCl]2 (Scheme 4.6). The orange complex was purified by 
chromatography on silica gel. The degree of purity of phosphinite-imidazolium salt 124 was 
important in order to obtain a clean complex. A test experiment, in which the crude 
phosphinite-imidazolium salt was used for complexation, yielded complex 131 with 
impurities that could not be separated by chromatography. 
(i)
BArF
Ir PPh2
ON
N
Ph
N N
Ph2PO
Ph
BArF
124 131  
Reagents and conditions: (i) [(η4-cod)IrCl]2, NaOtBu, THF, RT, 2h, (69%). 
Scheme 4.6 Synthesis of iridium complex 131. 
2D NMR analyses of complex 131 showed the presence of two species in solution. 
Assignment of the two structures confirmed that they were conformers (5:1 ratio), but no 
interconversion was observed by NOESY. NOESY data seem to indicate that, similar to the 
phosphine-imidazolin-2-ylidene complexes, the two conformers arise from a flip of the 
chelate ring. 
Comparison of the 13C-NMR chemical shifts of the cod olefinic C-atoms (89.0 ppm and 
95.7 ppm trans to P; 79.5 ppm and 81.1 ppm trans to C) suggested that the phosphine and the 
imidazolin-2-ylidene moieties of complex 131 have a comparable trans influence similar to 
complex 121b-c (see Table 4.1). 
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4.3.3 Attempted synthesis of a C(5) activated phosphinite-NHC 
iridium complex 
In iridium-catalysed hydrogenation, Ir-P,N complex with six-membered ring have proven to 
be the catalyst of choice.24 We were therefore interested in designing a phosphinite-NHC 
ligand with a six-membered chelate ring. A conventional approach would have been synthesis 
of ligands 132 depicted in Figure 4.10. However, such structure is not easily accessible given 
the instability of the corresponding alcohols 133, which are known to decompose to aldehydes 
134 and 1H-imidazole. 
N
PPh2
O
R2
N
R1
N OH
R2
N
NH
N O
R2
132 133 134  
Figure 4.10 Ligand 132: synthetic issues. 
A possible solution to this problem was suggested by the work of Crabtree on abnormal 
binding modes of NHCs.25-27 As already presented in the introduction, Crabtree recently 
reported that metalation of imidazolium salts can occur, under specific conditions, at C(5) 
instead of C(2). As depicted in Figure 4.11, synthesis of a phosphinite-imidazolium salt with a 
C(5) binding mode would solve the problem of the alcohol precursor instability. In order to 
ensure chelation at the C(5) position, C(2) protection of the phosphinite-imidazolium salts 
with R =  alkyl or aryl was envisaged. 
N
N
R1
R3
PR2
O
R4
R2protectinggroup
C(5) position
stable
structure
 
Figure 4.11 Design of phosphinite-imidazolium salt with a six-membered chelate ring. 
Synthesis of phosphinite-imidazolium salt 135 is depicted in Scheme 4.7. The key compound 
of the synthesis, imidazolecarbaldehyde 139, was synthesised in two steps, according to a 
literature procedure.28 Activation of bromomalonaldehyde 136, followed by condensation 
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with N-phenylbenzamidine 138 gave imidazolecarbaldehyde 139 in 77% overall yield. This 
reaction is quite remarkable since only one regioisomer is obtained. Aldehyde 139 was 
converted into alcohol 140 by Grignard reaction. Subsequent alkylation of imidazole using 
isopropyliodide, followed by counter-ion exchange using NaBArF yielded imidazolium salt 
141. The latter was purified by chromatography on silica gel. Phosphinite 135 was 
synthesised using diphenylphosphamide in combination with NEt3 and 4,5-dichloroimidazole 
and purified by chromatography on alox (Fluka, adjusted to grade III). 
OH
Br CHO
O
Br CHO
NH
NHPh
Ph N
N
OH
Ph
Ph
N
N
CHO
Ph
Ph(i) (ii) (iii)
N
N
OH
Ph
Ph
BArF
(i)
N
N
O
Ph
Ph
BArF
PPh2P N
Ph
Ph
(i)
136 137 138 139 140
141 130 135  
Reagents and conditions: (i) iPrOH, PTSA (cat.), cyclohexane, 100°C, ½h; (ii) K2CO3, CHCl3 and 
H2O (8:1), RT, 10h, (77%); (iii) MeMgCl, THF, -78°C→RT, 12h, (85%); (iv) iPrI, DMF, 95°C, 18h; (v) 
NaBArF, CH2Cl2, 15 min, (19% over two steps); (vi) 4,5-dichloroimidazole, NEt3, CH2Cl2, RT, 48h, 
(91%). 
Scheme 4.7 Synthesis of phosphinite-imidazolium salt 135. 
Complexation of phosphinite-imidazolium 135 proved to be more difficult than expected. 
Addition of NaOtBu to a solution of [(η4-cod)IrCl]2 and phosphinite-imidazolium salt 135 in 
THF did not yield the desired chelate complex. After chromatography on silica gel, the 
13C-NMR spectrum of the complex obtained (142) showed no signal in the region where 
carbene signals are expected (150-210 ppm). Moreover, ESI-MS of complex 142 proved that 
the C(5) position was not deprotonated using the conditions described above. Four species 
were observed by ESI-MS (Figure 4.12). The heaviest one had a mass-to-charge ratio 
m/z = 828.1 corresponding to complex 143. The signal at m/z = 719.2 was attributed to 
structure 143 without cod. Phosphinite-imidazolium salt 135 was observed at m/z = 491.3 and 
one product 145 from decomposition of the ligand showed a signal at m/z = 289.3. As shown 
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by coupled MS-MS experiments, the three lightest species arose from complex 143 
fragmentation during measurement. Since the chloride counter-ion in complex 143 can come 
either from the iridium precursor [(η4-cod)IrCl]2 or from the ESI-MS instrument, it is not 
possible to assign unequivocally structure 143 to complex 142. 
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Figure 4.12 ESI-MS spectrum of complex 142.  
Metalation at the C(5) position is thermodynamically much less favoured than at C(2).25 
Several methodologies were therefore investigated in order to activate the C(5) position. 
Stronger bases than NaOtBu, such as nBuLi, BEMP and KN(Si(CH3)3)2, the latter being the 
most efficient in the formation of acyclic diaminocarbene,29 were tested without success. 
Transmetalation via silver complexes was also investigated, but no complex formation with 
silver was observed when Ag2O was reacted with phosphinite-imidazolium salt 135. 
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4.4 Hydrogenation 
Phosphine carbene iridium complexes 121a, 121b and 121c and phosphinite-carbene complex 
131 were tested in the iridium-catalysed hydrogenation of five unfunctionalised olefins (146-
150), two functionalised olefins (151 and 152) and one imine (153) depicted in Figure 4.13. 
MeO MeO
MeO
COOEt
OH
N
Ph
146 147 148 149
153152151
MeO
150  
Figure 4.13 Substrates tested in the hydrogenation screen. 
In order to compare the results, all reactions were set up under inert atmosphere with 1 mol% 
catalyst and 0.1 mmol substrate in 0.5 ml of CH2Cl2. 
 
Unfunctionalised trisubstituted olefins 146-149 
Initial investigations of our catalysts were undertaken with unfunctionalised trisubstituted 
olefins 146-149 (Table 4.2-4.5). It quickly became apparent that our catalysts were not very 
active in comparison to the usual Ir-P,N complexes, for which TOF values up to 5000 h-1 
were measured for the hydrogenation of trans-α-methylstilbene.30 Twelve hours were not 
enough for substrates 146-149 to be fully hydrogenated. The lowest activities were measured 
with trans-α-methylstilbene 146 with conversion values as low as to 12% after 12 hours. 
Generally, phosphinite complex 131 was more active than phosphine complexes 121a, 121b 
and 121c. Low asymmetric induction was observed for all four catalysts. The highest 
enantiomeric excess (63%) was obtained by using catalyst 121c for the hydrogenation of 
trans-α-methylstilbene. 
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catalyst time (h) pressure (bar) N subst. conversion (%)[a] ee (%)[b]
121a 12 50 Me 10 rac. 
121b 12 50 iPr 21 5 (R) 
121c 12 50 2,4,6-Me3C6H2 38 63 (R) 
131 12 50 iPr 12 6 (R) 
[a] % Determined by GC. [b] Determined by HPLC. 
Table 4.2 Hydrogenation of trans-α-methylstilbene 146 at 50 bar H2. 
 
catalyst time (h) pressure (bar) N subst. conversion (%)[a] ee (%)[b]
121a 12 50 Me 68 rac. 
121b 12 50 iPr 80 rac. 
121c 12 50 2,4,6-Me3C6H2 77 36 (R) 
131 12 50 iPr >99 rac. 
[a] % Determined by GC. [b] Determined by HPLC. 
Table 4.3 Hydrogenation of (E)-2-(4-methoxyphenyl)-2-butene 147 at 50 bar H2. 
 
catalyst time (h) pressure (bar) N subst. conversion (%)[a] ee (%)[b]
121a 12 50 Me 52 5 (S) 
121b 12 50 iPr 68 rac. 
121c 12 50 2,4,6-Me3C6H2 61 10 (S) 
131 12 50 iPr 95 15 (R) 
[a] % Determined by GC. [b] Determined by HPLC. 
Table 4.4 Hydrogenation of (Z)-2-(4-methoxyphenyl)-2-butene 148 at 50 bar H2. 
 
 91
Chapter 4 
catalyst time (h) pressure (bar) N subst. conversion (%)[a] ee (%)[b]
121a 12 50 Me 29 14 (R) 
121b 12 50 iPr 38 28 (R) 
121c 12 50 2,4,6-Me3C6H2 18 rac. 
131 12 50 iPr 93 5 (R) 
[a] % Determined by GC. [b] Determined by HPLC. 
Table 4.5 Hydrogenation of 7-methoxy-4-methyl-1,2-dihydro-naphtalene 149 at 50 bar H2. 
Unfunctionalised disubstituted olefin 150 
The catalysts were then tested with terminal olefin 150, which is known to be easily 
hydrogenated.1,31 Under the same conditions described above, full conversion was obtained 
with all the complexes (Table 4.6). The enantiomeric excesses measured were again very low 
and with catalyst 121a and 131, a racemic mixture of the product was obtained. 
catalyst time (h) pressure (bar) N subst. conversion (%)[a] ee (%)[b]
121a 12 50 Me >99 rac. 
121b 12 50 iPr >99 5 (S) 
121c 12 50 2,4,6-Me3C6H2 >99 13 (S) 
131 12 50 iPr >99 rac. 
[a] % Determined by GC. [b] Determined by HPLC. 
Table 4.6 Hydrogenation of 2-(4-methoxyphenyl)-1-butene 150 at 50 bar H2. 
Since olefin 150 is known to give higher enantioselectivities when hydrogenated at low 
pressure, we reduced the hydrogen pressure to 1 bar. Under such conditions, double bond 
isomerisation was observed. At the end of the reaction, a mixture of olefin 150, E-isomer 147, 
Z-isomer 148 and the product was observed (Scheme 4.8, Table 4.7). 
MeO MeO MeO
∗
MeO
Ir-P,N
1 bar H2
E-147 Z-148150  
Scheme 4.8 Hydrogenation of substrate 150 at 1 bar H2. 
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catalyst time (h) Z (%)[a] E (%)[a] product (%)[a] ee (%)[b]
121a 2 15 12 10 13 (R) 
121b 2 16 9 7 - 
121c 2 22 8 11 22 (S). 
131 2 7 4 0 - 
[a] % Determined by GC. [b] Determined by HPLC. 
Table 4.7 Hydrogenation of 2-(4-methoxyphenyl)-1-butene 150 at 1 bar H2. 
Ester functionalised olefin 151 
Higher activity was observed during hydrogenation of (E)-2-methylcinnamic acid ethyl ester, 
which was fully hydrogenated in 12 hours by all the catalysts (Table 4.8). When the reaction 
time was reduced to three hours, catalysts 121b and 121c still achieved full conversion. The 
asymmetric induction was however low. The highest ee value (43%) was measured with 
catalyst 121b bearing an isopropyl group on the imidazol-2-ylidene. 
catalyst time (h) pressure (bar) N subst. conversion (%)[a] ee (%)[b]
121a 12 50 Me >99 20 (S) 
121b 12 50 iPr >99 43 (S) 
121c 12 50 2,4,6-Me3C6H2 >99 6 (S) 
131 12 50 iPr >99 11 (S) 
121a 6 50 Me 87 20 (S) 
121b 6 50 iPr >99 43 (S) 
121c 6 50 2,4,6-Me3C6H2 >99 10 (S) 
131 6 50 iPr 78 7 (S) 
121a 3 50 Me 35 9 (S) 
121b 3 50 iPr >99 43 (S) 
121c 3 50 2,4,6-Me3C6H2 >99 10 (S) 
131 3 50 iPr 39 rac. 
Table 4.8 Hydrogenation of (E)-2-methylcinnamic acid ethyl ester 151 at 50 bar H2. 
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Alcohol functionalised olefin 152 
Hydrogenation of alcohol functionalised olefin 152 was then investigated. The activities were 
higher than those observed for ester functionalised olefin 151. After 3 hours at 50 bar H2, full 
conversion was obtained for every catalysts (Table 4.9). The best asymmetric induction (42%) 
was obtained with catalyst 121b bearing an isopropyl substituent on the imidazol-2-ylidene. 
When the reaction time was reduced to 15 minutes, catalysts 121a and 121b still achieved full 
conversion. The high activities observed prompted us to perform a pressure dependence study 
of the catalysts. Three hydrogen pressures, 100 bar, 20 bar and 10 bar were investigated 
(Table 4.10). At 10 bar H2, the activities were still acceptable, even though only catalyst 121b 
gave full conversion. In terms of asymmetric induction, increasing the pressure resulted in an 
increase of enantioselectivity. A considerable increase in ee was observed for catalyst 121b, 
which almost doubled its enantioselectivity when the hydrogen pressure was raised from 
10 bar (24% ee) to 100 bar (43% ee). 
 
catalyst time (h) pressure (bar) N subst. conversion (%)[a] ee (%)[b]
121a 3 50 Me >99 37 (-) 
121b 3 50 iPr >99 42 (-) 
121c 3 50 2,4,6-Me3C6H2 >99 26 (-) 
131 3 50 iPr >99 23 (+) 
121a 1 50 Me >99 35 (-) 
121b 1 50 iPr >99 42 (-) 
121c 1 50 2,4,6-Me3C6H2 >99 26 (-) 
131 1 50 iPr 71 20 (+) 
121a 15 min. 50 Me >99 39 (-) 
121b 15 min. 50 iPr >99 41 (-) 
121c 15 min. 50 2,4,6-Me3C6H2 86 27 (-) 
131 15 min. 50 iPr 31 18 (+) 
[a] % Determined by GC. [b] Determined by HPLC. 
Table 4.9 Hydrogenation of (E)-2-methyl-3-phenyl-prop-2-en-1-ol 152 at 50 bar H2. 
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catalyst time (h) pressure (bar) N subst. conversion (%)[a] ee (%)[b]
121a 1 100 Me >99 39 (-) 
121b 1 100 iPr >99 43 (-) 
121c 1 100 2,4,6-Me3C6H2 >99 28 (-) 
131 1 100 iPr 83 24 (+) 
121a 3 20 Me >99 27 (-) 
121b 3 20 iPr >99 33 (-) 
121c 3 20 2,4,6-Me3C6H2 85 20 (-) 
131 3 20 iPr >99 20 (+) 
121a 3 10 Me 85 26 (-) 
121b 3 10 iPr >99 24 (-) 
121c 3 10 2,4,6-Me3C6H2 74 17 (-) 
131 3 10 iPr 51 16 (+) 
[a] % Determined by GC. [b] Determined by HPLC. 
Table 4.10 Pressure dependence study of (E)-2-methyl-3-phenyl-prop-2-en-1-ol 152. 
Imine 153 
High enantioselectivity and high turnover frequency (TOF) has proved difficult to achieve in 
the hydrogenation of acyclic N-arylamines.32 Imines have some peculiarities that makes their 
stereoselective hydrogenation more difficult than that of alkenes. They are often sensitive to 
hydrolysis; the presence of syn/anti isomers requires the catalyst to reduce all isomers with 
the same sense of enantioselectivity, and the product can co-ordinate to the catalyst thus 
reducing its activity. 
Among all the systems developed so far, three are noteworthy (Figure 4.14). The first one, 
catalyst Ir-154 in the presence of iodide and acids, which was developed for the 
hydrogenation of an intermediate for the Syngenta herbicide (1S)-Metolachlor, TOFs reached 
up to 200'000 h-1 and ee values of 80%.33 The second one, iridium catalyst Ir-PHOX 155 with 
a BArF- counter-ion, gave a TOF up to 2'820 h-1 and up to 81% ee in supercritical CO2.34 
More recently, Bolm developed sulfoxime phosphine ligand 156, which iridium complex in 
combination with iodide gave ee values of up to 96% with good activities.35 
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154 155 156  
Figure 4.14 Chiral ligands used in iridium-catalysed asymmetric hydrogenation of imines. 
The last substrate of our screen was imine 153. As a reference value, 0.1 mol% Ir-155 
complex hydrogenates imine 153 in less than 15 minutes with an ee value of 89%. Similar to 
the alcohol functionalised substrate 152, the catalysts showed generally good activities (Table 
4.11). In one hour at 50 bar H2, catalysts 121a, 121b and 131 fully hydrogenated imine 153. 
The substituent on the imidazol-2-ylidene plays an important role in terms of asymmetric 
induction. An increase from 6% (S) to 46% (R) ee was observed when R1 = methyl was 
replaced by an isopropyl group. 
 
catalyst time (h) pressure (bar) N subst. conversion (%)[a] ee (%)[b]
121a 3 50 Me >99 6 (S) 
121b 3 50 iPr >99 47 (R) 
121c 3 50 2,4,6-Me3C6H2 39 rac. 
131 3 50 iPr >99 46 (S) 
121a 1 50 Me >99 6 (S) 
121b 1 50 iPr >99 49 (R) 
121c 1 50 2,4,6-Me3C6H2 18 rac. 
131 1 50 iPr >99 46 (S) 
121a 15 min. 50 Me >99 6 (S) 
121b 15 min. 50 iPr 53 59 (R) 
121c 15 min. 50 2,4,6-Me3C6H2 6 rac. 
131 15 min. 50 iPr >99 48 (S) 
[a] % Determined by GC. [b] Determined by HPLC. 
Table 4.11 Hydrogenation of imine 153 at 50 bar H2. 
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A hydrogen pressure dependence study was performed with imine 153 (Table 4.12). At 10 bar 
H2, 3 hours were enough for catalysts 121a, 121b and 131 to achieve full conversion. Varying 
the pressure affected the enantioselectivity of only catalyst 121b. Contrary to alcohol 
functionalised substrate 152, increasing the pressure resulted in an decrease of 
enantioselectivity. A good correlation between the pressure and the enantioselectivity was 
found, as depicted in Figure 4.15. The highest enantiomeric excess (60% ee) was obtained 
with catalyst 121b at 10 bar H2 in three hours. 
 
catalyst time (h) pressure (bar) N subst. conversion (%)[a] ee (%)[b]
121a 1 100 Me >99 7 (S) 
121b 1 100 iPr >99 34 (R) 
121c 1 100 2,4,6-Me3C6H2 19 rac. 
131 1 100 iPr >99 46 (S) 
121a 3 20 Me >99 6 (S) 
121b 3 20 iPr >99 57 (R) 
121c 3 20 2,4,6-Me3C6H2 42 rac. 
131 3 20 iPr >99 47 (S) 
121a 3 10 Me >99 7 (S) 
121b 3 10 iPr 98 60 (R) 
121c 3 10 2,4,6-Me3C6H2 31 rac. 
131 3 10 iPr >99 48 (S) 
[a] % Determined by GC. [b] Determined by HPLC. 
Table 4.12 Pressure dependence study of imine 153. 
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Figure 4.15 Hydrogen pressure dependence of catalyst 121b enantioselectivity. 
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4.5 Conclusion 
Three chiral phosphine-imidazol-2-ylidene iridium complexes have been synthesised starting 
from amino-phosphine 111. As shown by NMR analysis, the three complexes exist as two 
conformers in solution at room temperature. 2D NMR analysis and X-ray diffraction studies 
of complex 121b, bearing a mesityl substituent on the imidazol-2-ylidene, showed that the 
conformers arose from a flip of the six-membered chelate ring. The electronic properties of 
complexes 121b and 121c were investigated by measuring the 13C-NMR chemical shifts of 
the cod olefinic C-atoms and the distance from the cod double bonds to iridium (Ir-(C=C) 
trans to the carbene and trans to the phosphine). In contrast to Ir-P,N complexes, almost no 
difference of the trans influence exerted on the two cod double bonds was observed.  
Phosphinite-carbene ligands were also investigated. A four step synthesis for phosphinite-
imidazolin-2-ylidene ligands was established starting from chiral epoxides. Using this 
procedure, one complex was prepared. 2D NMR analysis showed that this complex displays 
two conformers in solution at room temperature. 
In order to gain access to phosphinite-carbene complexes with a six-membered chelate ring, 
preparation of phosphinite ligands containing a NHC unit with a carbenoid centre at C(5) was 
attempted. Synthesis of the achiral imidazolium salt precursor was achieved in six steps. 
Despite investigating many complexation methods, activation of the C(5) position of the 
imidazolium salt was not possible. 
Iridium complexes 121a, 121b, 121c and 131 were tested in the catalytic hydrogenation of 
olefins. Unfunctionalised olefins were difficult to hydrogenate. Twelve hours at 50 bar H2 
were not enough for the catalysts to achieve full conversion. The asymmetric inductions 
observed were generally low. Much higher activities were measured when functionalised 
olefins 151 and 152 were hydrogenated. Alcohol functionalised olefin 152 was fully 
hydrogenated in one hour at 50 bar H2 by almost all catalysts. The highest enantiomeric 
excesses (42% ee for ester olefin 151 and 43% ee for alcohol olefin 152) were obtained by 
phosphine-imidazol-2-ylidene complex 121b with R1 = isopropyl. 
Similar to functionalised olefins, imine 153 was fully hydrogenated at 50 bar H2 in one hour 
by almost all catalysts. The highest enantiomeric excess, 47% ee, which was obtained with 
phosphine-imidazol-2-ylidene complex with R1 = isopropyl, was improved to 60% ee by 
reducing the pressure to 10 bar H2. 
The difference in reactivity observed between unfunctionalised olefins and α,β-unsaturated 
ester 151, allylic alcohol 152 and imine 153 emphasises the fact that the electronic properties 
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of the phosphine/phosphinite-carbene iridium complexes are considerably different from 
those of Ir-P,N complexes. The good activities (TOF up to 400 h-1) measured for the 
functionalised substrates are encouraging, in particular for imines, which remain difficult 
substrates to hydrogenate with high asymmetric induction and good TOF. 
The enantiomeric excesses measured throughout the screen are rather disappointing, 
especially for phosphine-imidazol-2-ylidene ligands 121a-c, which are structurally similar to 
the successful pyridyl-phosphinite ligands 105. Improvement of the asymmetric induction 
could be possible by rigidifying the structure of both phosphine- and phosphinite-carbene 
ligands. A possible variation would be to incorporate a chiral cyclopentane in the chelate ring 
of either the phosphine- or phosphinite-NHC ligands as shown in Figure 4.16. 
BArF
Ir PR2
ON
N
R1
N
N
R1
PR2Ir
BArF
 
Figure 4.16 Possible rigidification of the phosphine- and phosphinite-NHC iridium 
complexes 121 and 131. 
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 Synopsis 
5.1 Synopsis 
The general objective of this research work was to investigate the potential of N-heterocyclic 
carbenes as ligands for the asymmetric iridium-catalysed hydrogenation of olefins and imines. 
In this context, efficient synthetic routes were developed to access three new classes of NHC-
based ligands. The first class consists of chiral monodentate C2-symmetric NHCs which are 
combined with two different co-ligands, pyridine or triphenylphosphine, in order to give rise 
to direct analogues of Crabtree's catalyst. In the second class, the NHC is tethered to a chiral 
oxazoline unit and forms a six-membered-chelate ring upon complexation. Finally, the third 
class of ligands consists of bidentate ligands, in which the NHC is linked to either a 
phosphine or a phosphinite moiety. 
Analogues of Crabtree’s catalyst bearing a chiral C2-symmetric NHC 
Six iridium complexes, analogues of Crabtree's catalyst bearing monodentate NHCs, were 
synthesised starting from readily available enantiopure C2-symmetric imidazolium salts 
(Figure 5.1). 
N N N N
O O
Ir N
Ir
N N
O O
Ir PPh3
N N
Ir PPh3
N
N N
Ir N
N N
Ir N
PF6
PF6 PF6
PF6BArF BArF
(S,S)-62 (S,S)-63
(S,S)-69(R,R)-66
(S,S)-67(R,R)-64
 
Figure 5.1 Analogues of Crabtree's catalyst. 
Characterisation by crystallographic studies and 2D NMR gave insight into the geometry of 
the complexes and their dynamic behaviour. The catalytic activity of these new iridium 
complexes was tested in the enantioselective hydrogenation of a range of unfunctionalised 
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olefins. Full conversion of trisubstituted olefins was only obtained under forcing conditions 
(50 bar H2, 100C°, 16h). Higher activities were measured for terminal olefin 73, which was 
fully hydrogenated in 2 hours at room temperature and 50 bar H2. The low enantioselectivities 
observed overall (up to 44%) are probably due to the lack of rigidity of such compounds 
compared to chelate complexes. 
Oxazoline-NHC ligands 
Two sets of oxazoline-NHC iridium complexes 81a-f and 90a-o were synthesised (Figure 
5.2).  
N
NO
N
R1 R3
BArF
N
N
O
N
R2 R3
IrIr
BArF
R1 =
90a-o81a-f
iPr
tBu
R2 = tBu
1-Ad
2,6-Me2C6H3
R3 = Me, iPr, tBu
2,4,6-Me3C6H2
neopentyl, isobutyl  
Figure 5.2 Oxazoline-NHC iridium complexes. 
Simple and efficient syntheses, which enable easy variation of the ligand substituents, were 
developed for both classes. X-ray data analysis of one compound from each library confirmed 
that the electronic properties of the iridium are similar to those observed in Ir-P,N complexes. 
Complexes 81a-f and 90a-o were successfully tested in the asymmetric hydrogenation of 
unfunctionalised olefins. The high asymmetric inductions obtained (ee value up to 90% with 
trans-α-methylstilbene) were attributed to the rigidity generated by the six-membered chelate 
ring. Despite the wide range of catalysts investigated, the enantiomeric excesses measured 
with our two families did not compete with the most efficient Ir-P,N complexes. 
Phosphine/phosphinite-NHC ligands 
Three new iridium phosphine-NHC complexes 121a-c (R1 = Me, iPr and mesityl) were 
synthesised and fully characterised by X-ray diffraction studies and 2D NMR analysis (Figure 
5.3). 
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An efficient four step synthesis was developed from 2-phenyl oxirane, giving access to 
iridium complex 131. The electronic properties of the two types of iridium complexes were 
investigated by X-ray analyses and NMR studies. In contrast to Ir-P,N and oxazoline-NHC 
complexes, almost no difference of the trans influence exerted on the two cod double bonds 
was observed. 
BArF
Ir PPh2
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N
131
N
N
R1
PPh2Ir
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Figure 5.3 Phosphine/phosphinite-NHC iridium complexes. 
The four complexes were tested in the enantioselective hydrogenation of olefins. Low 
conversion values were measured in the hydrogenation of unfunctionalised olefins. However, 
promising activities (approximate TOF value of 400 h-1) were found when functionalised 
substrates such as allylic alcohol and imines were hydrogenated. The moderate 
enantioselectivities measured throughout the screen are thought to originate from the lack of 
rigidity of the two types of complexes, which display conformers at room temperature as 
shown by 2D NMR analyses. 
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 Experimental 
6.1 General aspects 
6.1.1 Analytical techniques 
TLC 
Macherey-Nagel Polygram plates (40 x 80 mm) SIL G/UV254 (0.2 mm silica gel) with 
fluorescence indicator or ALOX/UV254 (0.2 mm aluminium oxide) were used for thin-layer 
chromatography. 
Melting points 
Melting points were measured with Büchi 535 melting point apparatus and are not corrected. 
Optical rotation [ ]  20Dα
Optical rotations were measured with a Perkin Elmer Polarimeter 341 (l = 1 dm, c in 
g/100 ml). 
NMR spectra 
NMR spectra were recorded on Bruker Avance 250, 400 and 500 MHz spectrometers 
equipped with BBO broadband. When needed the signal were assigned by 2D NMR 
experiments (APT, DEPT, COSY, HMQC, HMBC and NOESY). 
For 1H-NMR and 13C-NMR spectra, solvent signals were used as internal reference: 
1H NMR: δ = 7.26 ppm (CHCl3), δ = 5.32 ppm (CH2Cl2). 
13C{1H} NMR: δ = 77.1 ppm (CHCl3), δ = 53.5 ppm (CH2Cl2). 
For 31P{1H} NMR, the following external references were used: 
Bruker Avance 250 and 400 MHz: H3PO4 = 0 ppm 
Bruker Avance 500 MHz: P=(PhO)3 = -18 ppm 
IR 
IR spectra were recorded on a Perkin Elmer 1600 series FTIR spectrometer. Spectra of liquids 
were measured as neat film between two NaCl plates; those of solids as KBr discs. 
MS 
EI and FAB mass spectra were recorded by Dr H. Nadig at the Department of Chemistry at 
the University of Basel on mass spectrometers VG70-250 (EI) and Finnigan MAT 312 (FAB), 
using 3-nitrobenzyl alcohol (3-NBA) as matrixes and sometimes KCl as additive in the latter 
case. The data are given in mass units per charge (m/e), and the intensities of the signals are 
indicated in percent of the basis ion. 
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Low resolution ESI (electrospray ionisation) mass spectra were measured by Dr Bruno Bulic, 
Dr Cara Humphrey, Dr Christian Markert and Antje Teichert with a Finnigan MAT LCQ 
octapole mass spectrometer. 
EA 
Elemental analyses were carried out by Mr Kirsch at the Department of Chemistry at the 
University of Basel on Leco CHN-900 (C-, H-, N-detection) and Leco RO-478 (O-detection) 
analysers. The data are indicated in mass percents. 
GC 
Carlo Erba HRGC Mega2 Series MFC 800 chromatographs were used. Achiral separation 
were mostly performed on the column Restek Rtx-1701, 0.25 μm, 30 m, 60 kPa He or H2. 
HPLC 
For HPLC analysis, Shimadzu systems with a SCL-10A system controller, CTO-10AC 
column oven, LC10-AD pump system, DGU-14A degasser and a SPD-M10A diode array 
detector or a UV-vis detector (220 and 254 nm) were used. Chiral columns Chiracel OD-H, 
OB-H, OJ and Chiralpak AD from Daicel Chemical Industries Ltd. were used. 
6.1.2 Working techniques and reagents 
Reaction with air- or moisture-sensitive products were performed under Ar using standard 
Schlenk techniques or under purified N2 in a MBraun glovebox (H2O < 1 ppm, O2 < 1 ppm). 
Glasware was oven dried and flame dried prior to use. 
Diethyl ether, pentane and tetrahydrofuran were dried over potassium or 
sodium/benzophenone, dichloromethane over CaH2 and freshly distilled under a stream of 
nitrogen prior to use. Other solvents were purchased dry at Fluka or Aldrich in septum sealed 
bottles and kept in an inert atmosphere over molecular sieves. When needed, solvents were 
degassed prior to use by three freeze-pump-thaw cycles. 
Chromatography purifications were performed on silica gel (silica gel 60, Merck-Schuchardt, 
particle size 40-63 μm, 230-400 mesh) or alox (Aldrich, activated, basic Brockmann I, ~150 
mesh, adjusted to grade III by adding 6% of water). Pressurised air or nitrogen were used to 
accelerate the purification. 
General conditions for catalytic hydrogenation at elevated pressure 
In a glove box, 0.1 mmol substrate, 1 mol% iridium complex and 0.5 ml CH2Cl2 were 
subsequently added to a 60 ml autoclave (Premex AG, Lengnau, Switzerland) with 4 glas 
inserts (1.5 ml) and magnetic stir bars. The autoclave was pressurised at 50 bar H2 (Carbagas 
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Switzerland, 99.995%) and stirred for 2 hours. After pressure release, the solvent was 
evaporated and heptane (3 ml) was added. The resulting suspension was filtered through a 
short plug of silica gel eluting with mixture of hexane and Et2O (typically 1:1) and the filtrate 
was analysed by GC and chiral HPLC to determine conversion and enantioselectivity (for 
analytical procedures and data, see J. Blankenstein and A. Pfaltz, Angew. Chem., Int. Ed. 
2001, 40, 4445-4447.) 
General conditions for catalytic hydrogenation at low pressure (1 bar H2) 
A solution of 0.1 mmol substrate with 1 mol% iridium complex in dry CH2Cl2 (2-3 ml) was 
prepared under inert atmosphere in a 20 ml Schlenk flask (Ø ~1.5 cm). The reaction mixture 
was stirred for ½-2 hours with slow bubbling of hydrogen gas through the solution, 
introduced through a stainless-steel needle. The temperature was kept constant at 25°C by a 
water bath. Work-up and analyses were performed as described for the hydrogenation at high 
pressure. 
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6.2 Analogues of Crabtree’s catalyst bearing chiral 
C2-symmetric NHC 
6.2.1 Synthesis of diamines 48, 52a and 52b 
(R,R)-N,N'-bis-(1-phenyl-ethyl)-ethane-1,2-diamine 48 
NH HN
 
1,2-dichlorethane (10.21 g, 103 mmol) was added over 1 ½ hours to (R)-1-phenyl-ethylamine 
(25.0 g, 206 mmol) heated at 100°C. After 16 hours, the reaction mixture was cooled at 70°C 
and saturated aqueous KOH was added until the formation of two phases. The mixture was 
then extracted three times with CH2Cl2. The combined organic layers were washed with brine 
and dried over anhydrous sodium sulfate an concentrated in vacuo to yield a yellow oil. The 
crude product was purified by distillation to yield a colourless oil (21.0 g, 78.3 mmol, 71%). 
b.p. 140-142°C at 0.15 mbar; 
[ ]20Dα = + 66.9 (c = 1.00, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 7.36-7.20 (m, 10H; arom CH); 3.66 (q, 3J(H,H) = 
6.6 Hz, 2H; CHCH3), 2.53 (mc, 4H; NCH2), 1.79 (br, 2H; NH), 1.34 (d, 3J(H,H) = 6.6 Hz, 
6H; CHCH3); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 146.1 (2C; arom C), 128.8 (4C; arom CH), 
127.2 (2C; arom CH), 127.0 (4C; arom CH), 58.6 (2C; CHCH3), 47.6 (2C; NCH2), 24.8 (2C; 
CHCH3); 
IR (NaCl): ν~  =  2962m, 2875w, 1598w, 1495w, 1464w, 1358m, 1189m, 1177s, 1097w, 
1019w, 993w, 940m, 884m, 816m, 786w, 730w, 664m cm-1; 
MS (FAB): m/z (%): 269 (56) [M + H]+, 105 (100); 
EA calcd (%) for C8H16ClNO2 (268.40): C 80.55, H 9.01, N 10.44; found: C 79.89, H 8.98, 
N 10.56. 
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(S,S)-1,2-diphenyl-N,N'-di-o-tolyl-ethane-1,2-diamine 52a 
NH HN
 
A solution of Pd(OAc)2 (52 mg, 0.231 mmol), (±)BINAP (288 mg, 0.463 mmol), NaOtBu 
(1.36 g, 14.15 mmol) in toluene (80 ml) was stirred at room temperature. After 20 minutes, 
(S,S)-diphenylethylenediamine (1.00 g, 4.71 mmol) and 1-bromo-2-methyl-benzene (1.69 g, 
9.90 mmol) were added to the mixture. The reaction mixture was stirred at 100°C for 16 hours 
then concentrated in vacuo to remove the toluene. The crude oil was purified by 
chromatography on silica gel eluting with a mixture of ethyl acetate and hexane (1:9) to yield 
a white solid (1.52 g, 3.86 mmol, 82%). If an oil is obtained at the end of the chromatography, 
trituration of the crude product in hexane produces white crystal. 
Rf = 0.50 (EtOAc/Hexane 1:9); 
m.p. 111-112°C (hexane); 
[ ]20Dα = -153.1 (c = 0.50, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 7.32-7.22 (m, 10H; arom CH), 7.04 (d, J(H,H) = 
7.3 Hz, 2H; arom CH), 6.92 (t, J(H,H) = 7.7 Hz, 2H; arom CH), 6.63 (t, J(H,H) = 7.4 Hz, 2H; 
arom CH), 6.31 (d, J(H,H) = 8.1 Hz, 2H; arom CH), 4.74 (s, 2H; NHCH), 4.52 (br, 2H; NH), 
2.17 (s, 6H; arom CH3); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 145.4 (2C; arom CH), 140.4 (2C; arom CH), 
130.4 (2C; arom CH), 129.1 (4C; arom CH), 128.1 (2C; arom CH), 127.6 (4C; arom CH), 
127.3 (2C; arom CH), 123.3 (2C; arom CH), 118.1 (2C; arom CH), 112.2 (2C; arom CH), 
64.3 (2C; NHCH), 18.0 (2C; CH3); 
IR (KBr): ν~  = 3411m, 3023m, 2918w, 2852m, 1606m, 1588m, 1508s, 1481m, 1450m, 
1346m, 1312m, 1264m, 1200w, 1130m, 1070w, 1051m, 1030w, 986w, 758m, 745s, 699s, 
518w, 442w cm-1; 
MS (FAB): m/z (%): 393 (4) [M + H]+, 196 (100); 
EA calcd (%) for C28H28N2 (392.55): C 85.67, H 7.19, N 7.14; found: C 85.51, H 6.95, 
N 7.11. 
 115
Chapter 6 
(S,S)-N,N'-bis-(2-isopropyl-phenyl)-1,2-diphenyl-ethane-1,2-diamine 52b 
NH HN
 
A solution of Pd(OAc)2 (52 mg, 0.231 mmol), (±)BINAP (288 mg, 0.463 mmol), NaOtBu 
(1.36 g, 14.15 mmol) in toluene (80 ml) was stirred at room temperature. After 20 minutes, 
(S,S)-diphenylethylenediamine (1.00 g, 4.71 mmol) and 1-bromo-2-isopropyl-benzene 
(1.97 g, 9.90 mmol) were added to the mixture, which was subsequently stirred at 100°C for 
14 hours. Hexane (100 ml) was added to the cooled mixture. Filtration through a plug of silica 
gel followed by concentration in vacuo gave a yellow oil, which was triturated in hexane to 
yield as a white solid (1.86 g, 4.14 mmol, 88%). 
Rf = 0.56 (EtOAc/Hexane 1:9); 
m.p. 85-86°C (hexane); 
[ ]20Dα = -141.8 (c = 0.39, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 7.35-7.20 (m, 10H; arom CH), 7.11 (d, J(H,H) = 
7.6 Hz, 2H; arom CH), 6.89 (t, J(H,H) = 7.5 Hz, 2H; arom CH), 6.69 (t, J(H,H) = 7.4 Hz, 2H; 
arom CH), 6.30 (d, J(H,H) = 8.1 Hz, 2H; arom CH), 4.75 (s, 2H; NHCH), 4.66 (br, 2H; NH), 
2.89 (hept, 3J(H,H) = 6.8 Hz, 2H; CH(CH3)2), 1.30 (d, 3J(H,H) = 6.8 Hz, 6H; CH(CH3)2), 1.16 
(d, 3J(H,H) = 6.8 Hz, 6H; CH(CH3)2); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 143.9 (2C; arom CH), 140.5 (2C; arom CH), 
133.6 (2C; arom CH), 129.1 (4C; arom CH), 128.1 (2C; arom CH), 127.5 (4C; arom CH), 
126.8 (2C; arom CH), 125.3 (2C; arom CH), 118.3 (2C; arom CH), 112.9 (2C; arom CH), 
64.3 (2C; NHCH), 27.8 (2C; CH(CH3)2), 22.9 (CH(CH3)2), 22.7 (CH(CH3)2); 
IR (KBr): ν~  = 3413w, 3061w, 3027w, 2960m, 2868m, 1603m, 1584m, 1505s, 1451m, 
1356w, 1301m, 1278m, 1258m, 1119w, 1078w, 927w, 893w, 774w, 744m, 700m, 521w cm-1; 
MS (FAB): m/z (%): 449 (4) [M + H]+, 224 (100); 
EA calcd (%) for C32H36N2 (448.65): C 85.67, H 8.09, N 6.24; found: C 85.42, H 8.11, 
N 6.04. 
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6.2.2 Synthesis of imidazolium salts 53a and 53b and 49 
(S,S)-[4,5-diphenyl-1,3-di-o-tolyl-4,5-dihydro-3H-imidazol-1-ium]-tetrafluoroborate 53a 
N N
BF4
 
A solution of diamine 52a (300 mg, 0.764 mmol) and NH4BF4 (84 mg, 0.80 mmol) in 
triethylorthoformate (1.0 ml, 6.5 mmol) was heated at 110°C for 5 hours. The crude oil was 
decanted and precipitation occurred upon addition of Et2O. The white solid was washed three 
times with Et2O and dissolved in CH2Cl2 (5 ml). The organic layer was filtered and 
concentrated in vacuo to yield a white solid (371mg, 0.756 mmol, 99%). 
m.p. 114-116°C; 
[ ]20Dα = -381 (c = 0.10, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 8.27 (s, NCHN), 7.45-7.32 (m, 12H; arom CH), 
7.22-7.09 (m, 6H; arom CH), 5.77 (s, 2H; NHCH), 2.44 (s, 6H; CH3); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 157.9 (NCHN), 133.92 (2C), 133.90 (2C), 
133.1 (2C), 132.1 (2C), 130.8 (2C), 130.5 (2C), 130.1 (4C), 128.6 (4C), 128.2 (2C), 128.1 
(2C), 76.6 (2C; NHCH), 18.0 (2C; CH3); 
IR (KBr): ν~  = 3063w, 1619s, 1600s, 1578m, 1495m, 1457m, 1269m, 1213m, 1190m, 
1059brs, 885w, 822w, 764m, 700m, 633w, 583w, 546w, 521w, 456w cm-1; 
MS (FAB): m/z (%): 403 (100) [M – BF4]+; 
EA calcd (%) for C29H27BF4N2 (490.34): C 71.04, H 5.55, N 5.71; found: C 70.58, H 5.51, 
N 5.78. 
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(S,S)-[1,3-bis-(2-isopropyl-phenyl)-4,5-diphenyl-4,5-dihydro-3H-imidazol-1-ium]-
tetrafluoroborate 53b 
N N
BF4
 
Synthesis according to the previous general procedure using diamine 52b (902 mg, 
2.01 mmol), NH4BF4 (253 mg, 2.41 mmol) and triethylorthoformate (2.5 ml) yielded an 
amorphous white hygroscopic solid (1066 mg, 1.95 mmol, 97%). 
m.p. not measurable due to the product hygroscopicity; 
[ ]20Dα = -94.2 (c = 0.20, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 8.27 (s, 1H; NCHN), 7.53 (mc, 2H; arom CH), 
7.48-7.28 (m, 14H; arom CH), 7.19 (mc, 2H; arom CH), 5.80 (s, 2H; NHCH), 3.12 (hept, 3J = 
6.8 Hz, 2H; CH(CH3)2), 1.32 (d, 3J(H,H) = 6.8 Hz, 6H; CH(CH3)2), 1.17 (d, 3J(H,H) = 6.8 Hz, 
6H; CH(CH3)2); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 157.8 (NCHN), 145.2 (2C; arom), 133.2 
(2C; arom), 131.3 (br, 4C; arom), 130.9 (2C; arom), 130.1 (4C; arom), 129.0 (4C; arom), 
128.6 (2C; arom), 128.1 (2C; arom), 127.4 (2C; arom), 29.0 (2C; CH(CH3)2), 25.0 (2C; 
CH(CH3)2), 24.4 (2C; CH(CH3)2), 2C NCHCHN under the CH3Cl signal; 
IR (KBr): ν~  = 3367w, 3282w, 3065w, 2967m, 2931w, 2872w, 1710w, 1619s, 1600m, 
1576m, 1491m, 1457m, 1389w, 1367w, 1276m, 1228m, 1213m, 1183w, 1059sbr, 877w, 
761m, 700m, 634w, 572w, 521m cm-1; 
MS (FAB): m/z (%): 459 (100) [M – BF4]+. 
 (R,R)-[1,3-bis-(1-phenyl-ethyl)-4,5-dihydro-3H-imidazol-1-ium]-tetrafluoroborate 49 
N N
BF4  
Synthesis according to the previous general procedure using diamine 48 (2.00 g, 7.45 mmol), 
NH4BF4 (937 mg, 8.94 mmol) and triethylorthoformate (6.5 ml) yielded a white solid (2.54 g, 
6.93 mmol, 97%). 
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m.p. 115-116°C; 
[ ]20Dα = -18.1 (c = 0.50, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 8.44 (s, 1H; NCHN), 7.41-7.28 (m, 10H; arom 
CH), 4.95 (q, 3J(H,H) = 6.9 Hz, 2H; CHCH3), 3.68 (mc, 4H; NCH2), 1.74 (d, 3J(H,H) = 6.9 
Hz, 6H; CHCH3); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 155.1 (NCHN), 137.9 (2C; arom C), 129.7 
(4C; arom CH), 129.3 (2C; arom CH), 127.4 (4C; arom CH), 58.6 (2C; NCH), 46.7 (2C; 
NCH2), 19.3 (2C; CH3) 
IR (KBr): ν~  = 3112w, 3031w, 2982w, 2943w, 2898w, 1638s, 1509w, 1495w, 1455m, 
1355w, 1330w, 1303w, 1269m, 1199m, 1127m, 1044s, 774m, 708m, 638w, 604w, 586w, 
542w, 521w, 507w, 464w cm-1; 
MS (FAB): m/z (%): 279 (100) [M – BF4]+; 
EA calcd (%) for C19H23N2BF4 (366.21): C 62.32, H 6.33, N 7.65; found: C 62.31, H 6.26, 
N 7.55. 
6.2.3 Synthesis of iridium precursors 58a and 58b 
(η4-1,5-cyclooctadiene)bis(pyridine)iridium(I)-hexafluorophosphate 58a 
PF6
Ir
N N
 
A solution of [(η4-cod)IrCl]2 (420 mg, 0.625 mmol), pyridine (0.7 ml, 8.7 mmol) and NH4PF6 
(310 mg, 1.90 mmol) in a degassed acetone water mixture (1:1, 20 ml) was stirred under 
argon at room temperature for 12 hours, or until the red solid has dissolved. The solution was 
concentrated in vacuo until the volume of the mixture was reduced to approximately 10 ml. 
The precipitate was filtered and washed with three portions (5 ml) of degassed water to yield 
a yellow crystalline solid (732 mg, 1.21 mmol, 97%). 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 8.72 (mc, 4H; arom CH), 7.72 (mc, 2H; arom 
CH), 7.48 (mc, 4H; arom CH), 3.83 (mc, 4H; cod CH), 2.47 (mc, 4H; cod CH2), 1.82 (mc, 
4H; cod CH2); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 150.1 (4C; arom CH), 139.1 (2C; arom CH), 
127.3 (4C; arom CH), 71.2 (4C; cod CH), 31.4 (8C; cod CH); 
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IR (KBr): ν~  = 3111w, 2980w, 2919w, 2890w, 2839w, 1605w, 1483w, 1449w, 1331w, 
1214w, 1158w, 1069w, 1006w, 835wbr, 762m, 698m, 556m, 493w; 
MS (FAB): m/z (%):459 (100) [M – PF6]+, 380 [M - PF6 – pyridine]+, 
EA calcd (%) for C18H22F6IrN2P (603.55): C 35.82, H 3.67, N 4.64; found: C 35.90, H 3.52, 
N 4.50. 
 (η4-1,5-cyclooctadiene)bis(pyridine)iridium(I)-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 
58b. 
BArF
Ir
N N
 
A solution of [(η4-cod)IrCl]2 (420 mg, 0.625 mmol), pyridine (0.7 ml, 8.7 mmol) and NaBArF 
(1.683 g, 1.90 mmol) in CH2Cl2 (20 ml) was stirred under argon at room temperature for 12 
hours. The solution was filtered and concentrated in vacuo to yield a yellow crystalline solid 
(1.566 mg, 1.18 mmol, 95%). 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 8.45 (mc, 4H; arom CH), 7.70 (mc, 8H; BArF 
ortho CH), 7.61 (mc, 2H; arom CH), 7.50 (mc, 4H; BArF para CH), 7.30 (mc, 4H; arom CH), 
3.81 (mc, 4H; cod CH), 2.39 (mc, 4H; cod CH2), 1.86 (mc, 4H; cod CH2); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 162.0 (q, 1J(B,C) = 49.9 Hz, 4C; BArF quat. 
C ipso to B), 149.4 (4C; arom CH), 139.6 (2C; arom CH), 135.2 (br, 8C; BArF ortho CH), 
129.4 (q, 2J(F,C) = 31.1 Hz, 8C; BArF C ipso to CF3), 127.4 (4C; arom CH), 124.9 (q, 1J(F,C) 
= 272.5 Hz, 8C; BArF CF3), 117.5 (br, 4C; BArF para CH), 72.0 (4C; cod CH), 31.6 (8C; cod 
CH); 
IR (KBr): ν~  = 3182w, 3069w, 2977w, 2889w, 2841w, 1611w, 1438m, 1357s, 1279s, 1127s, 
935w, 889m, 840w, 779w, 745w, 709m, 676m, 542w; 
MS (FAB): m/z (%): 459 (45) [M - BArF]+, 380 [M - BArF - pyridine]+, 
EA calcd (%) for C50H34BF24IrN2 (1321.79): C 45.43, H 2.59, N 2.12; found: C 45.58, 
H 2.41, N 2.20. 
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6.2.4 Synthesis of iridium complexes 62-69 
(S,S)-[(η4-1,5-cyclooctadiene)-(4,5-diphenyl-1,3-di-o-tolyl-imidazol-2-ylidene)-
(pyridine)iridium(I)]-hexafluorophosphate 62. 
N N
Ir N
PF6
 
Schwesinger base BEMP (224 mg, 0.816 mmol) was added to a solution of iridium complex 
58a (492 mg, 0.816 mmol) and imidazolium salt 53a (400 mg, 0.816 mmol) in CH2Cl2 
(20 ml). The reaction was stirred at room temperature for 6 hours then concentrated in vacuo 
to remove CH2Cl2. The crude product was purified by chromatography on silica gel eluting 
with 1% methanol in CH2Cl2 to yield a yellow solid. The complex was crystallised from a 
mixture of Et2O and CH2Cl2 to yield a yellow crystalline solid (393 mg, 0.424 mmol, 52%). 
Single crystals suitable for X-ray diffraction analysis were obtained by layering a saturated 
solution of the complex in CH2Cl2 with Et2O. 
[ ]20Dα = -250 (c = 0.287, CH2Cl2); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.92 (mc, 1H; pyr CH), 7.82 (mc, 2H; pyr CH), 
7.71 (mc, 1H; arom CH), 7.56 (mc, 1H; arom CH), 7.50-7.25 (m, 13H; 11 x arom CH, 2 x pyr 
CH), 7.23-7.13 (m, 3H; arom CH), 7.06 (mc, 2H; arom CH), 5.4 (d, 3J(H,H) = 5.5 Hz, 1H; 
NCH), 5.15 (d, 3J(H,H) = 5.3 Hz, 1H; NCH), 4.16 (mc, 1H; cod CH), 3.74 (mc, 1H; cod CH), 
3.19 (mc, 2H; cod CH), 2.42 (s, 3H; CH3), 2.37 (mc, 1H; cod CH2), 2.01 (mc, 2H; cod CH2), 
1.85 (mc, 1H; cod CH2), 1.69 (mc, 4H; 3 x CH3 + 1 x  cod CH2), 1.55 (mc, 1H; cod CH2), 
1.42 (mc, 1H; cod CH2), 1.29 (mc, 1H; cod CH2); two conformers present in a 100:7 ratio, 
only the major conformer is described; 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 202.7 (NCN), 151.1 (2C, pyr CH), 139.1 (C, 
pyr CH), 138.5 (arom C), 138.4 (arom C), 137.9 (arom C), 137.8 (arom C), 135.9 (arom C), 
134.1 (arom C), 132.5 (arom CH), 132.4 (arom CH), 131.4 (br, 2C; arom CH), 130.1 (br, 
arom CH), 130.0 (br, arom CH), 129.5 (br, arom CH), 127.3 (br, arom CH), 127.1 (br, arom 
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CH), 127.0 (2C; pyr CH), 85.6 (cod CH), 84.0 (cod CH), 76.5 (NCH), 76.3 (NCH), 65.5 (cod 
CH), 65.1 (cod CH), 33.7 (cod CH2), 31.3 (cod CH2), 30.5 (cod CH2), 28.5 (cod CH2), 19.8 
(CH3), 18.6 (CH3); 
IR (KBr): ν~  = 3028w, 2948w, 2882w, 2834w, 1605w, 1491m, 1458m, 1413m, 1390m, 
1341w, 1309m, 1268m, 1236m, 1217m, 1199m, 1159w, 1115w, 1003w, 952w, 850s, 828s, 
759m, 720m, 700m, 650w, 610w, 557m, 518w, 461w cm-1; 
MS (FAB): m/z (%): 782 (28) [M – PF6]+, 701 (100), 591 (23); 
EA calcd (%) for C42H43F6N3PIr·½CH2Cl2 (969.46): C 52.65, H 4.57, N 4.33; found: C 52.94, 
H 4.50, N 4.21. 
 (S,S)-[(η4-1,5-cyclooctadiene)-[1,3-bis-(2-isopropyl-phenyl)-4,5-diphenyl-imidazol-2-
ylidene]-(pyridine)iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 63 
N N
Ir N
BArF
 
Schwesinger base BEMP (151 mg, 0.549 mmol) was added to a solution of iridium complex 
58b (726 mg, 0.549 mmol) and imidazolium salt 53b (300 mg, 0.549 mmol) in toluene 
(14 ml). The reaction was stirred at room temperature for 4 hours then concentrated in vacuo 
to remove toluene. The crude product was purified by chromatography on silica gel eluting 
with a mixture of CH2Cl2 and pentane (1:1) to yield a yellow solid. The complex was 
crystallised from a mixture of Et2O and pentane to yield a yellow crystalline product (289 mg, 
0.170 mmol, 31%). 
[ ]20Dα = +138 (c = 0.237, CHCl3); 
IR (KBr): ν~  = 3038w, 2968w, 2930w, 2890w, 2843w, 1609w, 1488m, 1458m, 1413m, 
1355s, 1277s, 1127s, 898m, 887m, 839m, 756w, 711m, 698m, 682m, 869m, 542w cm-1; 
MS (FAB): m/z (%): 838 (19) [M – BArF]+, 757 (100), 647 (49); 
EA calcd (%) for C78H63BF24IrN3 (1701.36): C 55.07, H 3.73, N 2.47; found: C 55.04, 
H 3.60, N 2.33. 
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 (R,R)-[(η4-1,5-cyclooctadiene)-[1,3-bis-(1-phenyl-ethyl)-imidazol-2-ylidene]-
(pyridine)iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 64. 
N N
Ir N
BArF
 
Schwesinger base BEMP (137 mg, 0.500 mmol) was added to a solution of iridium complex 
58b (661 mg, 0.500 mmol) and imidazolium salt 49 (183 mg, 0.549 mmol) in toluene (12 ml). 
The reaction was stirred at room temperature for 4 hours then concentrated in vacuo to 
remove toluene. The crude product was purified by chromatography on silica gel eluting with 
a mixture of CH2Cl2 and pentane (1:1) to yield a yellow crystalline solid. (236 mg, 
0.155 mmol, 31%). 
[ ]20Dα = -26 (c = 0.146, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.13 (mc, 2H; pyr CH), 7.71 (mc, 8H; BArF ortho 
CH), 7.52 (mc, 5H; 4 x BArF para CH + 1 x pyr CH), 7.46-7.33 (m, 3H; arom CH), 7.31-7.18 
(m, 5H; arom CH), 7.05 (mc, 2H; pyr CH), 6.90 (mc, 2H; arom CH), 6.50 (q, 3J(H,H) = 6.9 
Hz, 2H; CHCH3), 6.43 (q, 3J(H,H) = 7.0 Hz, 1H; CHCH3), 3.83-3.77 (m, 2H; cod CH), 3.76-
3.67 (m, 2H; cod CH), 3.65-3.48 (m, 4H; NCH2), 2.40-2.25 (m, 3H; cod CH2), 2.08-1.97 (m, 
2H; cod CH2), 1.93 (mc, 1H; cod CH2), 1.82-1.65 (m, 5H; 2 x cod CH2 + 3 x CHCH3), 1.49 
(d, 3J(H,H) = 7.1 Hz, 3H; CHCH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 203.7 (NCN), 161.8 (q, 1J(B,C) = 49.9 Hz, 
4C; BArF quat. C ipso to B), 150.5 (2C, pyr CH), 140.3 (arom C), 139.4 (arom C), 138.3 (pyr 
CH), 134.9 (br, 8C; BArF ortho CH), 129.4 (2C; arom CH), 129.3 (2C; arom CH), 129.0 (qq, 
2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 128.5 (arom CH), 128.2 
(arom CH), 126.6 (2C; pyr CH), 126.0 (2C; arom CH), 125.2 (2C; arom CH), 124.6 (q, 
1J(F,C) = 272.5 Hz, 8C; BArF CF3), 117.6 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para CH), 85.1 
(cod CH), 84.7 (cod CH), 65.6 (cod CH), 65.4 (cod CH), 58.3 (CHCH3), 58.0 (CHCH3), 44.2 
(NCH2), 43.9 (NCH2), 33.1 (cod CH2), 31.8 (cod CH2), 30.2 (cod CH2), 29.2 (cod CH2), 
19.68 (NCH3), 19.63 (NCH3); 
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IR (KBr): ν~  = 2925w, 1609w, 1487m, 1449m, 1355s, 1275s, 1124s, 931w, 885m, 839m, 
753w, 714m, 698m, 681m, 669m cm-1; 
MS (FAB): m/z (%): 658 (11) [M – BArF]+, 579 (100) [M – BArF – pyridine]+, 469 (93); 
EA calcd (%) for C64H51BF24IrN3 (1521.11): C 50.54, H 3.38, N 2.76; found: C 50.56, 
H 3.31, N 2.70. 
 (R,R)-[(η4-1,5-cyclooctadiene)-[1,3-bis-(1-phenyl-ethyl)-imidazol-2-ylidene]iridium(I)]-
chloride 65. 
N N
Ir Cl
 
Schwesinger base BEMP (100 mg, 0.366 mmol) was added to a solution of [(η4-cod)IrCl]2 
(123 mg, 0.184 mmol) and imidazolium salt 49 (200 mg, 0.366 mmol) in THF (10 ml). The 
reaction was stirred at room temperature for 6 hours then concentrated in vacuo to remove 
THF. The crude product was purified by chromatography on silica gel eluting with a mixture 
of ethyl acetate and hexane (1:10) to yield a yellow solid (157 mg, 0.256 mmol, 70%). Single 
crystals suitable for X-ray diffraction analysis were obtained by layering a saturated solution 
of the complex in CH2Cl2 with pentane. 
[ ]20Dα = +34 (c = 0.139, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.71 (mc, 2H; arom CH), 7.42-7.34 (m, 6H; arom 
CH), 7.34-7.26 (m, 2H; arom CH), 6.55 (q, 3J(H,H) = 7.0 Hz, 1H; CHCH3), 6.45 (q, 3J(H,H) 
= 7.0 Hz, 1H; CHCH3), 4.60 (mc, 2H; cod CH), 3.38 (mc, 2H; NCH2), 3.29-3.15 (m, 3H; 
2 x cod CH + 1 x NCH2), 3.08 (mc, 1H; NCH2), 2.32-2.04 (m, 4H; cod CH2), 1.80-1.65 (m, 
9H; 6 x CH3 + 3 x  cod CH2), 1.55 (mc, 1H; cod CH2); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 205.8 (NCN), 141.1 (arom C), 139.4 (arom 
C), 128.7 (2C; arom CH), 128.5 (2C; arom CH), 127.8 (2C; arom CH), 127.6 (arom CH), 
127.4 (arom CH), 127.0 (2C; arom CH), 85.1 (cod CH), 85.0 (cod CH), 57.6 (CHCH3), 56.6 
(CHCH3), 52.4 (cod CH), 51.7 (cod CH), 43.3 (NCH2), 42.7 (NCH2), 33.7 (cod CH2), 33.2 
(cod CH2), 29.3 (cod CH2), 29.1 (cod CH2), 17.6 (CH3), 17.4 (CH3); 
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IR (KBr): ν~  = 2976m, 2933m, 2867m, 2834m, 1484m, 1443s, 1374m, 1321m, 1295m, 
1265s, 1213m, 1187m, 1153m, 1070w, 1025m, 966w, 863w, 786m, 756m, 702m, 649w, 
640m, 624w, 517w, 458w cm-1; 
MS (FAB): m/z (%): 614 (100), 579 (49) [M – Cl]+, 470 (75); 
EA calcd (%) for C27H34ClIrN2 (614.26): C 52.580, H 5.58, N 4.56; found: C 52.65, H 5.49, 
N 4.34. 
(R,R)-[(η4-1,5-cyclooctadiene)-[1,3-bis-(1-phenyl-ethyl)-imidazol-2-ylidene]-
(triphenylphosphine)iridium(I)]-hexafluorophosphate 66. 
N N
Ir PPh3
PF6
 
A solution of AgPF6 (61 mg, 0.244 mmol) in THF (2 ml) was added to a solution of iridium 
complex 65 (150 mg, 0.244 mmol) in a mixture of CH2Cl2 and THF (1:1, 2 ml). The mixture 
was stirred at room temperature for 10 minutes then filtered to remove silver chloride. A 
solution of PPh3 (64 mg, 0.244 mmol) in THF (2 ml) was added to the filtrate. The reaction 
mixture was stirred at room temperature for 30 minutes and was concentrated in vacuo to give 
a red solid. The crude product was purified by chromatography on silica gel eluting with 1% 
MeOH in CH2Cl2. The complex was crytallised by layering a saturated solution of the 
complex in CH2Cl2 with Et2O (219 mg, 0.222 mmol, 91%). 
[ ]20Dα = +13 (c = 0.151, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.51-7.45 (m, 3H; arom CH), 7.44-7.34 (m, 8H; 
arom CH), 7.32-7.21 (m, 7H; arom CH), 7.20-7.12 (m, 3H; arom CH), 7.11-7.04 (m, 3H; 
arom CH), 5.99 (q, 3J(H,H) = 7.1 Hz, 1H; CHCH3), 5.51 (q, 3J(H,H) = 7.2 Hz, 1H; CHCH3), 
4.36 (mc, 2H; cod CH), 4.11 (mc, 1H; NCH2), 4.00 (mc, 1H; cod CH), 3.86 (mc, 2H; NCH2), 
3.53 (mc, 1H; cod CH), 3.34 (mc, 1H; NCH2), 2.42-2.23 (m, 2H; cod CH2), 2.04 (mc, 1H; cod 
CH2), 1.92 (mc, 2H; cod CH2), 1.75 (d, 3J(H,H) = 7.1 Hz, 3H; CH3), 1.72-1.51 (m, 3H; cod 
CH2), 0.56 (d, 3J(H,H) = 7.1 Hz, 3H; CH3); 
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13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 202.7 (d, 2J(P,C) = 8.0 Hz; NCN), 142.2 
(arom C), 139.0 (arom C), 134.0, 133.9, 131.61, 131.59, 130.7 (arom C), 130.3 (arom C), 
129.3, 129.0, 128.9, 128.8, 128.1, 127.7, 127.3, 125.1, 88.1 (d, 2J(P,C) = 8.5 Hz; cod CH), 
82.9 (d, 2J(P,C) = 13.2 Hz; cod CH), 81.3 (cod CH), 78.3 (cod CH), 60.4 (CHCH3), 58.7 
(CHCH3), 45.6 (NCH2), 44.8 (NCH2), 32.34 (br, cod CH2), 32.27 (br, cod CH2), 29.7 (br, cod 
CH2), 28.6 (br, cod CH2), 20.2 (CH3), 19.5 (CH3); 
31P{1H} NMR (202.5 MHz, CDCl3, 295 K) : δ = 16.9 (s); 
IR (KBr): ν~  = 3056w, 2964w, 2885w, 2834w, 1481m, 1435m, 1327w, 1264m, 1208w, 
1149w, 1092m, 1024w, 999w, 837s, 783w, 750m, 636w, 612w, 558m, 532m, 511m, 493w, 
454w, 421w cm-1; 
MS (FAB): m/z (%): 841 (100) [M – BArF]+, 577 (20), 471 (68) [M – BArF – PPh3]+; 
EA calcd (%) for C45H49F6IrN2P2 (986.06): C 54.81, H 5.01, N 2.84; found: C 54.70, H 4.87, 
N 2.70. 
 (S,S)-[(η4-1,5-cyclooctadiene)-(isopropyl-bioxazolin-ylidene)-(pyridine)iridium(I)]-
hexafluorophosphate 67. 
N N
O O
Ir N
PF6
 
Schwesinger base BEMP (142 mg, 0.517 mmol) was added to a solution of iridium complex 
58a (312 mg, 0.517 mmol) and imidazolium salt 55 (200 mg, 0.517 mmol) in CH2Cl2 (20 ml). 
The reaction was stirred at room temperature for 6 hours then concentrated in vacuo to 
remove CH2Cl2. The crude product was purified by chromatography on silica gel eluting with 
a mixture of CH2Cl2 and pentane (2:1), CH2Cl2 and 1% methanol in CH2Cl2 to yield a yellow 
solid. The complex was crystallised from a mixture of pentane and CH2Cl2 to yield a yellow 
crystalline product (338 mg, 0.445 mmol, 86%). 
[ ]20Dα = -42.2 (c = 0.50, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.53 (mc, 2H; pyr CH), 7.89 (mc, 1H; pyr CH), 
7.57 (mc, 2H; pyr CH), 4.89 (mc, 1H; oxaz CH2), 4.75 (mc, 1H; oxaz CH2), 4.71-4.62 (m, 
3H; 1 x oxaz CH + 2 x oxaz CH2), 4.08 (mc, 1H; cod CH), 3.96 (mc, 1H; oxaz CH), 3.85 (mc, 
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1H; cod CH), 3.79 (mc, 2H; cod CH), 3.26 (mc, 2H; CH(CH3)2), 2.43-2.01 (m, 4H; cod CH2), 
2.33 (mc, 2H; cod CH2), 2.00 (mc, 2H; cod CH2), 1.18 (d, 3J(H,H) = 7.1 Hz, 3H; CH(CH3)2), 
1.14 (d, 3J(H,H) = 7.1 Hz, 3H; CH(CH3)2), 0.94 (d, 3J(H,H) = 6.8 Hz, 3H; CH(CH3)2), 0.87 
(d, 3J(H,H) = 6.9 Hz, 3H; CH(CH3)2). 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 154.4 (NCN), 151.0 (2C; pyr CH), 139.4 
(1C; pyr CH), 127.6 (2C; pyr CH), 126.4 (NCO), 125.9 (NCO), 84.7 (cod CH), 83.6 (cod 
CH), 76.3 (oxaz CH2), 76.2 (oxaz CH2), 66.2 (cod CH), 62.8 (oxaz CH), 62.5 (cod CH), 61.9 
(oxaz CH), 34.6 (cod CH2), 33.2 (CH(CH3)2), 32.0 (CH(CH3)2), 31.8 (cod CH2), 31.7 (cod 
CH2), 29.2 (cod CH2), 19.35 (CH(CH3)2), 19.27 (CH(CH3)2), 14.9 (CH(CH3)2), 14.7 
(CH(CH3)2). 
31P{1H} NMR (202.5 MHz, CDCl3, 295 K) : δ = -144.1 (sept, 1J(P,F) = 711 Hz; PF6); 
IR (KBr): ν~  = 2963m, 2934m, 2890m, 2836w, 1757m, 1483m, 1466m, 1447m, 1428m, 
1395m, 1377m, 1363m, 1337m, 1241w, 1198m, 1159w, 1118w, 1056w, 1000w, 978w, 929.0 
m, 836s, 763m, 703m, 668w, 616w, 558m, 490w, 467w cm-1; 
MS (FAB): m/z (%): 616 (100) [M – PF6]+, 535 (58); 
EA calcd (%) for C26H37F6IrN3O2P·(760.78): C 41.05, H 4.90, N 5.52; found: C 40.84, 
H 4.69, N 5.36. 
 (S,S)-[(η4-1,5-cyclooctadiene)-(isopropyl-bioxazolin-ylidene)iridium(I)]-chloride 68. 
N N
O O
Ir Cl
 
Schwesinger base BEMP (106 mg, 0.388 mmol) was added to a solution of [(η4-cod)IrCl]2 
(130 mg, 0.194 mmol) and imidazolium salt 55 (150 mg, 0.388 mmol) in CH2Cl2 (10 ml). The 
reaction was stirred at room temperature for 2 hours then concentrated in vacuo to remove 
CH2Cl2. The crude product was purified by chromatography on silica gel eluting with 0.5% 
methanol in CH2Cl2 to yield a yellow solid (155 mg, 0.272 mmol, 70%). 
[ ]20Dα = +16 (c = 0.238, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 4.79 (mc, 3H; 2 x oxaz CH2 + 1 x oxaz CH), 
4.71-4.58 (m, 3H; 2 x oxaz CH2 + 1 x cod CH), 4.48 (1 x cod CH + 1 x oxaz CH), 3.34-3.18 
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(m, 2H; CH(CH3)2), 3.14 (mc, 1H; cod CH), 3.02 (mc, 1H; cod CH), 2.23-2.04 (m, 4H; cod 
CH2), 1.82-1.54 (m, 4H; cod CH2), 1.04 (mc, 6H; CH(CH3)2), 0.90 (mc, 6H; CH(CH3)2); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 158.2 (NCN), 125.1 (NCO), 124.6 (NCO), 
84.1 (cod CH), 83.8 (cod CH), 76.0 (cod CH2), 75.7 (cod CH2), 61.7 (oxaz CH), 60.8 (oxaz 
CH), 51.3 (cod CH), 50.2 (cod CH), 34.1 (cod CH2), 33.5 (cod CH2), 31.7 (CH(CH3)2), 29.9 
(CH(CH3)2), 29.8 (cod CH2), 29.3 (cod CH2), 18.89 (CH(CH3)2), 18.86 (CH(CH3)2), 14.6 
(CH(CH3)2), 14.5 (CH(CH3)2); 
IR (KBr): ν~  = 2959m, 2932m, 2875m, 2828w, 1754m, 1464m, 1427s, 1378m, 1363m, 
1337m, 1202m, 1117w, 1054w, 1002w, 959w, 931m, 883w, 859m, 830m, 740w, 704w, 
620w, 520w, 476w, 432w, cm-1; 
MS (FAB): m/z (%): 572 (50), 237 (100); 
EA calcd (%) for C21H32ClIrN2O2·(572.16): C 44.08, H 5.64, N 4.90, O 5.59; found: C 44.02, 
H 5.50, N 4.82, O 5.41. 
 (S,S)-[(η4-1,5-cyclooctadiene)-(isopropyl-bioxazolin-ylidene)-
(triphenylphosphine)iridium(I)]-hexafluorophosphate 69. 
N N
O O
Ir PPh3
PF6
 
A solution of AgPF6 (46 mg, 0.181 mmol) in THF (1 ml) was added to a solution of iridium 
complex 68 (130 mg, 0.181 mmol) in a mixture of CH2Cl2 and THF (2:1, 3 ml). The mixture 
was stirred at room temperature for 10 minutes then filtered to remove silver chloride. The 
filtrate was added to a solution of PPh3 (48 mg, 0.181 mmol) in THF (1 ml). The reaction 
mixture was stirred at room temperature for 30 minutes and was concentrated in vacuo to give 
a red solid. The crude product was purified by chromatography on silica gel eluting with 1% 
MeOH in CH2Cl2 to yield a red solid (125 mg, 0.132 mmol, 73%). 
[ ]20Dα = -47 (c = 0.115, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.52 (mc, 3H; arom CH), 7.45 (mc, 6H; arom 
CH), 7.29 (mc, 6H; arom CH), 4.98 (mc, 1H; oxaz CH2), 4.88 (mc, 1H; cod CH), 4.72 (mc, 
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1H; oxaz CH2), 4.66 (mc, 1H; oxaz CH), 4.43-4.35 (m, 2H; 1 x oxaz CH2 + 1 x cod CH), 
3.88-3.78 (m, 2H; 1 x cod CH + 1 x oxaz CH2), 3.47 (mc, 1H; cod CH), 2.97 (mc, 1H; oxaz 
CH), 2.81 (mc, 1H; CH(CH3)2), 2.50-2.31 (m, 3H; 2 x cod CH2 + 1 x CH(CH3)2), 2.30-2.14 
(m, 3H; cod CH2), 2.07-1.92 (m, 2H; cod CH2), 1.76 (mc, 1H; cod CH2), 1.04 (d, 3J(H,H) = 
7.1 Hz, 3H; CH(CH3)2), 0.96 (d, 3J(H,H) = 6.9 Hz, 3H; CH(CH3)2), 0.86 (d, 3J(H,H) = 6.8 Hz, 
3H; CH(CH3)2), 0.59 (d, 3J(H,H) = 6.8 Hz, 3H; CH(CH3)2). 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 152.7 (d, 2J(P,C) = 9.6 Hz; NCN), 133.9 (d, 
6C, J(P,C) = 10.6 Hz; arom CH), 131.6 (d, 3C, J(P,C) = 1.9 Hz, arom CH), 130.6 (d, 3C, 
1J(P,C) = 50.4 Hz; arom C), 129.2 (d, 6C, J(P,C) = 10.1 Hz; arom CH), 126.6 (NCO), 126.2 
(NCO), 87.3 (d, 2J(P,C) = 12.5 Hz, cod CH), 86.9 (d, 2J(P,C) = 11.5 Hz, cod CH), 81.8 (cod 
CH), 78.6 (cod CH), 76.4 (oxaz CH2), 75.2 (oxaz CH2), 62.8 (oxaz CH), 61.9 (oxaz CH), 32.6 
(br, cod CH2), 32.0 (br, cod CH2), 31.9 (CH(CH3)2), 31.6 (CH(CH3)2), 30.2 (br, cod CH2), 
29.4 (br, cod CH2), 20.1 (CH(CH3)2), 19.3 (CH(CH3)2), 15.5 (CH(CH3)2), 14.4 (CH(CH3)2). 
31P{1H} NMR (202.5 MHz, CDCl3, 295 K) : δ = 19.4.9 (s), -144.9 (sept, 1J(P,F) = 711 Hz; 
PF6); 
IR (KBr): ν~  = 3056w, 2962w, 2972w, 1752w, 1480w, 1435m, 1395w, 1376w, 1337w, 
1200w, 1094w, 1056w, 998w, 974w, 920w, 840s, 750w, 697m, 558m, 532m, 512w, 455w, 
421w cm-1; 
MS (ESI): m/z (%): 799.2 (100) [M – PF6]+; 
EA calcd (%) for C39H47F6IrN2O2P2·(943.96): C 49.62, H 5.02; N 2.97, O 3.39; found 
C 50.09, H 5.36; N 3.00, O 3.68. 
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6.3 Oxazoline-imidazolin-2-ylidene ligands 
6.3.1 Synthesis of chloroacetamides 78a-b 
(S)-2-chloro-N-(1-hydroxymethyl-2,2-dimethyl-propyl)-acetamide 78a 
N
H
Cl
HO
O
 
A solution of (S)-tert-leucinol (3.02 g, 25.8 mmol) and triethylamine (5.2 g, 51.6 mmol) in 
CH2Cl2 (100 ml) was cooled to -20°C under argon. Chloroacetyl chloride (2.91 g, 25.8 mmol) 
was added dropwise over 5 minutes. The cooling bath was removed and the reaction mixture 
was stirred at room temperature for 12 hours then concentrated in vacuo. Ethyl acetate was 
added (30 ml) and the mixture was filtered and concentrated in vacuo to remove the solvent. 
The crude product was purified by chromatography on silica gel eluting with AcOEt to yield a 
white solid (4.14 g, 21.4 mmol, 83%). 
Rf = 0.57, AcOEt 
m.p. 69-70°C; 
[ ]20Dα = -18.7 (c = 1.00, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 6.75 (br, 1H; NH), 4.10 (mc, 2H; ClCH2), 3.86 
(mc, 2H; CH2OH + CHCC(CH3)3), 3.62 (mc, 1H; CH2OH ), 2.13 (br, 1H; OH), 0.97 (s, 9H; 
C(CH3)3); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 167.4 (NHCO), 63.1 (NCH2OH), 60.5 
(NCHC(CH3)3), 43.3 (ClCH2), 34.0 (C(CH3)3), 27.2 (C(CH3)3); 
IR (KBr): ν~  = 3405mbr, 3277m, 2963m, 1665s, 1636s, 1531s, 1369w, 1276w, 1088w, 
1049m, 911w, 771w, 666w cm-1; 
MS (FAB): m/z (%): 194 (100) [M + H]+; 
EA calcd (%) for C8H16ClNO2 (193.67): C 49.61, H 8.33, N 7.23, O 16.52; found: C 49.22, 
H 8.37, N 7.04, O 16.68. 
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 (S)-2-chloro-N-(1-hydroxymethyl-2-methyl-propyl)-acetamide 78b 
N
H
Cl
HO
O
 
Synthesis according to the previous general procedure using (S)-valinol (5.46 g, 53.0 mmol), 
triethylamine (5.52 g, 54.6 mmol) and chloroacetyl chloride (5.95 g, 52.7  mmol) yielded a 
colourless oil (8.42 g, 89%). 
Rf = 0.45, AcOEt; 
[ ]20Dα = -34.1 (c = 1.00, CH2Cl2); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 6.75 (br, 1H; NH), 4.09 (mc, 2H; ClCH2), 3.76 
(mc, 1H; NCHCH(CH3)2), 3.71 (mc, 2H; CH2OH), 2.41 (br, 1H; OH), 1.94 (mc, 1H; 
CH(CH3)2), 0.98 (d, 3J(H,H) = 6.9 Hz, 3H; CH(CH3)2), 0.90 (d, 3J(H,H) = 7.1 Hz, 3H; 
CH(CH3)2); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 166.7 (CONH), 63.4, (CH2OH), 57.4 
(NCHCH(CH3)2), 42.8 (ClCH2), 28.9 (CH(CH3)2), 19.5 (CH(CH3)2), 18.6 (CH(CH3)2); 
IR (NaCl): ν~  =  3297mbr, 2963m, 1660sbr, 1542mbr, 1466w, 1243w, 1082w, 776w cm-1; 
MS (FAB): m/z (%): 180 (100) [M + H]+; 
EA calcd (%) for C7H14ClNO2 (179.64): C 46.80, H 7.86, N 7.80; found: C 46.93, H 7.64, 
N 7.71. 
6.3.2 Synthesis of chloromethyloxazolines 79a-b 
(S)-4-tert-butyl-2-chloromethyl-4,5-dihydro-oxazole 79a 
N
O Cl
 
A solution of chloroacetamide 78a (1.29 g, 6.65 mmol) and methyl-N-
triethylammoniosulfonyl-carbamate (1.74 g, 7.32 mmol) in THF (20 ml) was refluxed for 12 
hours. The reaction mixture was concentrated in vacuo. The residue was diluted with 
dichloromethane and extracted three times with water. The organic layer was dried over 
anhydrous magnesium sulfate and concentrated in vacuo. The crude product was purified by 
distillation (50°C, 0.1 mbar) to yield a colourless oil (1.45 g, 8.25 mmol, 50%). 
 131
Chapter 6 
b.p. 50°C at 0.1 mbar; 
[ ]20Dα = -108.5 (c = 0.94, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 4.28 (mc, 1H; CH2O), 4.15 (mc, 1H; CH2O), 4.10 
(mc, 2H; ClCH2), 3.91 (mc, 1H; NCHC(CH3)3), 0.89 (s, 9H; C(CH3)3); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 162.4 (OCN), 76.1 (NCHCH(CH3)2), 69.8 
(CH2O), 36.5 (ClCH2), 33.8 (C(CH3)3), 25.8 (C(CH3)3); 
IR (NaCl): ν~  =  2957s, 2906m, 2870m, 1671s, 1479m, 1430w, 1395w, 1360m, 1243m, 
1155w, 983s, 944w, 892w, 733w cm-1; 
MS (FAB, Xe 8 kV): m/z (%): 176 (100) [M + H]+; 
EA calcd (%) for C8H14ClNO (175.66): C 54.70, H 8.03, N 7.97; found: C 53.83, H 7.90, 
N 8.03 
 (S)-2-chloromethyl-4-isopropyl-4,5-dihydro-oxazole 79b 
N
O Cl
 
Synthesis according to the previous general procedure using chloroacetamide 78b (4.10 g, 
22.8 mmol) and Burgess reagent (5.61 g, 23.5 mmol) yielded a colourless oil (2.42 g, 66%, 
15.0 mmol). 
b.p. 42°C at 0.05 mbar; 
[ ]20Dα = -98.9 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 4.33 (mc, 1H; CH2O), 4.09 (mc, 2H; ClCH2), 
4.04 (mc, 1H; CH2O), 3.95 (mc, 1H; NCHCH(CH3)2), 1.76 (mc, 1H; CH(CH3)2), 0.95 (d, 
3J(H,H) = 7.0 Hz, 3H; CH(CH3)2), 0.87 (d, 3J(H,H) = 7.0 Hz, 3H; CH(CH3)2); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 162.3 (OCN), 72.4 (NCHCH(CH3)2), 71.2 
(CH2O), 36.4 (ClCH2), 32.5 (CH(CH3)2), 18.7 (CH(CH3)2), 18.1 (CH(CH3)2); 
IR (NaCl): ν~  =  2961s, 1669s, 1468w, 1360m, 1243m, 1155w, 982s, 891w, 718w cm-1; 
MS (FAB, Xe 8 kV): m/z (%): 162 (100) [M + H]+; 
EA calcd (%) for C7H12ClNO (161.63): C 52.02, H 7.48, N 8.67; found: C 51.57, H 7.49, 
N 8.50. 
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6.3.3 Synthesis of imidazolium salts 80a-g 
(S)-[1-(4-tert-butyl-4,5-dihydro-oxazol-2-ylmethyl)-3-methyl-3H-imidazol-1-ium]-
tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 80a 
N
O N
N
BArF  
A solution of chloromethyloxazoline 79a (235 mg, 1.33 mmol) and 1-methyl-1H-imidazole 
(93 mg, 1.33 mmol) in DMF (0.4 ml) was heated at 80°C for 8 hours. The reaction mixture 
was concentrated in vacuo at 80°C and the residue was diluted in CH2Cl2 (5 ml). NaBArF 
(1.18 g, 1.33 mmol) was added to the solution which was stirred at room temperature for 30 
minutes. The mixture was filtered and concentrated in vacuo. The crude product was purified 
by chromatography on a plug of silica gel eluting with CH2Cl2 (1L) to yield a white solid 
(1.13 g, 1.03 mmol, 78%). 
m.p. 103-104°C; 
[ ]20Dα = -8.2 (c = 0.50, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 8.31 (s, 1H; NCHN), 7.69 (mc, 8H; BArF ortho 
CH), 7.53 (mc, 4H; BArF para CH), 7.15 (mc, 1H; imid CH), 6.95 (mc, 1H; imid CH), 4.71 
(mc, 2H; NCH2), 4.27 (mc, 1H; oxaz CH2), 4.14 (mc, 1H; oxaz CH2), 3.88 (mc, 1H; oxaz 
CH), 3.70 (s, 3H, NCH3), 0.82 (s, 9H; tBu CH3); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 162.1 (q, 1J(B,C) = 49.9 Hz, 4C; BArF quat. 
C ipso to B), 158.1 (OCN), 135.7 (NCHN), 135.1 (br, 8C; BArF ortho CH), 129.3 (qq, 2J(F,C) 
= 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.9 (q, 1J(F,C) = 272.5 Hz, 8C; 
BArF CF3), 124.2 (imid CH), 123.8 (imid CH), 117.9 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para 
CH), 76.4 (oxaz CH), 71.0 (oxaz CH2), 46.7 (NCH2), 37.0 (NCH3), 33.8 (tBu C), 25.8 (3C; 
tBu CH3); 
IR (KBr): ν~  = 3185w, 2967w, 1686w, 1610w, 1356m, 1277s, 1115bs, 887w, 838w, 743w, 
711w, 682w, 671w, 623w cm-1; MS (FAB): m/z (%): 222 (100) [M - BArF]+; 
EA calcd (%) for C44H32BF24N3O (1085.52): C 48.68, H 2.97, N 3.87; found: C 48.72, 
H 2.99, N 3.84. 
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(S)-[1-(4-isopropyl-4,5-dihydro-oxazol-2-ylmethyl)-3-methyl-3H-imidazol-1-ium]-
tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 80b 
N
O N
N
BArF  
Synthesis according to the previous general procedure using chloromethyloxazoline 79b 
(623 mg, 3.85 mmol), methylimidazole (316 mg, 3.85 mmol) and NaBArF (3.41 g, 
3.85 mmol) yielded a white solid (3.02 g, 73%, 2.81 mmol). 
m.p. 93-94°C; 
[ ]20Dα = -8.7 (c = 0.50, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 8.31 (s, 1H; NCHN), 7.69 (mc, 8H; BArF ortho 
CH), 7.53 (mc, 4H; BArF para CH), 7.13 (mc, 1H; imid CH), 6.94 (mc, 1H; imid CH), 4.69 
(mc, 2H; NCH2), 4.33 (mc, 1H; oxaz CH2), 4.03 (mc, 1H; oxaz CH2), 3.89 (mc, 1H; oxaz 
CH), 3.70 (s, 3H, NCH3), 1.67 (mc, 1H; iPr CH3), 0.89 (d, 3J(H,H) = 6.6 Hz, 3H; iPr CH3), 
0.82 (d, 3J(H,H) = 6.7 Hz, 3H; iPr CH3); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 161.7 (q, 1J(B,C) = 49.9 Hz, 4C; BArF quat. 
C ipso to B), 157.9 (OCN), 135.7 (NCHN), 134.7 (br, 8C; BArF ortho CH), 129.1 (qq, 2J(F,C) 
= 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.7 (q, 1J(F,C) = 272.5 Hz, 8C; 
BArF CF3), 123.8 (imid CH), 123.3 (imid CH), 117.6 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para 
CH), 72.9 (oxaz CH), 72.5 (oxaz CH2), 46.2 (NCH2), 36.6 (NCH3) 32.4 (iPr CH), 18.5 (iPr 
CH3), 18.1 (iPr CH3); 
IR (KBr): ν~  = 3182w, 2969w, 1689w, 1610w, 1358m, 1280s, 1120bs, 889w, 835w, 740w, 
712w, 674w, 621w cm-1; 
MS (FAB): m/z (%): 208 (100) [M - BArF]+; 
EA calcd (%) for C43H30BF24N3O (1071.49): C 48.20, H 2.82, N 3.92; found: C 48.16, 
H 2.90, N 3.70. 
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 (S)-[1-(4-tert-butyl-4,5-dihydro-oxazol-2-ylmethyl)-3-isopropyl-3H-imidazol-1-ium]-
tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 80c 
N
O N
N
BArF  
Synthesis according to the previous general procedure using chloromethyloxazoline 79a 
(150 mg, 0.854 mmol), isopropylimidazole (94 mg, 0.854 mmol) and NaBArF (757 mg, 
0.854 mmol) yielded a white solid (608 mg, 64%, 0.546 mmol) 
m.p. 102-103°C; 
[ ]20Dα = -7.1 (c = 0.50, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.46 (s, 1H; NCHN), 7.68 (mc, 8H; BArF ortho 
CH), 7.52 (mc, 4H; BArF para CH), 7.15 (mc, 1H; imid CH), 7.11 (mc, 1H; imid CH), 4.71 
(mc, 2H; NCH2), 4.41 (mc, 1H; iPr CH), 4.26 (mc, 1H; oxaz CH2), 4.12 (mc, 1H; oxaz CH2), 
3.88 (mc, 1H; oxaz CH), 1.47 (mc, 6H; iPr CH3), 0.81 (s, 9H; CH3 tBu); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 161.6 (q, 1J(B,C) = 49.9 Hz, 4C; BArF quat. 
C ipso to B), 158.0 (OCN), 134.7 (br, 8C; BArF ortho CH), 133.3 (NCHN), 128.9 (qq, 2J(F,C) 
= 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.6 (q, 1J(F,C) = 272.5 Hz, 8C; 
BArF CF3), 123.4 (imid CH), 120.4 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para 
CH), 75.9 (oxaz CH), 70.6 (oxaz CH2), 54.6 (iPr CH), 46.2 (NCH2), 33.4 (tBu C), 25.4 (3C; 
tBu CH3), 22.4 (2C; iPr CH3); 
IR (KBr): ν~  = 3184w, 2982w, 1692w, 1610w, 1591w, 1561w, 1467w, 1356m, 1277s, 
1124bs, 976w, 935w, 886w, 712w, 682w cm-1; 
MS (FAB): m/z (%): 250 (100) [M - BArF]+; 
EA calcd (%) for C46H36BF24N3O (1113.57): C 49.62, H 3.26, N 3.77; found: C 49.51, 
H 3.30, N 3.74. 
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(S)-[1-(4-tert-butyl-4,5-dihydro-oxazol-2-ylmethyl)-3-(2,4,6-trimethyl-phenyl)-3H-imidazol-
1-ium]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 80d 
N
O N
N
BArF
 
Synthesis according to the previous general procedure using chloromethyloxazoline 79a 
(253 mg, 1.44 mmol), mesitylimidazole (268 mg, 1.44 mmol) and NaBArF (1.28 g, 
1.44 mmol) yielded a white solid (1.00 g, 58%, 0.840 mmol). 
m.p. 119-120°C; 
[ ]20Dα = -3.4 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.45 (s, 1H; NCHN), 7.70 (mc, 8H; BArF ortho 
CH), 7.52 (mc, 4H; BArF para CH), 7.32 (mc, 1H; imid CH), 7.18 (mc, 1H; imid CH), 4.85 
(mc, 2H; NCH2), 4.30 (mc, 1H; oxaz CH2), 4.16 (mc, 1H; oxaz CH2), 3.87 (mc, 1H; oxaz 
CH), 2.33 (mc, 3H; CaromCH3), 1.95 (mc, 6H; CaromCH3), 0.79 (s, 9H; tBu CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 161.8 (q, 1J(B,C) = 49.9 Hz, 4C; BArF quat. 
C ipso to B), 158.7 (OCN), 142.9 (arom C), 136.6 (NCHN), 134.9 (br, 8C; BArF ortho CH), 
133.8 (2C; arom C), 130.4 (2C; arom CH), 129.8 (arom C), 128.9 (qq, 2J(F,C) = 31.12 Hz, 
3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.6 (q, 1J(F,C) = 272.5 Hz, 8C; BArF CF3), 
124.1 (imid CH), 124.0 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para CH), 75.9 
(oxaz CH), 71.1 (oxaz CH2), 46.6 (NCH2), 33.5 (tBu C), 25.5 (3C; tBu CH3), 21.1 
(CaromCH3), 16.9 (2C; CaromCH3); 
IR (KBr): ν~  = 3162w, 2968w, 1686w, 1611w, 1557w, 1561w, 1481w, 1356m, 1277s, 
1121bs, 971w, 930w, 888w, 837w, 745w, 712w, 670w cm-1; 
MS (FAB): m/z (%): 326 (100) [M - BArF]+; 
EA calcd (%) for C52H40BF24N3O (1189.67): C 52.50, H 3.39, N 3.53; found: C 52.53, 
H 3.33, N 3.53. 
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(S)-[1-(4-tert-butyl-4,5-dihydro-oxazol-2-ylmethyl)-3-(2,2-dimethyl-propyl)-3H-imidazol-1-
ium]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 80e 
N
O N
N
BArF  
Synthesis according to the previous general procedure using chloromethyloxazoline 79a 
(154 mg, 0.876 mmol), neopentylimidazole (121 mg, 0.876 mmol) and NaBArF (776 mg, 
0.876 mmol) yielded a white solid (640 mg, 64%, 0.561 mmol). 
m.p. 114-115°C; 
[ ]20Dα = -6.0 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.37 (s, 1H; NCHN), 7.69 (mc, 8H; BArF ortho 
CH), 7.53 (mc, 4H; BArF para CH), 7.09 (mc, 1H; imid CH), 6.99 (mc, 1H; imid CH), 4.71 
(mc, 2H; CH2), 4.28 (mc, 1H; oxaz CH2), 4.13 (mc, 1H; oxaz CH2), 3.83 (mc, 1H; oxaz CH), 
3.79 (mc, 2H, NCH2C(CH3)3), 0.92 (s, 9H, NCH2C(CH3)3), 0.79 (s, 9H; tBu CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 161.7 (q, 1J(B,C) = 49.9 Hz, 4C; BArF quat. 
C ipso to B), 158.3 (OCN), 135.7 (NCHN), 134.7 (br, 8C; BArF ortho CH), 128.9 (qq, 2J(F,C) 
= 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.6 (q, 1J(F,C) = 272.5 Hz, 8C; 
BArF CF3), 123.5 (imid CH), 123.0 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para 
CH), 75.8 (oxaz CH), 70.8 (oxaz CH2), 62.6 (NCH2C(CH3)3), 46.2 (NCH2), 33.3 (tBu C), 
32.5 (NCH2C(CH3)3), 26.5 (3C; NCH2C(CH3)3), 25.4 (3C; tBu CH3); 
IR (KBr): ν~  = 3186w, 2970w, 1687w, 1610w, 1480w, 1357m, 1279s, 1125bs, 898w, 837w, 
741w, 714w, 675w, cm-1; 
MS (FAB): m/z (%): 278 (100) [M - BArF]+; 
EA calcd (%) for C48H40BF24N3O (1141.62): C 50.50, H 3.53, N 3.68; found: C 50.60, 
H 3.52, N 3.63. 
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 (S)-[1-(4-tert-butyl-4,5-dihydro-oxazol-2-ylmethyl)-3-isobutyl-3H-imidazol-1-ium]-
tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 80f 
N
O N
N
BArF  
Synthesis according to the previous general procedure using chloromethyloxazoline 79a 
(154 mg, 0.876 mmol), isobutylimidazole (108 mg, 0.876 mmol) and NaBArF (776 mg, 
0.876 mmol) yielded a white solid (621 mg, 63%, 0.551 mmol). 
m.p. 96-97°C; 
[ ]20Dα = -6.5 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.34 (s, 1H; NCHN), 7.69 (mc, 8H; BArF ortho 
CH), 7.53 (mc, 4H; BArF para CH), 7.11 (mc, 1H; imid CH), 6.99 (mc, 1H; imid CH), 4.70 
(mc, 2H; NCH2), 4.28 (mc, 1H; oxaz CH2), 4.14 (mc, 1H; oxaz CH2), 3.87 (mc, 1H; oxaz 
CH), 3.81 (mc, 2H, NCH2CH(CH3)2), 2.01 (mc, 1H, NCH2CH(CH3)2), 0.89 (mc, 6H, 
NCH2CH(CH3)2), 0.80 (s, 9H; tBu CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 161.7 (q, 1J(B,C) = 49.9 Hz, 4C; BArF quat. 
C ipso to B), 158.2 (OCN), 135.0 (NCHN), 134.7 (br, 8C; BArF ortho CH), 129.0 (qq, 2J(F,C) 
= 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 8C; 
BArF CF3), 123.6 (imid CH), 122.4 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para 
CH), 75.8 (oxaz CH), 70.7 (oxaz CH2), 58.0 (NCH2CH(CH3)2), 46.2 (NCH2), 33.4 (tBu C), 
29.4 (NCH2CH(CH3)2), 25.5 (3C; tBu CH3), 18.9 (2C; NCH2CH(CH3)2); 
IR (KBr): ν~  = 3179w, 2971w, 1687w, 1610w, 1473w, 1357m, 1279s, 1123bs, 953w, 897w, 
837w, 715w, 675w, cm-1; 
MS (FAB): m/z (%): 264 (100) [M - BArF]+; 
EA calcd (%) for C47H38BF24N3O (1127.60): C 50.06, H 3.40, N 3.73; found: C 50.05, 
H 3.26, N 3.71. 
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(S)-[3-tert-butyl-1-(4-tert-butyl-4,5-dihydro-oxazol-2-ylmethyl)-3H-imidazol-1-ium]-
tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 80g 
N
O N
N
BArF
 
Synthesis according to the previous general procedure using chloromethyloxazoline 79a 
(150 mg, 0.854 mmol), tert-butylimidazole (106 mg, 0.854 mmol) and NaBArF (756 g, 
0.854 mmol) yielded a white solid (652 mg, 68%, 0.578 mmol). 
m.p. 95-96°C; 
[ ]20Dα = -6.9 (c = 0.50, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 8.55 (s, 1H; NCHN), 7.69 (mc, 8H; BArF ortho 
CH), 7.52 (mc, 4H; BArF para CH), 7.21 (mc, 1H; imid CH), 7.16 (mc, 1H; imid CH), 4.72 
(mc, 2H; NCH2), 4.27 (mc, 1H; oxaz CH2), 4.13 (mc, 1H; oxaz CH2), 3.89 (mc, 1H; oxaz 
CH), 2.01 (mc, 1H, NCH2CH(CH3)2), 1.55 (s, 9H; tBuimid CH3), 0.81 (s, 9H; tBuoxaz CH3); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 161.7 (q, 1J(B,C) = 49.9 Hz, 4C; BArF quat. 
C ipso to B), 158.5 (OCN), 134.7 (br, 8C; BArF ortho CH), 129.0 (qq, 2J(F,C) = 31.12 Hz, 
3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 133.4 (NCHN), 124.5 (q, 1J(F,C) = 272.5 Hz, 8C; 
BArF CF3), 123.6 (imid CH), 120.2 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para 
CH), 76.3 (oxaz CH), 71.0 (oxaz CH2), 62.0 (tBuimid C), 46.6 (NCH2), 33.8 (tBuoxaz C), 29.8 
(3C; tBuimid CH3), 25.8 (3C; tBuoxaz CH3); 
IR (KBr): ν~  = 3186w, 2978w, 1695w, 1610w, 1468w, 1356m, 1277s, 1124bs, 935w, 888w, 
838w, 712w, 682w, 671w cm-1; 
MS (FAB): m/z (%): 264 (100) [M - BArF]+; 
EA calcd (%) for C47H38BF24N3O (1127.60): C 50.06, H 3.40, N 3.73; found: C 49.69, 
H 3.26, N 3.45. 
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6.3.4 Synthesis of iridium complexes 6a-f 
(S)-{(η4-1,5-cyclooctadiene)-[1-(4-tert-butyl-4,5-dihydro-oxazol-2-ylmethyl)-3-methyl-
imidazolin-2-ylidene]iridium(I)}-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 81a 
N
O N
N
BArF
Ir
 
Freshly sublimed NaOtBu (14.3 mg, 0.148 mmol) was added to a solution of imidazolium salt 
80a (161 mg, 0.148 mmol) and [(η4-cod)IrCl]2 (50 mg, 0.074 mmol) in THF (10 ml). The 
reaction mixture was stirred at room temperature for 3 hours then concentrated in vacuo to 
remove the solvent. The crude product was purified by chromatography on silica gel eluting 
with CH2Cl2 to yield a yellow/orange solid (134 mg, 0.096 mmol, 65%). 
[ ]20Dα = +48 (c = 0.159, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.70 (mc, 8H; BArF ortho CH), 7.53 (mc, 4H; 
BArF para CH), 6.81 (mc, 1H; imid CH), 6.79 (mc, 1H; imid CH), 4.98 (mc, 1H; NCH2), 4.61 
(mc, 1H; oxaz CH2), 4.49 (mc, 1H; cod CH), 4.38 (mc, 2H; NCH2 + oxaz CH2), 4.15 (mc, 2H; 
cod CH), 3.86 (mc, 1H; cod CH), 3.80 (mc, 1H; oxaz CH), 3.74 (s, 3H, NCH3), 2.29 (mc, 2H; 
cod CH2), 2.11 (mc, 2H; cod CH2), 2.00 (mc, 2H; cod CH2), 1.75 (mc, 1H; cod CH2), 1.63 
(mc, 1H; cod CH2), 0.73 (s, 9H; tBu CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 174.1 (NCN), 165.1 (OCN), 161.7 (q, 
1J(B,C) = 49.9 Hz, 4C; BArF quat. C ipso to B), 134.8 (br, 8C; BArF ortho CH), 128.9 (qq, 
2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 
8C; BArF CF3), 123.5 (imid CH), 121.1 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF 
para CH), 85.4 (cod CH), 81.9 (cod CH), 73.3 (oxaz CH), 72.8 (oxaz CH2), 64.4 (cod CH), 
59.0 (cod CH), 46.8 (NCH2), 38.0 (NCH3), 34.0 (cod CH2), 33.5 (tBu C), 31.1 (cod CH2), 
29.9 (cod CH2), 28.3 (cod CH2), 25.1 (3C; tBu CH3); 
IR (KBr): ν~  = 2971w, 1648w, 1610w, 1435w, 1355m, 1277s, 1124bs, 960w, 894w, 839w, 
712w, 682w, 671w cm-1; 
MS (FAB): m/z (%): 522 (100) [M - BArF]+; 
EA calcd (%) for C52H43BF24IrN3O (1384.91): C 45.10, H 3.13, N 3.03; found: C 45.25, 
H 3.24, N 2.87. 
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(S)-{(η4-1,5-cyclooctadiene)-[1-(4-isopropyl-4,5-dihydro-oxazol-2-ylmethyl)-3-methyl-
imidazolin-2-ylidene]iridium(I)}-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 81b 
N
O N
N
BArF
Ir
 
Synthesis according to the previous general procedure using imidazolium salt 80b (200 mg, 
0.187 mmol), [(η4-cod)IrCl]2 (63 mg, 0.094 mmol) and NaOtBu (18 mg, 0.187 mmol) yielded 
an orange solid (129 mg, 50%, 0.094 mmol). 
[ ]20Dα = +33 (c = 0.165, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.70 (mc, 8H; BArF ortho CH), 7.53 (mc, 4H; 
BArF para CH), 6.76 (mc, 2H; imid CH), 4.91 (mc, 1H; NCH2), 4.55-4.30 (m, 4H; 1 x cod CH 
+ 2 x oxaz CH2 + 1 x NCH2), 4.15 (mc, 2H; cod CH), 4.00 (mc, 1H; oxaz CH), 3.94 (mc, 1H; 
cod CH), 3.75 (s, 3H, NCH3), 2.37 (mc, 1H; cod CH2), 2.26 (mc, 1H; cod CH2), 2.16 (mc, 
2H; cod CH2), 2.00 (mc, 2H; cod CH2), 1.80 (mc, 1H; iPr CH), 1.71 (mc, 1H; cod CH2), 1.60 
(mc, 1H; cod CH2), 0.77 (d, 3J(H,H) = 6.9 Hz, 3H; iPr CH3), 0.64 (d, 3J(H,H) = 7.0 Hz, 3H; 
iPr CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 174.3 (NCN), 165.4 (OCN), 161.7 (q, 
1J(B,C) = 49.9 Hz, 4C; BArF quat. C ipso to B), 135.8 (br, 8C; BArF ortho CH), 129.1 (qq, 
2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 
8C; BArF CF3), 124.1 (imid CH), 121.5 (imid CH), 117.8 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF 
para CH), 84.6 (cod CH), 82.9 (cod CH), 72.4 (oxaz CH2), 69.6 (oxaz CH), 65.7 (cod CH), 
60.1 (cod CH), 47.0 (NCH2), 38.6 (NCH3), 34.7 (cod CH2), 32.1 (iPr CH), 31.2 (cod CH2), 
31.0 (cod CH2), 28.4 (cod CH2), 17.9 (3C; iPr CH3), 16.3 (3C; iPr CH3); 
IR (KBr): ν~  = 2969w, 2890w, 1652w, 1610w, 1456w, 1430w, 1355m, 1277s, 1124bs, 962w, 
893w, 839w, 713w, 681w, 671w cm-1; 
MS (FAB): m/z (%): 508 (100) [M - BArF]+; 
EA calcd (%) for C51H41BF24IrN3O (1370.88): C 44.68, H 3.01, N 3.07; found: C 44.57, 
H 3.19, N 3.13. 
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(S)-{(η4-1,5-cyclooctadiene)-[1-(4-tert-butyl-4,5-dihydro-oxazol-2-ylmethyl)-3-isopropyl-
imidazolin-2-ylidene]iridium(I)}-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 81c 
N
O N
N
BArF
Ir
 
Synthesis according to the previous general procedure using imidazolium salt 80c (166 mg, 
0.148 mmol), [(η4-cod)IrCl]2 (50 mg, 0.074 mmol) and NaOtBu (14 mg, 0.148 mmol) yielded 
of an orange solid (96 mg, 46%, 0.068 mmol). 
[ ]20Dα = +36 (c = 0.128, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.71 (mc, 8H; BArF ortho CH), 7.53 (mc, 4H; 
BArF para CH), 6.95 (mc, 1H; imid CH), 6.85 (mc, 1H; imid CH), 5.02 (mc, 1H; NCH2), 4.86 
(mc, 1H; CH iPr), 4.56 (mc, 2H; oxaz CH2 + cod CH), 4.38 (mc, 2H; NCH2 + oxaz CH2), 
4.11 (mc, 1H; cod CH), 3.92 (mc, 1H; cod CH), 3.79 (mc, 2H; oxaz CH + cod CH), 2.36 (mc, 
1H; cod CH2), 2.24 (mc, 2H; cod CH2), 2.16 (mc, 1H; cod CH2), 2.09 (mc, 1H; cod CH2), 
1.96 (mc, 1H; cod CH2), 1.65 (mc, 1H; cod CH2), 1.55 (mc, 1H; cod CH2), 1.39 (d, 3J(H,H) = 
7.0 Hz, 3H; iPr CH3), 1.35 (d, 3J(H,H) = 7.0 Hz, 3H; iPr CH3), 0.71 (s, 9H; tBu CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 173.9 (NCN), 165.2 (OCN), 161.7 (q, 
1J(B,C) = 49.9 Hz, 4C; BArF quat. C ipso to B), 134.8 (br, 8C; BArF ortho CH), 128.9 (qq, 
2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 
8C; BArF CF3), 122.1 (imid CH), 117.8 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF 
para CH), 85.3 (cod CH), 82.1 (cod CH), 73.4 (oxaz CH), 72.9 (oxaz CH2), 65.8 (cod CH), 
58.0 (cod CH), 52.5 (iPr CH), 46.8 (NCH2), 34.8 (cod CH2), 33.5 (tBu C), 30.7 (cod CH2), 
30.5 (cod CH2), 27.6 (cod CH2), 25.0 (3C; tBu CH3), 23.7 (iPr CH3), 23.6 (iPr CH3); 
IR (KBr): ν~  = 2971w, 1651w, 1610w, 1440w, 1354m, 1272s, 1124bm, 960w, 897w, 839w, 
712w, 682w, 670w cm-1; 
MS (FAB): m/z (%): 550 (100) [M - BArF]+; 
EA calcd (%) for C54H47BF24IrN3O (1412.96): C 45.90, H 3.35, N 2.97; found: C 46.02, 
H 3.28, N 2.75. 
 142
 Experimental 
(S)-{(η4-1,5-cyclooctadiene)-[1-(4-tert-butyl-4,5-dihydro-oxazol-2-ylmethyl)-3-(2,4,6-
trimethyl-phenyl)-imidazolin-2-ylidene]iridium(I)}-tetrakis[3,5-
bis(trifluoromethyl)phenyl]borate 81d 
N
O N
N
BArF
Ir
 
Synthesis according to the previous general procedure using imidazolium salt 80d (176 mg, 
0.148 mmol), [(η4-cod)IrCl]2 (50 mg, 0.074 mmol) and NaOtBu (14 mg, 0.148 mmol) yielded 
an orange solid (100 mg, 45%, 0.067 mmol). 
[ ]20Dα = +45 (c = 0.116, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.71 (mc, 8H; BArF ortho CH), 7.53 (mc, 4H; 
BArF para CH), 7.03 (mc, 1H, arom CH), 7.00 (mc, 1H; imid CH), 6.96 (mc, 1H, arom CH), 
6.85 (mc, 1H; imid CH), 5.04 (mc, 1H; NCH2), 4.65 (mc, 1H; oxaz CH2), 4.48 (mc, 1H; 
NCH2), 4.38 (mc, 1H; oxaz CH2), 4.22 (mc, 2H; cod CH), 3.85 (mc, 1H; oxaz CH), 3.57 (mc, 
1H; cod CH), 2.92 (mc, 1H; cod CH), 2.34 (s, 3H, CaromCH3), 2.06 (mc, 4H; 1 x cod CH2 + 
CaromCH3), 1.97 (mc, 5H; 2 x cod CH2+ CaromCH3), 1.55 (mc, 5H; cod CH2), 0.87 (s, 9H; tBu 
CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 172.6 (NCN), 165.3 (OCN), 161.7 (q, 
1J(B,C) = 49.9 Hz, 4C; BArF quat. C ipso to B), 140.5 (arom C), 134.8 (br, 8C; BArF ortho 
CH), 134.6 (arom C), 134.5 (arom C), 134.4 (arom C), 129.6 (arom CH), 129.4 (arom CH), 
128.9 (qq, 2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (imid CH), 
124.5 (q, 1J(F,C) = 272.5 Hz, 8C; BArF CF3), 121.0 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 
4C; BArF para CH), 85.6 (cod CH), 79.5 (cod CH), 72.6 (oxaz CH2), 72.4 (oxaz CH), 63.4 
(cod CH), 62.3 (cod CH), 46.7 (NCH2), 33.8 (tBu C), 33.5 (cod CH2), 31.8 (cod CH2), 30.3 
(cod CH2), 27.6 (cod CH2), 25.2 (3C; tBu CH3), 21.0 (Carom CH3), 18.6 (Carom CH3), 17.6 
(Carom CH3); 
IR (KBr): ν~  = 2967w, 1648w, 1611w, 1483w, 1443w, 1414w, 1355m, 1279s, 1124bm, 
962w, 886w, 839w, 744w, 714w, 682w, 670w cm-1; 
MS (FAB): m/z (%): 626 (100) [M - BArF]+; 
EA calcd (%) for C60H51BF24IrN3O (1489.06): C 48.40, H 3.45, N 2.82; found: C 48.37, 
H 3.47, N 2.59. 
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(S)-{(η4-1,5-cyclooctadiene)-[1-(4-tert-butyl-4,5-dihydro-oxazol-2-ylmethyl)-3-(2,2-
dimethyl-propyl)-imidazolin-2-ylidene]iridium(I)}-tetrakis[3,5-
bis(trifluoromethyl)phenyl]borate 81e 
N
O N
N
BArF
Ir
 
Synthesis according to the previous general procedure using imidazolium salt 80e (170 mg, 
0.148 mmol), [(η4-cod)IrCl]2 (50 mg, 0.074 mmol) and NaOtBu (14 mg, 0.148 mmol) yielded 
an orange solid (100 mg, 47%, 0.070 mmol). 
[ ]20Dα = +31 (c = 0.133, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.70 (mc, 8H; BArF ortho CH), 7.53 (mc, 4H; 
BArF para CH), 6.91 (mc, 1H; imid CH), 6.81 (mc, 1H; imid CH), 4.99 (mc, 1H; NCH2), 4.59 
(mc, 1H; oxaz CH2), 4.38 (mc, 3H; cod CH + CH2 + oxaz CH2), 4.17 (mc, 1H; cod CH), 4.12 
(mc, 1H; cod CH), 3.89 (mc, 3H; oxaz CH + cod CH + NCH2C(CH3)3), 3.65 (mc, 3H, 
NCH2C(CH3)3), 2.35 (mc, 1H; cod CH2), 2.20 (mc, 2H; cod CH2), 2.10 (mc, 1H; cod CH2), 
2.00 (mc, 2H; cod CH2), 1.61 (mc, 1H; cod CH2), 1.50 (mc, 1H; cod CH2), 0.92 (s, 9H, 
NCH2C(CH3)3), 0.80 (s, 9H; tBu CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 173.8 (NCN), 164.7 (OCN), 161.7 (q, 
1J(B,C) = 49.9 Hz, 4C; BArF quat. C ipso to B), 134.8 (br, 8C; BArF ortho CH), 128.9 (qq, 
2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 
8C; BArF CF3), 123.7 (imid CH), 120.8 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF 
para CH), 84.0 (cod CH), 79.2 (cod CH), 73.2 (oxaz CH), 72.6 (oxaz CH2), 64.2 (cod CH), 
61.1 (NCH2C(CH3)3), 60.1 (cod CH), 46.8 (NCH2), 34.2 (cod CH2), 33.6 (tBu C), 32.6 
(NCH2C(CH3)3), 30.7 (cod CH2), 30.2 (cod CH2), 28.1 (3C; NCH2C(CH3)3), 28.0 (cod CH2), 
25.2 (3C; tBu CH3); 
IR (KBr): ν~  = 2967w, 1651w, 1611w, 1478w, 1441w, 1357m, 1279s, 1128bs, 890w, 838w, 
714w, 674w cm-1; 
MS (FAB): m/z (%): 578 (100) [M - BArF]+; 
EA calcd (%) for C56H51BF24IrN3O (1441.01): C 46.68, H 3.57, N 2.92; found: C 46.79, 
H 3.68, N 2.99. 
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(S)-{(η4-1,5-cyclooctadiene)-[1-(4-tert-butyl-4,5-dihydro-oxazol-2-ylmethyl)-3-isobutyl-
imidazolin-2-ylidene]iridium(I)}-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 81f 
N
O N
N
BArF
Ir
 
Synthesis according to the previous general procedure using imidazolium salt 80f (168 mg, 
0.148 mmol), [(η4-cod)IrCl]2 (50 mg, 0.074 mmol) and NaOtBu (14 mg, 0.148 mmol) yielded 
an orange solid (93 mg, 44%, 0.065 mmol). 
[ ]20Dα = +36 (c = 0.138, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.70 (mc, 8H; BArF ortho CH), 7.53 (mc, 4H; 
BArF para CH), 6.83 (mc, 1H; imid CH), 6.80 (mc, 1H; imid CH), 4.99 (mc, 1H; NCH2), 4.61 
(mc, 1H; oxaz CH2), 4.45 (mc, 1H; cod CH), 4.38 (mc, 2H; NCH2 + oxaz CH2), 4.13 (mc, 1H; 
cod CH), 4.05 (mc, 1H; cod CH), 3.91 (mc, 2H; cod CH + NCH2CH(CH3)2), 3.81 (mc, 1H; 
oxaz CH),), 3.57 (mc, 3H, NCH2CH(CH3)2), 2.35 (mc, 2H; cod CH2 + NCH2CH(CH3)2), 2.22 
(mc, 1H; cod CH2), 2.14 (mc, 2H; cod CH2), 2.01 (mc, 2H; cod CH2), 1.72 (mc, 1H; cod 
CH2), 1.58 (mc, 1H; cod CH2), 0.95 (d, 3J(H,H) = 6.6 Hz, 9H, NCH2CH(CH3)2), 0.81 (d, 
3J(H,H) = 6.6 Hz 9H, NCH2CH(CH3)2), 0.75 (s, 9H; tBu CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 173.3 (NCN), 165.1 (OCN), 161.7 (q, 
1J(B,C) = 49.9 Hz, 4C; BArF quat. C ipso to B), 134.8 (br, 8C; BArF ortho CH), 128.9 (qq, 
2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 
8C; BArF CF3), 123.0 (imid CH), 120.8 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF 
para CH), 84.9 (cod CH), 80.8 (cod CH), 73.1 (oxaz CH), 72.8 (oxaz CH2), 64.5 (cod CH), 
58.9 (cod CH), 58.1 (NCH2CH(CH3)2), 46.9 (NCH2), 34.1 (cod CH2), 33.5 (tBu C), 31.2 
(NCH2CH(CH3)2), 31.0 (cod CH2), 30.0 (cod CH2), 28.2 (cod CH2), 25.1 (3C; tBu CH3), 19.9 
(2C; NCH2CH(CH3)2), 19.2 (2C; NCH2CH(CH3)2); 
IR (KBr): ν~  = 2965w, 1680w, 1647w, 1609w, 1471w, 1419w, 1356m, 1279s, 1128bs, 971w, 
889w, 838w, 713w, 676w cm-1; 
MS (FAB): m/z (%): 564 (100) [M - BArF]+; 
EA calcd (%) for C55H49BF24IrN3O (1426.99): C 46.29, H 3.46, N 2.94; C 46.39, H 3.56, 
N 3.04 
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6.3.5 Synthesis of amides 85a,f,k 
(S)-2-(2,2-dimethyl-propionylamino)-3-hydroxy-propionic acid methyl ester 85a 
N
H
OH
O CO2Me
 
A solution of (S)-serine methyl ester hydrochloride (6.00 g, 38.6 mmol) and triethylamine 
(11.7 g, 115.7 mmol) in CH2Cl2 (150 ml) was cooled down to -10°C under argon. Pivaloyl 
chloride (4.65 g; 38.6 mmol) was added dropwise over 5 minutes. The reaction mixture was 
stirred at room temperature for 12 hours then diluted with water (100 ml). The 
dichloromethane layer was separated, dried over magnesium sulfate and concentrated in 
vacuo to yield an yellow oil. The crude product was purified by chromatography on silica gel 
eluting with a mixture of AcOEt and hexane (4:1) to yield a colourless oil (5.90 g, 30.8 mmol, 
80%). 
Rf = 0.43 (AcOEt/Hex 4:1) 
[ ]20Dα = +24.6 (c = 1.00, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 6.61 (br, 1H; NH), 4.63 (mc, 1H; 
NHCHCO2CH3), 3.93 (mc, 2H; CH2OH), 3.78 (s, 3H, CO2CH3), 2.68 (br, 1H, OH), 1.23 (s, 
9H, C(CH3)3); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 179.7 (NCO), 171.6 (CO2CH3), 64.1 
(CH2OH), 55.2 (NHCHCO2), 53.2 (CO2CH3), 39.2 (C(CH3)3), 27.8 (C(CH3)3); 
IR (NaCl): ν~  =  3396sbr, 2960s, 2878m, 1744s, 1645s, 1521s, 1438m, 1368m, 1204s, 
1081m, 979w, 938w, 857w cm-1; 
MS (FAB): m/z (%): 204 (100) [M + H]+, 57 (66); 
EA calcd (%) for C9H17NO4 (203.24): C 53.19, H 8.43, N 6.89; found: C 52.88, H 8.54, 
N 7.00. 
 146
 Experimental 
 (S)-2-[(adamantane-1-carbonyl)-amino]-3-hydroxy-propionic acid methyl ester 85f 
N
H
OH
O CO2Me
 
Synthesis according to the previous general procedure using 1-adamantanecarbonylchloride 
(10.0 g, 50.3 mmol), (S)-serine methyl ester hydrochloride (7.83 g, 50.3 mmol) and 
triethylamine (15.3 g, 151 mmol) yielded a white solid (13.1 g, 93%, 46.8 mmol). 
Rf = 0.59 (AcOEt/Hexane 1 :1); 
m.p. 102-103°C; = +21.8 (c = 1.00, CHCl[ ]20Dα 3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 6.59 (br, 1H; NH), 4.64 (mc, 1H; 
NHCHCO2CH3), 3.92 (mc, 2H; CH2OH), 3.78 (s, 3H, CO2CH3), 2.76 (br, 1H, OH), 2.05 (mc, 
3H; adam CH), 1.89 (mc, 6H; adam CH2), 1.71 (mc, 6H; adam CH2); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 179.2 (NCO), 171.6 (CO2CH3), 64.2 
(CH2OH), 55.1 (NHCHCO2), 53.2 (CO2CH3), 41.1 (adam C), 39.5 (adam CH2), 36.8 (adam 
CH2), 28.4 (adam CH); 
IR (KBr): ν~  =  3446mbr, 3326mbr, 2902s, 1761s, 1622s, 1540s, 1451m, 1401w, 1344m, 
1208m, 1071m, 975w, 647w cm-1; 
MS (FAB): m/z (%): 282 (100) [M + H]+, 135 (58); 
EA calcd (%) for C15H23NO4 (281.35): C 64.04, H 8.24, N 4.98; found: C 64.14, H 8.30, 
N 4.90. 
 (S)-3-hydroxy-2-(2,4,6-trimethyl-benzoylamino)-propionic acid methyl ester 85k 
N
H
OH
O CO2Me
 
Synthesis according to the previous general procedure using 2,6-dimethylbenzoylchloride 
(10.0 g, 59.4 mmol), (S)-serine methyl ester hydrochloride (9.24 g, 59.4 mmol) and 
triethylamine (18.0 g, 178 mmol) yielded a white solid (12.9 g, 86%, 51.1 mmol). 
Rf = 0.55 (AcOEt/Hexane 4 :1); 
m.p. 110-111°C; 
[ ]20Dα = +3.2 (c = 0.50, CHCl3); 
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1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 7.16 (t, 3J(H,H) = 7.6 Hz, 1H; arom CH), 7.01 (d, 
3J(H,H) = 7.6 Hz, 2H; arom CH), 6.67 (br, 1H; NH), 4.84 (mc, 1H; NHCHCO2CH3), 4.06 
(mc, 1H; CH2OH), 3.95 (mc, 1H; CH2OH), 3.79 (s, 3H; CO2CH3), 2.68 (br, 1H; OH), 2.32 (s, 
6H, CCH3); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 171.1 (CO2CH3), 137.0 (arom CCN), 134.7 
(2C; arom CCH3), 129.4 (arom CH), 127.9 (2C; arom CH), 63.7 (CH2OH), 54.8 (NHCHCO2), 
53.1 (CO2CH3), 19.5 (2C; CCH3), 1 quat. C not detected; 
IR (KBr): ν~  =  3289sbr, 2957w, 2856w, 1741m, 1635.2s, 1545m, 1231m, 1161m, 1070m, 
984w, 778m, 637m cm-1; 
MS (FAB): m/z (%): 252 (46) [M + H]+, 133 (100); 
EA calcd (%) for C13H17NO4 (251.29): C 62.14, H 6.82, N 5.57, O 25.47; found: C 61.98, 
H 6.77, N 5.64, O 25.61. 
6.3.6 Synthesis of esters 86a,f,k 
(S)-2-tert-butyl-4,5-dihydro-oxazole-4-carboxylic acid methyl ester 86a 
N
O
CO2Me
 
A solution of amide 85a (2.40 g, 12.6 mmol) and methyl-N-triethylammoniosulfonyl-
carbamate (3.29 g, 13.8 mmol) in THF (40 ml) was refluxed for 12 hours. The reaction 
mixture was concentrated in vacuo and the residue was diluted in dichloromethane. The 
organic layer was extracted three times with water, dried over magnesium sulfate in 
concentrated in vacuo to give an oil. The crude product was purified by distillation to yield a 
colourless oil (1.51 g, 8.2 mmol, 65%). 
b.p. 45°C at 0.08 mbar; 
[ ]20Dα = +150.9 (c = 0.94, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 4.67 (mc, 1H; oxaz CH), 4.42 (mc, 1H; oxaz 
CH2), 4.34 (mc, 1H; oxaz CH2), 3.74 (s, 3H; CO2CH3), 1.20 (s, 9H, C(CH3)3); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 177.3 (NCO), 172.3 (CO2CH3), 69.8 (oxaz 
CH2), 68.5 (oxaz CH), 52.9 (CO2CH3), 33.8 (C(CH3)3), 28.1 (C(CH3)3); 
IR (NaCl): ν~  =  2975s, 1742s, 1651s, 1482m, 1438m, 1396w, 1363m, 1300m, 1144s,1061w, 
981m, 785w, 728w cm-1; 
 148
 Experimental 
MS (FAB): m/z (%): 186 (100) [M + H]+; 
EA calcd (%) for C9H15NO3 (185.22): C 58.36, H 8.16, N 7.56; found: C 58.17, H 7.98, 
N 7.61. 
 (S)-2-adamantan-1-yl-4,5-dihydro-oxazole-4-carboxylic acid methyl ester 86f 
N
O
CO2Me
 
Synthesis according to the previous general procedure using amide 85f (12.0 g, 42.6 mmol) 
and methyl-N-triethylammoniosulfonyl-carbamate (11.2 g, 46.9 mmol) yielded a colourless 
oil (8.07 g, 72%, 51.1 mmol). 
Rf = 0.59 (AcOEt/Hexane, 1 :1); 
[ ]20Dα = +93.4 (c = 1.20, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 4.69 (mc, 1H; oxaz CH), 4.42 (mc, 1H; oxaz 
CH2), 4.34 (mc, 1H; oxaz CH2), 3.80 (s, 3H; CO2CH3), 2.04 (mc, 3H; adam CH), 1.94 (mc, 
6H; adam CH2), 1.74 (mc, 6H; adam CH2); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 176.7 (NCO), 172.4 (CO2CH3), 69.4 (oxaz 
CH2), 68.3 (oxaz CH), 52.9 (CO2CH3), 39.8 (adam CH2), 36.9 (adam CH2), 35.8 (adam C), 
28.3 (adam CH); 
IR (NaCl): ν~  =  2906s, 2851m, 1744s, 1648m, 1452m, 1351w, 1275w, 1208m, 1056m, 970w 
cm-1; 
MS (FAB): m/z (%): 264 (100) [M + H]+; 
EA calcd (%) for C15H21NO3 (263.33): C 68.42, H 8.04, N 5.32; found: C 68.46, H 7.82, 
N 5.21. 
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 (S)-2-(2,6-dimethyl-phenyl)-4,5-dihydro-oxazole-4-carboxylic acid methyl ester 86k 
N
O
CO2Me
 
Synthesis according to the previous general procedure using amide 85k (10.0 g, 39.8 mmol) 
and methyl-N-triethylammoniosulfonyl-carbamate (10.4 g, 43.7 mmol) yielded a colourless 
oil (6.53 g, 70%, 28.0 mmol). 
Rf = 0.65 (AcOEt/Hexane 4 :1); 
[ ]20Dα = +95.4 (c = 1.00, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 7.19 (t, 3J(H,H) = 7.6 Hz, 1H; arom CH), 7.03 (d, 
3J(H,H) = 7.6 Hz, 2H; arom CH), 4.99 (mc, 1H; oxaz CH), 4.67 (mc, 1H; oxaz CH2), 4.55 
(mc, 1H; oxaz CH2), 3.82 (s, 3H; OCH3), 2.33 (s, 6H, CCH3); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 172.1 (CO2CH3), 167.5 (NCO), 137.5 (2C; 
arom CCH3), 130.1 (arom CH), 128.3 (arom CCN), 127.8 (2C; arom CH), 69.7 (oxaz CH2), 
69.1 (oxaz CH), 53.1 (CO2CH3), 20.0 (2C; CCH3); 
IR (NaCl): ν~  =  2956w, 1744s, 1656m, 1466w, 1352w, 1286w, 1207m, 1051w, 965w, 776w 
cm-1; 
MS (FAB): m/z (%): 234 (100) [M + H]+; 
EA calcd (%) for C13H15NO3 (233.27): C 66.94, H 6.48, N 6.00; found: C 66.55, H 6.47, 
N 6.21. 
6.3.7 Synthesis of ester 86p 
(S)-2-phenyl-4,5-dihydro-oxazole-4-carboxylic acid methyl ester 86p 
N
O
CO2Me
 
Ethyl benzimidate hydrochloride (5.00 g, 26.9 mmol) was dissolved in dichloromethane 
(100 ml). The solution was extracted three times with an aqueous solution of NaHCO3 and 
concentrated in vacuo to yield an oil (3.77 g, 25.3 mmol). The oil was diluted in 1,2-
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dichlorethane (150 ml) and (S)-serine methyl ester hydrochloride (4.32 g, 27.8 mmol) was 
added. The suspension was refluxed for 20 hours then filtered and concentrated in vacuo to 
remove the solvent. The crude product was purified by chromatography on silica gel eluting 
with a mixture of AcOEt and hexane (3:1) to yield a colourless oil (5.02 g, 24.5 mmol, 91%). 
Rf = 0.57 (AcOEt/Hex 3:1) 
[ ]20Dα = +99.3 (c = 1.36, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 7.97 (mc, 2H; arom CH), 7.49 (mc, 1H; arom 
CH), 7.40 (mc, 2H; arom CH), 4.95 (mc, 1H; oxaz CH), 4.69 (mc, 1H; oxaz CH2), 4.59 (mc, 
1H; oxaz CH2), 3.81 (s, 3H, OCH3); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 172.0 (CO2CH3), 166.7 (NCO), 132.3 (arom 
CH), 129.0 (2C; arom CH), 128.8 (2C; arom CH), 127.3 (arom, C), 70.0 (oxaz CH2), 69.0 
(oxaz CH), 53.1 (CO2CH3); 
IR (NaCl): ν~  =  2953w, 1742s, 1642m, 1450w, 1362m, 1210m, 1090m, 1026w, 971w, 779w, 
697m cm-1; MS (FAB): m/z (%): 206 (100) [M + H]+; 
EA calcd (%) for C11H11NO3 (205.21): C 64.38, H 5.40, N 6.83; found: C 64.26, H 5.66, 
N 7.06. 
6.3.8 Synthesis of oxazoline alcohols 87p,a,f,k 
(R)-(2-Phenyl-4,5-dihydro-oxazol-4-yl)-methanol 87p 
N
O
OH
 
Ester 86p (11.0 g, 53.9 mmol) and 300 ml of dried THF were added under argon to a 2L 
round bottom flask equipped with a thermometer and an addition funnel. A solution of 
DIBAL in THF (170 ml, 1.0 mmol/ml) was added dropwise at -10°C. The reaction mixture 
was stirred overnight at room temperature. At the end of the reaction, a solution of Seignette’s 
salt (400 ml, 20% w/w) was carefully added under stirring and the mixture was extracted 
three times with ethyl acetate. The combined organic layers were dried over magnesium 
sulfate and concentrated in vacuo to yield an yellow oil. The crude product was purified by 
chromatography on silica gel eluting with AcOEt to yield a white solid (6.4 g, 36.1 mmol, 
67%). 
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Rf = 0.33 (AcOEt) 
m.p. 99-100°C; 
[ ]20Dα = +89.0 (c = 1.00, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 7.97 (mc, 2H; arom CH), 7.42 (mc, 1H; arom 
CH), 7.31 (mc, 2H; arom CH), 4.30 – 4.50 (m, 3H; 2 x oxaz CH2 + 1 x oxaz CH), 3.99 (mc, 
1H; CH2OH), 3.65 (mc, 1H; CH2OH), 3.53 (br, 1H; OH); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 166.0 (NCO), 131.9 (arom CH), 128.7 (2C; 
arom CH), 128.6 (2C; arom CH), 127.5 (arom, C), 69.5 (oxaz CH2), 68.5 (oxaz CH), 64.1 
(CH2OH); 
IR (KBr): ν~  =  3266sbr, 2928m, 1652s, 1500m, 1363m, 1276m, 1098m, 958m, 783w, 693m 
cm-1; 
MS (FAB): m/z (%): 178 (100) [M + H]+; 
EA calcd (%) for C10H11NO2 (177.20): C 67.78, H 6.26, N 7.90, O 18.06; found: C 67.60, 
H 6.28, N 7.87, O 17.80. 
(R)-(2-tert-butyl-4,5-dihydro-oxazol-4-yl)-methanol 87a 
N
O
OH
 
Synthesis according to the previous general procedure using ester 86a (6.00 g, 32.4 mmol) 
and a solution of DIBAL in THF (100 ml, 1.0 mmol/ml) yielded a white solid (4.00 g, 78%, 
25.4 mmol). 
m.p. 37-38°C; 
b.p. 62°C at 0.1 mbar; 
[ ]20Dα = +93.4 (c = 1.00, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 4.30 (mc, 1H; oxaz CH2), 4.21 (mc, 1H; oxaz 
CH), 4.09 (mc, 1H; oxaz CH2), 3.78 (mc, 1H; CH2OH), 3.54 (mc, 1H; CH2OH), 2.66 (br, 1H; 
OH), 1.22 (s, 9H, C(CH3)3); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 176.8 (NCO), 69.8 (oxaz CH2), 67.7 (oxaz 
CH), 64.7 (CH2OH), 33.8 (C(CH3)3), 28.3 (C(CH3)3); 
IR (KBr): ν~  =  3228sbr, 2960s, 1648s, 1459m, 1226w, 1148m, 970m, 904w, 816w cm-1; 
MS (FAB): m/z (%): 158 (100) [M + H]+, 57 (63), 43 (35), 41 (35); 
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EA calcd (%) for C8H15NO2 (157.21): C 61.12, H 9.62, N 8.91; found: C 60.71, H 9.83, 
N 8.74. 
 (R)-(2-adamantan-1-yl-4,5-dihydro-oxazol-4-yl)-methanol 87f 
N
O
OH
 
Synthesis according to the previous general procedure using ester 86f (7.50 g, 28.5 mmol) and 
a solution of DIBAL in THF (88 ml, 1.0 mmol/ml) yielded a white solid (4.26 g, 63%, 
18.1 mmol). 
Rf = 0.21 (AcOEt); 
m.p. 104-105°C; = +66.7 (c = 1.00, CHCl[ ]20Dα 3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 4.28 (mc, 1H; oxaz CH2), 4.21 (mc, 1H; oxaz 
CH), 4.08 (mc, 1H; oxaz CH2), 3.79 (mc, 1H; CH2OH), 3.53 (mc, 1H; CH2OH), 2.68 (br, 1H; 
OH), 2.01 (mc, 3H; adam CH), 1.89 (mc, 6H; adam CH2), 1.71 (mc, 6H; adam CH2); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 176.5 (NCO), 69.5 (oxaz CH2), 67.3 (oxaz 
CH), 64.6 (CH2OH), 40.0 (adam CH2), 36.9 (adam CH2), 35.9 (adam C), 28.3 (adam CH); 
IR (KBr): ν~  =  3222sbr, 2907s, 1648s, 2848s, 1651s, 1473w, 1452m, 1354m, 1268w, 
1230m, 1059m, 813w, 608w cm-1; 
MS (FAB): m/z (%): 236 (100) [M + H]+; 
EA calcd (%) for C14H21NO2 (235.32): C 71.46, H 8.99, N 5.95; found: C 71.09, H 8.81, 
N 5.72. 
 (R)-[2-(2,6-dimethyl-phenyl)-4,5-dihydro-oxazol-4-yl]-methanol 87k 
N
O
OH
 
Synthesis according to the previous general procedure using ester 86k (6.50 g, 27.9 mmol) 
and a solution of DIBAL in THF (87 ml, 1.0 mmol/ml) yielded a white solid (3.00 g, 52%, 
14.0 mmol). 
 153
Chapter 6 
Rf = 0.17 (AcOEt/Hexane 2 :1); 
m.p. 104-105°C; 
[ ]20Dα = +66.0 (c = 0.50, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 7.19 (t, 3J(H,H) = 7.6 Hz, 1H; arom CH), 7.04 (d, 
3J(H,H) = 7.6 Hz, 2H; arom CH), 4.46 (mc, 2H; oxaz CH2), 4.24 (mc, 1H; oxaz CH), 3.87 
(mc, 1H; CH2OH), 3.65 (mc, 1H; CH2OH), 2.85 (br, 1H; OH), 2.30 (s, 6H, CCH3); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 166.4 (NCO), 137.2 (2C; arom CCH3), 
129.9 (arom CH), 129.0 (arom CCN), 127.8 (2C; arom CH), 69.5 (oxaz CH2), 68.7 (oxaz 
CH), 64.6 (CH2OH), 20.1 (2C; CCH3); 
IR (KBr): ν~  =  3210mbr, 2925m, 1663s, 1594w, 1467m, 1349m, 1299w, 1261m, 1107m, 
1054m, 940m, 701w cm-1; 
MS (FAB): m/z (%): 206 (100) [M + H]+; 
EA calcd (%) for C12H15NO2 (205.25): C 70.22, H 7.37, N 6.82; found: C 70.10, H 7.31, 
N 6.68. 
6.3.9 Synthesis of tosylates 88p,a,f,k 
(S)-toluene-4-sulfonic acid 2-phenyl-4,5-dihydro-oxazol-4-ylmethyl ester 88p 
N
O
OTs
 
Triethylamine (3.98 g, 39.4 mmol) was added dropwise to a solution of alcohol 87p (6.35 g, 
35.8 mmol) and tosyl chloride (13.65 g, 71.6 mmol) in dichloromethane (40 ml). The reaction 
mixture was stirred at room temperature for 8 hours then concentrated in vacuo to remove the 
solvent. The crude product was purified by chromatography on silica gel eluting with a 
mixture of AcOEt and hexane (from 3:7 to 7:3) to yield a colourless oil which crystallised on 
standing (8.41 g, 25.4 mmol, 71%). 
Rf = 0.48 (AcOEt/Hexane 1 :1); 
m.p. 109-110°C; 
[ ]20Dα = +96.5 (c = 1.00, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 7.86 (mc, 2H; tos CH), 7.77 (mc, 2H; tos CH), 
7.49 (mc, 1H; arom CH), 7.40 (mc, 2H; arom CH), 7.30 (mc, 2H; arom CH), 4.49 (mc, 2H; 
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oxaz CH + oxaz CH2), 4.34 (mc, 1H; oxaz CH2), 4.27 (mc, 1H; CH2OH), 4.04 (mc, CH2OH), 
2.43 (s, 3H; tos CH3); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 145.4 (tos C), 132.9 (tos C), 132.3 (arom 
CH), 130.3 (2C, tos CH), 128.8 (2C; arom CH), 128.8 (2C; arom CH), 128.4 (2C, tos CH), 
127.3 (arom, C), 71.1 (CH2), 70.3 (CH2), 65.4 (oxaz CH), 22.1 (tos CH3), 1 quat. C not 
detected; 
IR (NaCl): ν~  =  2976w, 1648m, 1452w, 1366s, 1269w,1176s, 1023m, 969m, 837m, 690m, 
555m cm-1; 
MS (FAB): m/z (%): 332 (100) [M + H]+; 
EA calcd (%) for C17H17NO4S (331.39): C 61.61, H 5.17, N 4.23, O 19.31; found: C 61.56, 
H 5.20, N 4.19, O 19.50. 
(S)-toluene-4-sulfonic acid 2-tert-butyl-4,5-dihydro-oxazol-4-ylmethyl ester 88a 
N
O
OTs
 
Synthesis according to the previous general procedure using alcohol 87a (2.00 g, 12.6 mmol), 
tosyl chloride (4.82 g, 25.3 mmol) and triethylamine (1.28 g, 12.6 mmol) yielded a white 
solid (2.83 g, 72%, 9.10 mmol). 
Rf = 0.54 (AcOEt/Hexane 1 :1); 
m.p. 63-64°C; 
[ ]20Dα = +81.3 (c = 1.44, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 7.77 (mc, 2H; arom CH), 7.34 (mc, 2H; arom 
CH), 4.26 (mc, 2H; oxaz CH + oxaz CH2), 4.14 (mc, 2H; oxaz CH2 + CH2OH), 3.91 (mc, 1H; 
CH2OH), 2.44 (s, 3H; tos CH3), 1.16 (s, 9H, C(CH3)3); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 145.4 (arom C), 133.0 (arom C), 130.3 (2C, 
arom CH), 128.4 (2C, arom CH), 71.2 (CH2), 70.2 (CH2), 64.7 (oxaz CH), 33.7 (C(CH3)3), 
28.1 (C(CH3)3), 22.1 (tos CH3), 1 quat. C not detected; 
IR (KBr): ν~  =  2980m, 1735w, 1658s, 1598m, 1481m, 1360s, 1284w, 1180s, 1175s, 1027w, 
947s, 706w, 668s, 555s cm-1; 
MS (FAB): m/z (%): 312 (64) [M + H]+, 57 (100), 41 (36); 
EA calcd (%) for C15H21NO4S (311.40): C 57.86, H 6.80, N 4.50, O 20.55; found: C 57.88, 
H 6.84, N 4.44, O 20.47. 
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 (S)-toluene-4-sulfonic acid 2-adamantan-1-yl-4,5-dihydro-oxazol-4-ylmethyl ester 88f 
N
O
OTs
 
Synthesis according to the previous general procedure using alcohol 87f (3.80 g, 16.1 mmol), 
tosyl chloride (6.15 g, 32.3 mmol) and triethylamine (1.63 g, 16.1 mmol) yielded a colourless 
oil (5.20 g, 83%, 13.3 mmol). 
Rf = 0.52 (AcOEt/Hexane 1 :1); 
[ ]20Dα = +58.8 (c = 1.00, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 7.77 (mc, 2H; arom CH), 7.34 (mc, 2H; arom 
CH), 4.23 (mc, 2H; oxaz CH + oxaz CH2), (4.12 mc, 2H; oxaz CH2 + CH2O), 3.92 (mc, 1H; 
CH2OH), 2.44 (s, 3H; tos CH3), 1.98 (mc, 3H; adam CH), 1.81 (mc, 6H; adam CH2), 1.69 
(mc, 6H; adam CH2); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 145.4 (arom C), 133.0 (arom C), 130.3 (2C, 
arom CH), 128.4 (2C, arom CH), 71.2 (CH2), 69.9 (CH2), 64.3 (oxaz CH), 39.8 (adam CH2), 
36.8 (adam CH2), 35.8 (adam C), 28.2 (adam CH), 22.1 (tos CH3), 1 quat. C not detected; 
IR (NaCl): ν~  =  2905s, 2852w, 1650m, 1453m, 1370m, 1227w, 1177s, 1055w, 971m, 
813.5w, 665m cm-1; 
MS (FAB): m/z (%): 390 (100) [M + H]+; 
EA calcd (%) for C21H27NO4S (389.51): C 64.75, H 6.99, N 3.60; found: C 64.76, H 7.19, 
N 3.48. 
 (S)-toluene-4-sulfonic acid 2-(2,6-dimethyl-phenyl)-4,5-dihydro-oxazol-4-ylmethyl ester 88k 
N
O
OTs
 
Synthesis according to the previous general procedure using alcohol 87k (2.65 g, 12.9 mmol), 
tosyl chloride (4.92 g, 25.8 mmol) and triethylamine (1.31 g, 12.9 mmol) yielded a colourless 
oil (2.30 g, 50%, 6.40 mmol). 
Rf = 0.49 (AcOEt/Hexane 1 :1); 
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[ ]20Dα = +69.2 (c = 1.00, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 7.80 (mc, 2H; tos CH), 7.34 (mc, 2H; tos CH), 
7.49 (mc, 1H; arom CH), 7.17 (t, 3J(H,H) = 7.6 Hz, 1H; arom CH), 7.01 (d, 3J(H,H) = 7.6 Hz, 
2H; arom CH), 4.57 (mc, 1H; oxaz CH), 4.44 (mc, 1H; oxaz CH2), 4.32 (mc, 1H; oxaz CH2), 
4.26 (mc, 1H; CH2OH), 4.13 (mc, 1H; CH2OH), 2.44 (s, 3H; tos CH3), 2.26 (s, 6H, CCH3); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 167.0 (NCO), 145.6 (tos C), 137.3 (2C; 
arom CCH3), 132.9 (tos C), 130.4 (2C, tos CH), 130.0 (arom CH), 128.6 (arom CCN), 128.4 
(2C, tos CH), 127.8 (2C; arom CH), 70.7 (oxaz CH2), 69.3 (CH2OH), 65.8 (oxaz CH), 22.1 
(tos CH3), 20.1 (2C; CCH3); 
IR (NaCl): ν~  =  2962w, 2922w, 1662m, 1596w, 1464w, 1360s, 1179s, 1096m, 1046m, 
957m, 818m, 777m, 666m cm-1; 
MS (FAB): m/z (%): 360 (100) [M + H]+; 
EA calcd (%) for C19H21NO4S (359.44): C 63.49, H 5.89, N 3.90; found: C 63.36, H 5.98, 
N 3.88. 
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6.3.10 Synthesis of imidazolium salts 89a-p 
(R)-1-(2-tert-butyl-4,5-dihydro-oxazol-4-ylmethyl)-3-methyl-3H-imidazol-1-ium 89a 
N
O
N
N
BArF  
A solution of tosylate 88a (400 mg, 1.28 mmol) and 1-methyl-1H-imidazole (105 mg, 
1.28 mmol) in DMF (0.5 ml) was heated at 80°C for 8 hours. The reaction mixture was 
concentrated in vacuo at 80°C and the residue was diluted in acetone (5 ml). NaBArF (1.13 g, 
1.28 mmol) was added to the solution which was stirred at room temperature for 30 minutes. 
The reaction mixture was filtered and concentrated in vacuo to remove the solvent. The crude 
product was purified by chromatography on a plug of silica gel eluting with CH2Cl2 (1L) to 
yield a white solid (1.06 g, 0.973 mmol, 76%). 
m.p. 120-121°C; 
[ ]20Dα = +35.5 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.45 (s, 1H; NCHN), 7.69 (mc, 8H; BArF ortho 
CH), 7.52 (mc, 4H; BArF para CH), 7.07 (mc, 1H; imid CH), 6.92 (mc, 1H; imid CH), 4.40 
(mc, 1H; oxaz CH2), 4.30 (mc, 1H; oxaz CH), 4.05 (mc, 1H; NCH2), 3.81 (mc, 2H; oxaz CH2 
+ NCH2), 3.72 (s, 3H, NCH3), 1.16 (s, 9H; tBu CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 178.0 (OCN), 161.7 (q, 1J(B,C) = 49.9 Hz, 
4C; BArF quat. C ipso to B), 135.3 (NCHN), 134.7 (br, 8C; BArF ortho CH), 129.0 (qq, 
2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 
8C; BArF CF3), 123.7 (imid CH), 122.9 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF 
para CH), 69.2 (oxaz CH2), 64.7 (oxaz CH), 54.1 (NCH2), 36.5 (NCH3), 33.5 (tBu C), 27.4 
(3C; tBu CH3); 
IR (KBr): ν~  = 3163w, 3098w, 2980w, 1655w, 1610w, 1577w, 1562w, 1482w, 1356m, 
1282s, 1122sbr, 932w, 889w, 839w, 745w, 713w, 682w, 671w, 624w cm-1; 
MS (FAB): m/z (%): 222 (100) [M - BArF]+; 
EA calcd (%) for C44H32BF24N3O (1085.52): C 48.68, H 2.97, N 3.87; found: C 48.63, 
H 3.15, N 3.64. 
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 Experimental 
(R)-1-(2-tert-butyl-4,5-dihydro-oxazol-4-ylmethyl)-3-isopropyl-3H-imidazol-1-ium 89b 
N
O
N
N
BArF  
Synthesis according to the previous general procedure using tosylate 88a (400 mg, 
1.28 mmol), isopropylimidazole (141 mg, 1.28 mmol) and NaBArF (1.13 g, 1.28 mmol) 
yielded a white solid (1.03 g, 72%, 0.922 mmol). 
m.p. 63-64°C; 
[ ]20Dα = +32.1 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.56 (s, 1H; NCHN), 7.69 (mc, 8H; BArF ortho 
CH), 7.53 (mc, 4H; BArF para CH), 7.08 (mc, 2H; imid CH), 4.40 (mc, 2H; oxaz CH2 + iPr 
CH), 4.32 (mc, 1H; oxaz CH), 4.08 (mc, 1H; NCH2), 3.85-3.75 (m, 2H; oxaz CH2 + NCH2), 
3.72 (mc, 6H, iPr CH3), 1.16 (s, 9H; tBu CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 178.1 (OCN), 161.7 (q, 1J(B,C) = 49.9 Hz, 
4C; BArF quat. C ipso to B), 134.7 (br, 8C; BArF ortho CH), 133.3 (NCHN), 129.0 (qq, 
2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 
8C; BArF CF3), 123.6 (imid CH), 120.0 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF 
para CH), 69.2 (oxaz CH2), 64.6 (oxaz CH), 54.2 (NCH2), 54.0 (iPr CH), 33.4 (tBu C), 27.4 
(3C; tBu CH3), 22.4 (iPr CH3), 22.4 (iPr CH3); 
IR (KBr): ν~  = 3172w, 2981w, 1651w, 1611w, 1585w, 1552w, 1466w, 1356m, 1282s, 
1121sbr, 987w, 936w, 905w, 889w, 839w, 737w, 714w, 682w, 671w, 652w cm-1; 
MS (FAB): m/z (%): 250 (100) [M - BArF]+; 
EA calcd (%) for C46H36BF24N3O (1113.26): C 49.62, H 3.26, N 3.77; found: C 49.88, 
H 3.21, N 3.49. 
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Chapter 6 
 (R)-1-(2-tert-butyl-4,5-dihydro-oxazol-4-ylmethyl)-3-(2,4,6-trimethyl-phenyl)-3H-imidazol-
1-ium 89c 
N
O
N
N
BArF
 
Synthesis according to the previous general procedure using tosylate 88a (400 mg, 
1.28 mmol), mesitylimidazole (239 mg, 1.28 mmol) and NaBArF (1.13 g, 1.28 mmol) yielded 
a white solid (1.20 g, 78%, 1.00 mmol). 
m.p. 142-143°C; 
[ ]20Dα = +19.8 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.48 (s, 1H; NCHN), 7.69 (mc, 8H; BArF ortho 
CH), 7.51 (mc, 4H; BArF para CH), 7.31 (mc, 1H; imid CH), 7.15 (mc, 1H; imid CH), 7.03 
(mc, 2H; arom CH), 4.39 (mc, 2H; oxaz CH2 + oxaz CH), 4.21 (mc, 1H; NCH2), 3.96 (mc, 
1H; NCH2), 3.83 (mc, 1H; oxaz CH2), 2.33 (s, 3H, CaromCH3), 1.96 (br, 3H, CaromCH3), 1.93 
(br, 3H, CaromCH3), 1.15 (s, 9H; tBu CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 177.9 (OCN), 161.7 (q, 1J(B,C) = 49.9 Hz, 
4C; BArF quat. C ipso to B), 142.6 (arom C), 136.0 (NCHN), 134.7 (br, 8C; BArF ortho CH), 
133.9 (arom C), 133.7 (arom C), 130.2 (arom CH), 130.1 (arom CH), 129.8 (arom C), 129.0 
(qq, 2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 
272.5 Hz, 8C; BArF CF3), 123.9 (imid CH), 123.4 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 
4C; BArF para CH), 69.1 (oxaz CH2), 64.9 (oxaz CH), 54.4 (NCH2), 33.4 (tBu C), 27.5 (3C; 
tBu CH3), 21.0 (CaromCH3), 16.8 (CaromCH3), 16.9 (CaromCH3); 
IR (KBr): ν~  = 3161w, 2978w, 1654w, 1610w, 1560w, 1482w, 1355m, 1278s, 1121sbr, 
931w, 887w, 839w, 744w, 713w, 682w, 670w, 624w, 577 cm-1; 
MS (FAB): m/z (%): 326 (100) [M - BArF]+; 
EA calcd (%) for C52H40BF24N3O (1189.67): C 52.50, H 3.39, N 3.53; found: C 52.06, 
H 3.46, N 3.34. 
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 Experimental 
 (R)-1-(2-tert-butyl-4,5-dihydro-oxazol-4-ylmethyl)-3-(2,2-dimethyl-propyl)-3H-imidazol-1-
ium 89d 
N
O
N
N
BArF
 
Synthesis according to the previous general procedure using tosylate 88a (400 mg, 
1.28 mmol), neopentylimidazole (177 mg, 1.28 mmol) and NaBArF (1.13 g, 1.28 mmol) 
yielded a colourless oil (1.00 g, 68%, 0.870 mmol). 
[ ]20Dα = +26.2 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.48 (s, 1H; NCHN), 7.68 (mc, 8H; BArF ortho 
CH), 7.53 (mc, 4H; BArF para CH), 7.01 (mc, 1H; imid CH), 6.95 (mc, 1H; imid CH), 4.42 
(mc, 1H; oxaz CH2), 4.31 (mc, 1H; oxaz CH), 4.07 (mc, 1H; NCH2), 3.85-3.75 (m, 4H; oxaz 
CH2 + NCH2 + NCH2C(CH3)3), 1.17 (s, 9H; tBu CH3), 0.93 (s, 9H; NCH2C(CH3)3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 161.7 (q, 1J(B,C) = 49.9 Hz, 4C; BArF quat. 
C ipso to B), 135.5 (NCHN), 134.7 (br, 8C; BArF ortho CH), 129.0 (qq, 2J(F,C) = 31.12 Hz, 
3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 8C; BArF CF3), 
123.4 (imid CH), 122.6 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para CH), 69.3 
(oxaz CH2), 64.6 (oxaz CH), 62.4 (NCH2C(CH3)3), 54.0 (NCH2), 32.5 (tBu C), 27.4 (3C; tBu 
CH3), 26.6 (3C; NCH2C(CH3)3), 2 quat. C not detected; 
IR (NaCl): ν~  = 3174w, 2979w, 1648w, 1610w, 1590w, 1560w, 1482w, 1358m, 1281s, 
1120sbr, 986w, 935w, 905w, 889w, 839w, 738w, 714w, 682w, 670w, 628w cm-1; 
MS (FAB): m/z (%): 278 (100) [M - BArF]+; 
EA calcd (%) for C48H40BF24N3O (1141.62): C 50.50, H 3.53, N 3.68; found: C 49.63, 
H 3.37, N 3.46. 
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Chapter 6 
 (R)-3-tert-butyl-1-(2-tert-butyl-4,5-dihydro-oxazol-4-ylmethyl)-3H-imidazol-1-ium 89e 
N
O
N
N
BArF
 
Synthesis according to the previous general procedure using tosylate 88a (400 mg, 
1.28 mmol), tert-butylimidazole (160 mg, 1.28 mmol) and NaBArF (1.13 g, 1.28 mmol) 
yielded of a white solid (1.08 g, 75%, 0.960 mmol). 
m.p. 84-85°C; 
[ ]20Dα = +35.1 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.65 (s, 1H; NCHN), 7.69 (mc, 8H; BArF ortho 
CH), 7.53 (mc, 4H; BArF para CH), 7.17 (mc, 1H; imid CH), 7.07 (mc, 1H; imid CH), 4.40 
(mc, 1H; oxaz CH2), 4.32 (mc, 1H; oxaz CH), 4.08 (mc, 1H; NCH2), 3.82 (mc, 2H; oxaz CH2 
+ NCH2), 1.55 (s, 9H; tBuimid CH3), 1.17 (s, 9H; tBuoxaz CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 178.0 (OCN), 161.7 (q, 1J(B,C) = 49.9 Hz, 
4C; BArF quat. C ipso to B), 134.7 (br, 8C; BArF ortho CH), 133.0 (NCHN), 129.0 (qq, 
2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 
8C; BArF CF3), 123.5 (imid CH), 119.4 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF 
para CH), 69.2 (oxaz CH2), 64.6 (oxaz CH), 61.1 (tBuimid C), 53.9 (NCH2), 33.4 (tBuoxaz C), 
29.4 (3C; tBuimid CH3), 27.4 (3C; tBuoxaz CH3); 
IR (KBr): ν~  = 3176w, 2981w, 1652w, 1611w, 1581w, 1550w, 1546w, 1466w, 1357m, 
1281s, 1120sbr, 986w, 936w, 901w, 889w, 839w, 737w, 714w, 682w, 670w, 656w cm-1; 
MS (FAB): m/z (%): 264 (100) [M - BArF]+; 
EA calcd (%) for C47H38BF24N3O (1127.51): C 50.06, H 3.31, N 3.73; found: C 49.99, 
H 3.33, N 3.51. 
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 Experimental 
 (R)-1-(2-adamantan-1-yl-4,5-dihydro-oxazol-4-ylmethyl)-3-methyl-3H-imidazol-1-ium 89f 
N
O
N
N
BArF
 
Synthesis according to the previous general procedure using tosylate 88f (400 mg, 
1.03 mmol), methylimidazole (84 mg, 1.03 mmol) and NaBArF (913 mg, 1.03 mmol) yielded 
a white solid (778 mg, 65%, 0.670 mmol). 
m.p. 142-143°C; 
[ ]20Dα = +29.5 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.48 (s, 1H; NCHN), 7.70 (mc, 8H; BArF ortho 
CH), 7.53 (mc, 4H; BArF para CH), 7.08 (mc, 1H; imid CH), 6.92 (mc, 1H; imid CH), 4.37 
(mc, 1H; oxaz CH2), 4.30 (mc, 1H; oxaz CH), 4.06 (mc, 1H; NCH2), 3.82 (mc, 2H; oxaz CH2 
+ NCH2), 3.72 (s, 3H, NCH3), 2.01 (mc, 3H; adam CH), 1.82 (mc, 6H; adam CH2), 1.75 (mc, 
3H; adam CH2), 1.66 (mc, 3H; adam CH2); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 161.7 (q, 1J(B,C) = 49.9 Hz, 4C; BArF quat. 
C ipso to B), 135.3 (NCHN), 134.7 (br, 8C; BArF ortho CH), 129.0 (qq, 2J(F,C) = 31.12 Hz, 
3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 8C; BArF CF3), 
123.7 (imid CH), 122.9 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para CH), 68.7 
(oxaz CH2), 64.4 (oxaz CH), 54.2 (NCH2), 39.4 (adam CH2), 36.5 (NCH3), 36.2 (adam CH2), 
35.5 (adam C), 27.6 (adam CH), 1 C quat. not detected; 
IR (KBr): ν~  = 2916w, 2862w, 1651w, 1612w, 1566w, 1458w, 1350m, 1272s, 1103sbr, 
887w, 833w, 748w, 710w, 671w cm-1; 
MS (FAB): m/z (%): 300 (100) [M - BArF]+; 
EA calcd (%) for C50H38BF24N3O (1163.63): C 51.61, H 3.29, N 3.61; found: C 51.42, 
H 3.28, N 3.54. 
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Chapter 6 
(R)-1-(2-adamantan-1-yl-4,5-dihydro-oxazol-4-ylmethyl)-3-isopropyl-3H-imidazol-1-ium 89g 
N
O
N
N
BArF
 
Synthesis according to the previous general procedure using tosylate 88f (400 mg, 
1.03 mmol), isopropylimidazole (113 mg, 1.03 mmol) and NaBArF (913 mg, 1.03 mmol) 
yielded a colourless oil (613 mg, 50%, 515 mmol). 
[ ]20Dα = +20.4 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.59 (s, 1H; NCHN), 7.73 (mc, 8H; BArF ortho 
CH), 7.56 (mc, 4H; BArF para CH), 7.12 (mc, 1H; imid CH), 7.10 (mc, 1H; imid CH), 4.50-
4.25 (m, 3H; oxaz CH2 + oxaz CH + iPr CH), 4.11 (mc, 1H; NCH2), 3.90-3.75 (m, 2H; oxaz 
CH2 + NCH2), 2.01 (mc, 3H; adam CH), 1.84 (mc, 6H; adam CH2), 1.69 (mc, 3H; adam 
CH2), 1.49 (mc, 3H; adam CH2), 1.48 (mc, 6H; iPr CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 177.2 (OCN), 161.7 (q, 1J(B,C) = 49.9 Hz, 
4C; BArF quat. C ipso to B), 134.7 (br, 8C; BArF ortho CH), 133.3 (NCHN), 129.0 (qq, 
2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 
8C; BArF CF3), 123.6 (imid CH), 119.9 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF 
para CH), 68.7 (oxaz CH2), 64.5 (oxaz CH), 54.2 (NCH2), 54.1 (iPr CH), 39.4 (adam CH2), 
36.1 (adam CH2), 35.4 (adam C), 27.7 (adam CH), 22.4 (iPr CH3), 22.3 (iPr CH3); 
IR (NaCl): ν~  = 2908w, 2854w, 1643w, 1612w, 1558w, 1458w, 1350m, 1273s, 1111sbr, 
975w, 933w, 887w, 833w, 741w, 710w, 671w cm-1; 
MS (FAB): m/z (%): 328 (100) [M - BArF]+; 
EA calcd (%) for C52H42BF24N3O (1191.68): C 52.41, H 3.55, N 3.53; found: C 52.27, 
H 3.55, N 3.51. 
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 Experimental 
 (R)-1-(2-adamantan-1-yl-4,5-dihydro-oxazol-4-ylmethyl)-3-(2,4,6-trimethyl-phenyl)-3H-
imidazol-1-ium 89h 
N
O
N
N
BArF
 
Synthesis according to the previous general procedure using tosylate 88f (400 mg, 
1.03 mmol), mesitylimidazole (191 mg, 1.03 mmol) and NaBArF (913 mg, 1.03 mmol) 
yielded a colourless oil (835 mg, 64%, 0.660 mmol). 
[ ]20Dα = +14.3 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.59 (s, 1H; NCHN), 7.74 (mc, 8H; BArF ortho 
CH), 7.55 (mc, 4H; BArF para CH), 7.40 (mc, 1H; imid CH), 7.18 (mc, 1H; imid CH), 7.02 
(mc, 2H; arom CH), 4.39 (mc, 2H; oxaz CH2 + oxaz CH), 4.25 (mc, 1H; NCH2), 3.98 (mc, 
1H; NCH2), 3.83 (mc, 1H; oxaz CH2), 2.32 (s, 3H, CaromCH3), 2.01 (mc, 3H; adam CH), 1.99 
(br, 3H, CaromCH3), 1.93 (br, 3H, CaromCH3), 1.83 (mc, 6H; adam CH2), 1.75 (mc, 3H; adam 
CH2), 1.66 (mc, 3H; adam CH2); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 177.2 (OCN), 161.7 (q, 1J(B,C) = 49.9 Hz, 
4C; BArF quat. C ipso to B), 142.6 (arom C), 136.1 (NCHN), 134.7 (br, 8C; BArF ortho CH), 
134.2 (arom C), 133.7 (arom C), 130.2 (arom CH), 129.8 (arom CH), 129.0 (qq, 2J(F,C) = 
31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 8C; BArF 
CF3), 123.9 (imid CH), 123.8 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para CH), 
68.6 (oxaz CH2), 64.8 (oxaz CH), 54.4 (NCH2), 39.4 (adam CH2), 36.2 (adam CH2), 35.4 
(adam C), 27.7 (adam CH), 20.9 (CaromCH3), 18.6 (CaromCH3), 16.8 (CaromCH3), 1 quat. C not 
detected; 
IR (NaCl): ν~  = 2916w, 2854w, 1720w, 1634w, 1612w, 1551w, 1458w, 1350m, 1273s, 
1111sbr, 972w, 933w, 887w, 841w, 748w, 710w, 671w cm-1; 
MS (FAB): m/z (%): 404 (100) [M - BArF]+; 
EA calcd (%) for C58H46BF24N3O (1267.78): C 54.95, H 3.66, N 3.31; found: C 54.65, 
H 3.93, N 3.44. 
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Chapter 6 
(R)-1-(2-adamantan-1-yl-4,5-dihydro-oxazol-4-ylmethyl)-3-(2,2-dimethyl-propyl)-3H-
imidazol-1-ium 89i 
N
O
N
N
BArF
 
Synthesis according to the previous general procedure using tosylate 88f (400 mg, 
1.03 mmol), neopentylimidazole (142 mg, 1.03 mmol) and NaBArF (913 mg, 1.03 mmol) 
yielded a white solid (829 mg, 66%, 0.680 mmol). 
m.p. 85-86°C; 
[ ]20Dα = +29.7 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.50 (s, 1H; NCHN), 7.70 (mc, 8H; BArF ortho 
CH), 7.53 (mc, 4H; BArF para CH), 7.07 (mc, 1H; imid CH), 6.97 (mc, 1H; imid CH), 4.38 
(mc, 1H; oxaz CH2), 4.31 (mc, 1H; oxaz CH), 4.10 (mc, 1H; NCH2), 3.90-3.75 (m, 4H; 1 x 
oxaz CH2 + 1 x NCH2 + 2 x CH2C(CH3)3), 2.00 (mc, 3H; adam CH), 1.81 (mc, 6H; adam 
CH2), 1.74 (mc, 3H; adam CH2), 1.65 (mc, 3H; adam CH2), 0.92 (mc, 9H; CH2C(CH3)3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 161.7 (q, 1J(B,C) = 49.9 Hz, 4C; BArF quat. 
C ipso to B), 135.6 (NCHN), 134.7 (br, 8C; BArF ortho CH), 129.0 (qq, 2J(F,C) = 31.12 Hz, 
3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 8C; BArF CF3), 
123.4 (imid CH), 122.7 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para CH), 68.8 
(oxaz CH2), 64.4 (oxaz CH), 62.4 (CH2C(CH3)3), 54.1 (NCH2), 39.4 (adam CH2), 36.2 (adam 
CH2), 35.2 (adam C), 32.4 (CH2C(CH3)3), 27.6 (adam CH), 26.5 (3C; CH2C(CH3)3), 1 quat. C 
not detected; 
IR (KBr): ν~  = 2908w, 2854w, 1643w, 1612w, 1558w, 1450w, 1350m, 1273s, 1111sbr, 
987w, 933w, 887w, 833w, 741w, 710w, 671w cm-1; 
MS (FAB): m/z (%): 356 (100) [M - BArF]+; 
EA calcd (%) for C54H46BF24N3O (1219.74): C 53.17, H 3.80, N 3.45; found: C 53.21, 
H 3.95, N 3.39. 
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(R)-1-(2-adamantan-1-yl-4,5-dihydro-oxazol-4-ylmethyl)-3-tert-butyl-3H-imidazol-1-ium 89j 
N
O
N
N
BArF
 
Synthesis according to the previous general procedure using tosylate 88f (400 mg, 
1.03 mmol), tert-butylimidazole (128 mg, 1.03 mmol) and NaBArF (913 mg, 1.03 mmol) 
yielded a white solid (782 mg, 63%, 0.649 mmol). 
m.p. 79-80°C; 
[ ]20Dα = +29.2 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.68 (s, 1H; NCHN), 7.70 (mc, 8H; BArF ortho 
CH), 7.53 (mc, 4H; BArF para CH), 7.17 (mc, 1H; imid CH), 7.07 (mc, 1H; imid CH), 4.37 
(mc, 2H; oxaz CH2 + oxaz CH), 4.11 (mc, 1H; NCH2), 3.90-3.75 (m, 2H; oxaz CH2 + NCH2), 
2.01 (mc, 3H; adam CH), 1.82 (mc, 6H; adam CH2), 1.75 (mc, 3H; adam CH2), 1.66 (mc, 3H; 
adam CH2), 1.56 (mc, 9H; tBu CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 161.7 (q, 1J(B,C) = 49.9 Hz, 4C; BArF quat. 
C ipso to B), 134.7 (br, 8C; BArF ortho CH), 133.0 (NCHN), 129.0 (qq, 2J(F,C) = 31.12 Hz, 
3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 8C; BArF CF3), 
123.4 (imid CH), 119.5 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para CH), 68.9 
(oxaz CH2), 64.1 (oxaz CH), 61.1 (tBu C), 53.8 (NCH2), 39.3 (adam CH2), 36.2 (adam CH2), 
35.5 (adam C), 29.4 (3C; tBu CH3), 27.6 (adam CH), 1 quat. C not detected; 
IR (KBr): ν~  = 2918w, 2856w, 1654w, 1610w, 1561w, 1456w, 1355m, 1277s, 1128sbr, 
992w, 932w, 887w, 839w, 744w, 712w, 682w, 671w cm-1; 
MS (FAB): m/z (%): 342 (100) [M - BArF]+; 
EA calcd (%) for C53H44BF24N3O (1205.71): C 52.80, H 3.68, N 3.49; found: C 52.92, 
H 3.91, N 3.43. 
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(R)-1-[2-(2,6-dimethyl-phenyl)-4,5-dihydro-oxazol-4-ylmethyl]-3-methyl-3H-imidazol-1-ium 
89k 
N
O
N
N
BArF
 
Synthesis according to the previous general procedure using tosylate 88k (400 mg, 
1.11 mmol), methylimidazole (91 mg, 1.11 mmol) and NaBArF (984 mg, 1.11 mmol) yielded 
a white solid (864 mg, 69%, 0.762 mmol). 
m.p. 81-82°C; 
[ ]20Dα = +40.0 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.57 (s, 1H; NCHN), 7.71 (mc, 8H; BArF ortho 
CH), 7.53 (mc, 4H; BArF para CH), 7.25 (mc, 1H; arom CH), 7.08 (mc, 3H, 2 x arom CH + 
1 x imid CH), 6.92 (mc, 1H, imid CH), 4.61 (mc, 2H; oxaz CH2 + oxaz CH), 4.16 (mc, 1H; 
NCH2), 4.03 (mc, 2H; oxaz CH2 + NCH2), 3.72 (s, 3H; NCH3), 2.26 (s, 6H; CaromCH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 167.9 (OCN), 161.7 (q, 1J(B,C) = 49.9 Hz, 
4C; BArF quat. C ipso to B), 136.5 (2C; arom CCH3), 135.5 (NCHN), 134.7 (br, 8C; BArF 
ortho CH), 130.4 (arom CH), 129.0 (qq, 2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C 
ipso to CF3), 127.8 (2C; arom CH), 127.1 (arom C), 124.5 (q, 1J(F,C) = 272.5 Hz, 8C; BArF 
CF3), 123.6 (imid CH), 123.1 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para CH), 
68.8 (oxaz CH2), 65.7 (oxaz CH), 54.4 (NCH2), 36.5 (NCH3), 19.5 (2C; CaromCH3); 
IR (KBr): ν~  = 3165w, 3107w, 2927w, 1647w, 1610w, 1561w, 1467w, 1356m, 1286s, 
1121sbr, 968w, 933w, 887w, 838w, 779w, 750w, 711w, 682w, 671w cm-1; 
MS (FAB): m/z (%): 270 (100) [M - BArF]+; 
EA calcd (%) for C48H32BF24N3O (1133.56): C 50.86, H 2.85, N 3.71; found: C 50.96, 
H 2.83, N 3.62. 
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(R)-1-[2-(2,6-dimethyl-phenyl)-4,5-dihydro-oxazol-4-ylmethyl]-3-isopropyl-3H-imidazol-1-
ium 89l 
N
O
N
N
BArF
 
Synthesis according to the previous general procedure using tosylate 88k (400 mg, 
1.11 mmol), isopropylimidazole (122 mg, 1.11 mmol) and NaBArF (984 mg, 1.11 mmol) 
yielded a white solid (788 mg, 61%, 0.678 mmol). 
m.p. 113-114°C; 
[ ]20Dα = +35.1 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.62 (s, 1H; NCHN), 7.70 (mc, 8H; BArF ortho 
CH), 7.53 (mc, 4H; BArF para CH), 7.25 (mc, 1H; arom CH), 7.10-6.60 (m, 4H, 2 x arom CH 
+ 2 x imid CH), 4.63 (mc, 2H; oxaz CH2 + oxaz CH), 4.42 (sept, 3J(H,H) = 6.7 Hz, 1H; 
CH(CH3)2), 4.18 (mc, 1H; NCH2), 4.02 (mc, 2H; oxaz CH2 + NCH2), 2.26 (s, 6H; CaromCH3), 
1.46 (mc, 6H; CH(CH3)2); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 167.9 (OCN), 161.7 (q, 1J(B,C) = 49.9 Hz, 
4C; BArF quat. C ipso to B), 136.7 (2C; arom CCH3), 134.7 (br, 8C; BArF ortho CH), 133.4 
(NCHN), 130.4 (arom CH), 129.0 (qq, 2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso 
to CF3), 127.8 (2C; arom CH), 127.0 (arom C), 124.5 (q, 1J(F,C) = 272.5 Hz, 8C; BArF CF3), 
123.6 (imid CH), 119.9 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para CH), 68.8 
(oxaz CH2), 65.6 (oxaz CH), 54.4 (CH(CH3)2), 54.2 (NCH2), 22.5 (CH(CH3)2), 22.5 
(CH(CH3)2), 19.7 (2C; CaromCH3); 
IR (KBr): ν~  = 3155w, 2986w, 1659w, 1612w, 1558w, 1465w, 1351m, 1273s, 1111sbr, 
964w, 933w, 887w, 841w, 779w, 740w, 710w, 671w cm-1; 
MS (FAB): m/z (%): 298 (100) [M - BArF]+; 
EA calcd (%) for C50H36BF24N3O (1161.61): C 51.70, H 3.12, N 3.62; found: C 51.72, 
H 3.05, N 3.54. 
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(R)-1-[2-(2,6-dimethyl-phenyl)-4,5-dihydro-oxazol-4-ylmethyl]-3-(2,4,6-trimethyl-phenyl)-
3H-imidazol-1-ium 89m 
N
O
N
N
BArF
 
Synthesis according to the previous general procedure using tosylate 88k (400 mg, 
1.11 mmol), mesitylimidazole (207 mg, 1.11 mmol) and NaBArF (984 mg, 1.11 mmol) 
yielded a white solid (896 mg, 65%, 0.723 mmol). 
m.p. 78-79°C; 
[ ]20Dα = +22.9 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.68 (s, 1H; NCHN), 7.72 (mc, 8H; BArF ortho 
CH), 7.53 (mc, 4H; BArF para CH), 7.36 (mc, 1H; imid CH), 7.24 (mc, 1H; aromoxaz CH), 
7.17 (mc, 1H; imid CH), 7.07 (mc, 2H, aromimid CH), 7.01 (mc, 2H, aromoxaz CH), 4.65 (mc, 
2H; oxaz CH2 + oxaz CH), 4.33 (mc, 1H; NCH2), 4.17 (mc, 1H; oxaz CH2), 4.06 (mc, 1H; 
NCH2), 3.72 (s, 3H; NCH3), 2.32 (mc, 6H; Carom oxazCH3), 2.27 (s, 3H, Carom imidCH3), 1.91 (br, 
6H, Carom imidCH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 167.8 (OCN), 161.7 (q, 1J(B,C) = 49.9 Hz, 
4C; BArF quat. C ipso to B), 142.6 (aromimid C), 136.7 (2C; aromoxaz CCH3), 136.3 (NCHN), 
134.7 (br, 8C; BArF ortho CH), 134.0 (aromimid C), 133.8 (aromimid C), 130.4 (aromoxaz CH), 
130.2 (aromimid CH), 130.1 (aromimid CH), 129.8 (aromimid C), 129.0 (qq, 2J(F,C) = 31.12 Hz, 
3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 127.8 (2C; aromoxaz CH), 127.0 (aromoxaz C), 
124.5 (q, 1J(F,C) = 272.5 Hz, 8C; BArF CF3), 124.0 (imid CH), 123.4 (imid CH), 117.5 (sept, 
3J(F,C) = 3.8 Hz, 4C; BArF para CH), 68.7 (oxaz CH2), 65.9 (oxaz CH), 54.6 (NCH2), 20.9 
(Carom imidCH3), 19.7 (2C; Carom oxazCH3), 16.8 (Carom imidCH3), 16.8 (Carom imidCH3); 
IR (KBr): ν~  = 3165w, 3012w, 2927w, 1647w, 1610w, 1575w, 1561w, 1467w, 1357m, 
1286s, 1116sbr, 968w, 933w, 886w, 838w, 780w, 750w, 711w, 682w, 671w, 622w cm-1; 
MS (FAB): m/z (%): 374 (100) [M - BArF]+, 187 (93); 
EA calcd (%) for C56H40BF24N3O (1237.71): C 54.34, H 3.26, N 3.39; found: C 54.25, 
H 3.24, N 3.08. 
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(R)-1-[2-(2,6-dimethyl-phenyl)-4,5-dihydro-oxazol-4-ylmethyl]-3-(2,2-dimethyl-propyl)-3H-
imidazol-1-ium 89n 
N
O
N
N
BArF
 
Synthesis according to the previous general procedure using tosylate 88k (400 mg, 
1.11 mmol), neopentylimidazole (153 mg, 1.11 mmol) and NaBArF (984 mg, 1.11 mmol) 
yielded a white solid (863 mg, 65%, 0.725 mmol). 
m.p. 141-142°C; 
[ ]20Dα = +35.7 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.56 (s, 1H; NCHN), 7.72 (mc, 8H; BArF ortho 
CH), 7.55 (mc, 4H; BArF para CH), 7.25 (mc, 1H; arom CH), 7.20-6.80 (m, 4H, 2 x arom CH 
+ 2 x imid CH), 4.62 (mc, 2H; oxaz CH2 + oxaz CH), 4.25 (mc, 1H; NCH2), 4.06 (mc, 2H; 
oxaz CH2 + NCH2), 3.80 (mc, 2H; NCH2C(CH3)3), 2.27 (s, 6H; CaromCH3), 0.88 (mc, 9H; 
NCH2C(CH3)3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 167.8 (OCN), 161.7 (q, 1J(B,C) = 49.9 Hz, 
4C; BArF quat. C ipso to B), 136.7 (2C; arom CCH3), 135.6 (NCHN), 134.7 (br, 8C; BArF 
ortho CH), 130.4 (arom CH), 129.0 (qq, 2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C 
ipso to CF3), 127.8 (2C; arom CH), 127.0 (arom C), 124.5 (q, 1J(F,C) = 272.5 Hz, 8C; BArF 
CF3), 123.5 (imid CH), 123.4 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para CH), 
68.7 (oxaz CH2), 65.8 (oxaz CH), 62.4 (NCH2C(CH3)3), 54.3 (NCH2), 32.4 (NCH2C(CH3)3), 
26.5 (3C; NCH2C(CH3)3), 19.7 (2C; CaromCH3); 
IR (KBr): ν~  = 3163w, 2970w, 1659w, 1612w, 1558w, 1473w, 1350m, 1273s, 1111sbr, 
964w, 888w, 841w, 779w, 748w, 710w, 671w cm-1; 
MS (FAB): m/z (%): 326 (100) [M - BArF]+; 
EA calcd (%) for C52H40BF24N3O (1189.67): C 52.50, H 3.39, N 3.53; found: C 52.06, 
H 3.36, N 3.38. 
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(R)-3-tert-butyl-1-[2-(2,6-dimethyl-phenyl)-4,5-dihydro-oxazol-4-ylmethyl]-3H-imidazol-1-
ium 89o 
N
O
N
N
BArF
 
Synthesis according to the previous general procedure using tosylate 88k (400 mg, 
1.11 mmol), tert-butylimidazole (138 mg, 1.11 mmol) and NaBArF (984 mg, 1.11 mmol) 
yielded a white solid (709 mg, 54%, 0.603 mmol). 
m.p. 135-136°C; 
[ ]20Dα = +39.9 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.61 (s, 1H; NCHN), 7.71 (mc, 8H; BArF ortho 
CH), 7.54 (mc, 4H; BArF para CH), 7.25 (mc, 1H; arom CH), 7.19 (mc, 1H, imid CH), 7.16 
(mc, 1H, imid CH), 7.08 (mc, 2H; arom CH), 4.62 (mc, 2H; oxaz CH2 + oxaz CH), 4.21 (mc, 
1H; NCH2), 4.03 (mc, 2H; oxaz CH2 + NCH2), 2.26 (s, 6H; CaromCH3), 1.53 (mc, 9H; tBu 
CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 167.7 (OCN), 161.7 (q, 1J(B,C) = 49.9 Hz, 
4C; BArF quat. C ipso to B), 136.7 (2C; arom CCH3), 134.7 (br, 8C; BArF ortho CH), 132.7 
(NCHN), 130.3 (arom CH), 129.0 (qq, 2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso 
to CF3), 127.9 (2C; arom CH), 127.0 (arom C), 124.5 (q, 1J(F,C) = 272.5 Hz, 8C; BArF CF3), 
123.6 (imid CH), 119.7 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para CH), 68.7 
(oxaz CH2), 65.7 (oxaz CH), 61.4 (tBu C), 54.2 (NCH2), 29.4 (tBu CH3), 19.7 (2C; 
CaromCH3); 
IR (KBr): ν~  = 3173w, 2993w, 1670w, 1610w, 1552w, 1468w, 1354m, 1273s, 1121sbr, 
962w, 935w, 888w, 839w, 786w, 744w, 713w, 682w, 671w, 626w cm-1; 
MS (FAB): m/z (%): 312 (100) [M - BArF]+; 
EA calcd (%) for C51H38BF24N3O (1175.64): C 52.10, H 3.26, N 3.57; found: C 51.92, 
H 3.27, N 3.51. 
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(R)-1-(2-phenyl-4,5-dihydro-oxazol-4-ylmethyl)-3-(2,4,6-trimethyl-phenyl)-3H-imidazol-1-
ium 89p 
N
O
N
N
BArF
 
Synthesis according to the previous general procedure using tosylate 88p (250 mg, 
0.749 mmol), mesitylimidazole (83 mg, 0.749 mmol) and NaBArF (664 mg, 0.749 mmol) 
yielded a colourless oil (601 mg, 69%, 0.517 mmol). 
[ ]20Dα = +29.5 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 8.50 (s, 1H; NCHN), 7.85 (d, 3J(H,H) = 7.8 Hz, 
2H; aromoxaz CH), 7.72 (mc, 8H; BArF ortho CH), 7.53 (mc, 5H; 4 x BArF para CH + 1 x 
aromoxaz CH), 7.40 (t, 3J(H,H) = 7.8 Hz, 2H; aromoxaz CH), 7.37 (mc, 1H; imid CH), 7.16 (mc, 
1H; imid CH), 7.03 (br, 1H; aromimid CH), 6.98 (br, 1H; aromimid CH), 4.67 (mc, 1H; oxaz 
CH), 4.61 (mc, 1H; oxaz CH2), 4.44 (mc, 1H; NCH2), 4.16 (mc, 1H; NCH2), 4.08 (mc, 1H; 
oxaz CH2), 2.32 (s, 3H, CaromCH3), 1.98 (br, 3H, CaromCH3), 1.77 (br, 3H, CaromCH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 167.2 (OCN), 161.7 (q, 1J(B,C) = 49.9 Hz, 
4C; BArF quat. C ipso to B), 142.8 (aromimid C), 136.1 (NCHN), 134.9 (br, 8C; BArF ortho 
CH), 133.9 (aromimid C), 133.8 (aromimid C), 132.9 (aromoxaz CH), 130.3 (2C; aromimid CH), 
129.8 (aromimid C), 129.0 (qq, 2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 
128.9 (2C; aromoxaz CH), 128.5 (2C; aromoxaz CH), 125.9 (aromoxaz C), 124.5 (q, 1J(F,C) = 
272.5 Hz, 8C; BArF CF3), 124.2 (imid CH), 123.7 (imid CH), 117.7 (sept, 3J(F,C) = 3.8 Hz, 
4C; BArF para CH), 69.1 (oxaz CH2), 65.3 (oxaz CH), 54.1 (NCH2), 21.1 (CaromCH3), 17.0 
(CaromCH3), 16.7 (CaromCH3); 
IR (NaCl): ν~  = 3159w, 2963w, 2927w,1704w, 1645w, 1610w, 1550w, 1452w, 1354m, 
1273s, 1121sbr, 977w, 932w, 888w, 839w, 782w, 743w, 698w, 671w cm-1; 
MS (FAB): m/z (%): 346 (100) [M - BArF]+; 
EA calcd (%) for C54H36BF24N3O (1209.66): C 53.62, H 2.91, N 3.47; found: C 53.54, 
H 3.10, N 3.33. 
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6.3.11 Synthesis of iridium complexes 90a-p 
(R)-{(η4-1,5-cyclooctadiene)-[1-(2-tert-butyl-4,5-dihydro-oxazol-4-ylmethyl)-3-methyl-
imidazolin-2-ylidene]iridium(I)}-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 90a 
N
O
N
N
BArF
Ir
 
Synthesis according to the metalation procedure 6.3.4 using imidazolium salt 89a (200 mg, 
0.184 mmol), [(η4-cod)IrCl]2 (62 mg, 0.092 mmol) and NaOtBu (18 mg, 0.184 mmol) yielded 
an orange solid (209 mg, 82%, 0.151 mmol). 
[ ]20Dα = +72 (c = 0.150, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.70 (mc, 8H; BArF ortho CH), 7.53 (mc, 4H; 
BArF para CH), 6.68 (mc, 1H; imid CH), 6.65 (mc, 1H; imid CH), 5.21 (mc, 1H; NCH2), 4.61 
(mc, 2H; oxaz CH2 + oxaz CH), 4.52 (mc, 1H; cod CH), 4.37 (mc, 1H; cod CH), 4.01 (mc, 
1H; cod CH), 3.81 (mc, 3H; cod CH + NCH2 + oxaz CH2), 3.66 (s, 3H, NCH3), 2.33 (mc, 1H; 
cod CH2), 2.24 (mc, 1H; cod CH2), 2.10 (mc, 2H; cod CH2), 1.91 (mc, 2H; cod CH2), 1.75 
(mc, 2H; cod CH2), 1.22 (s, 9H; tBu CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 181.2 (OCN), 175.4 (NCN), 161.7 (q, 
1J(B,C) = 49.9 Hz, 4C; BArF quat. C ipso to B), 134.8 (br, 8C; BArF ortho CH), 128.9 (qq, 
2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 
8C; BArF CF3), 122.4 (imid CH), 122.1 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF 
para CH), 86.0 (cod CH), 80.3 (cod CH), 71.0 (oxaz CH2), 62.5 (cod CH), 62.4 (oxaz CH), 
57.8 (cod CH), 51.6 (NCH2), 37.1 (NCH3), 33.9 (tBu C), 32.9 (cod CH2), 32.4 (cod CH2), 
29.8 (cod CH2), 29.0 (cod CH2), 28.5 (3C; tBu CH3); 
IR (KBr): ν~  = 2968w, 2892w, 1610m, 1459w, 1406w, 1356m, 1279s, 1134bs, 889w, 839w, 
716w, 685w, 669w cm-1; 
MS (FAB): m/z (%): 522 (100) [M - BArF]+; 
EA calcd (%) for C52H43BF24IrN3O (1384.91): C 45.10, H 3.13, N 3.03; found: C 45.05, 
H 3.18, N 3.10. 
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(R)-{(η4-1,5-cyclooctadiene)-[1-(2-tert-butyl-4,5-dihydro-oxazol-4-ylmethyl)-3-isopropyl-
imidazolin-2-ylidene]iridium(I)}-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 90b 
N
O
N
N
BArF
Ir
 
Synthesis according to the metalation procedure 6.3.4 using imidazolium salt 89b (200 mg, 
0.180 mmol), [(η4-cod)IrCl]2 (60 mg, 0.090 mmol) and NaOtBu (17 mg, 0.148 mmol) yielded 
an orange solid (178 mg, 70%, 0.126 mmol). 
[ ]20Dα = +79 (c = 0.191, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.70 (mc, 8H; BArF ortho CH), 7.53 (mc, 4H; 
BArF para CH), 6.80 (mc, 1H; imid CH), 6.73 (mc, 1H; imid CH), 5.25 (mc, 1H; NCH2), 4.61 
(mc, 3H; oxaz CH2 + oxaz CH + iPr CH), 4.45 (mc, 1H; cod CH), 4.35 (mc, 1H; cod CH), 
3.85 (mc, 2H; cod CH), 3.80 (mc, 2H; NCH2 + oxaz CH2), 2.28 (mc, 2H; cod CH2), 2.10 (mc, 
2H; cod CH2), 2.01 (mc, 1H; cod CH2), 1.85 (mc, 1H; cod CH2), 1.78 (mc, 1H; cod CH2), 
1.65 (mc, 1H; cod CH2), 1.36 (d, 3J(H,H) = 7.1 Hz, 3H; iPr CH3), 1.29 (d, 3J(H,H) = 7.1 Hz, 
3H; iPr CH3), 1.24 (s, 9H; tBu CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 181.1 (OCN), 174.0 (NCN), 161.7 (q, 
1J(B,C) = 49.9 Hz, 4C; BArF quat. C ipso to B), 134.8 (br, 8C; BArF ortho CH), 128.9 (qq, 
2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 
8C; BArF CF3), 123.1 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para CH), 116.6 
(imid CH), 85.3 (cod CH), 79.7 (cod CH), 70.9 (oxaz CH2), 62.9 (cod CH), 62.5 (oxaz CH), 
57.8 (cod CH), 52.3 (iPr CH), 51.3 (NCH2), 33.8 (tBu C), 33.3 (cod CH2), 32.1 (cod CH2), 
29.6 (cod CH2), 29.1 (cod CH2), 28.5 (3C; tBu CH3), 24.9 (iPr CH3), 22.2 (iPr CH3); 
IR (KBr): ν~  = 2982w, 1611m, 1425w, 1356m, 1275s, 1126bs, 886w, 839w, 714w, 681w, 
670w cm-1; 
MS (FAB): m/z (%): 550 (100) [M - BArF]+; 
EA calcd (%) for C54H47BF24IrN3O (1412.96): C 45.90, H 3.35, N 2.97; found: C 45.93, 
H 3.30, N 3.00. 
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(R)-{(η4-1,5-cyclooctadiene)-[1-(2-tert-butyl-4,5-dihydro-oxazol-4-ylmethyl)-3-(2,4,6-
trimethyl-phenyl)-imidazolin-2-ylidene]iridium(I)}-tetrakis[3,5-
bis(trifluoromethyl)phenyl]borate 90c 
N
O
N
N
BArF
Ir
 
Synthesis according to the metalation procedure 6.3.4  using imidazolium salt 89c (222 mg, 
0.186 mmol), [(η4-cod)IrCl]2 (63 mg, 0.093 mmol) and NaOtBu (18 mg, 0.186 mmol) yielded 
an orange solid (149 mg, 54%, 0.100 mmol). 
[ ]20Dα = +58 (c = 0.164, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.71 (mc, 8H; BArF ortho CH), 7.53 (mc, 4H; 
BArF para CH), 6.99 (mc, 1H, arom CH), 6.95 (mc, 1H, arom CH), 6.84 (mc, 1H; imid CH), 
6.73 (mc, 1H; imid CH), 4.88 (mc, 1H; oxaz CH), 4.81 (mc, 1H; NCH2), 4.51 (mc, 1H; oxaz 
CH2), 4.34 (mc, 1H; cod CH), 3.97 (mc, 1H; oxaz CH2), 3.88 (mc, 2H; cod CH + NCH2), 3.61 
(mc, 1H; cod CH), 3.10 (mc, 1H; cod CH), 2.32 (s, 3H; CaromCH3), 2.07 (mc, 1H; cod CH2), 
1.97 (mc, 8H; 3 x CaromCH3 + 2 x cod CH2), 1.85 (mc, 1H; cod CH2), 1.74 (mc, 1H; cod CH2), 
1.68 (mc, 1H; cod CH2), 1.52 (mc, 1H; cod CH2), 1.36 (s, 9H; tBu CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 180.8 (OCN), 171.8 (NCN), 161.7 (q, 
1J(B,C) = 49.9 Hz, 4C; BArF quat. C ipso to B), 140.3 (arom C), 134.8 (br, 8C; BArF ortho 
CH), 134.6 (arom C), 134.3 (arom C), 134.1 (arom C), 129.6 (arom CH), 129.3 (arom CH), 
128.9 (qq, 2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 
272.5 Hz, 8C; BArF CF3), 124.1 (imid CH), 122.4 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 
4C; BArF para CH), 85.1 (cod CH), 76.6 (cod CH), 70.2 (oxaz CH2), 64.0 (cod CH), 62.3 
(oxaz CH), 62.0 (cod CH), 50.7 (NCH2), 34.1 (2C; cod CH2 overlap with tBu C), 31.3 (cod 
CH2), 31.0 (cod CH2), 28.7 (3C; tBu CH3), 27.7 (cod CH2), 21.0 (CaromCH3), 18.6 (CaromCH3), 
17.5 (CaromCH3); 
IR (KBr): ν~  = 2960w, 1611m, 1482w, 1356m, 1275s, 1127bs, 887w, 839w, 713w, 682w, 
670w cm-1; 
MS (FAB): m/z (%): 626 (100) [M - BArF]+; 
EA calcd (%) for C60H51BF24IrN3O (1489.06): C 48.40, H 3.45, N 2.82; found: C 48.66, 
H 3.35, N 2.98. 
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 Experimental 
(R)-{(η4-1,5-cyclooctadiene)-[1-(2-tert-butyl-4,5-dihydro-oxazol-4-ylmethyl)-3-(2,2-
dimethyl-propyl)-imidazolin-2-ylidene]iridium(I)}-tetrakis[3,5-
bis(trifluoromethyl)phenyl]borate 90d 
N
O
N
N
BArF
Ir
 
Synthesis according to the metalation procedure 6.3.4  using imidazolium salt 89d (200 mg, 
0.175 mmol), [(η4-cod)IrCl]2 (59 mg, 0.087 mmol) and NaOtBu (17 mg, 0.175 mmol) yielded 
an orange solid (161 mg, 64%, 0.112 mmol). 
[ ]20Dα = +83 (c = 0.153, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.70 (mc, 8H; BArF ortho CH), 7.53 (mc, 4H; 
BArF para CH), 6.89 (mc, 1H; imid CH), 6.77 (mc, 1H; imid CH), 5.35 (mc, 1H; NCH2), 4.60 
(mc, 2H; oxaz CH2 + oxaz CH), 4.45 (mc, 1H; cod CH), 4.22 (mc, 1H; cod CH), 3.95 (mc, 
3H; 2 x cod CH + 1 x NCH2C(CH3)3), 3.80 (mc, 2H; NCH2 + oxaz CH2), 3.55 (mc, 1H; 
NCH2C(CH3)3), 2.27 (mc, 2H; cod CH2), 2.16 (mc, 1H; cod CH2), 2.05 (mc, 2H; cod CH2), 
1.93 (mc, 1H; cod CH2), 1.71 (mc, 1H; cod CH2), 1.60 (mc, 1H; cod CH2), 1.20 (s, 9H; tBu 
CH3), 0.93 (s, 9H, NCH2C(CH3)3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 181.2 (OCN), 176.3 (NCN), 161.7 (q, 
1J(B,C) = 49.9 Hz, 4C; BArF quat. C ipso to B), 134.8 (br, 8C; BArF ortho CH), 128.9 (qq, 
2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 
8C; BArF CF3), 122.8 (imid CH), 121.5 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF 
para CH), 85.3 (cod CH), 78.6 (cod CH), 70.8 (oxaz CH2), 62.8 (cod CH), 62.5 (oxaz CH), 
61.1 (NCH2C(CH3)3), 60.0 (cod CH), 51.9 (NCH2), 33.9 (tBu C), 33.7 (cod CH2), 32.0 
(NCH2C(CH3)3), 31.7 (cod CH2), 29.8 (cod CH2), 28.9 (cod CH2), 28.4 (3C; tBu CH3), 27.7 
(NCH2C(CH3)3); 
IR (KBr): ν~  = 2982w, 1612w, 1439w, 1356m, 1278s, 1126bs, 888w, 839w, 713w, 681w, 
671w cm-1; 
MS (FAB): m/z (%): 578 (100) [M - BArF]+; 
EA calcd (%) for C56H51BF24IrN3O (1441.01): C 46.68, H 3.57, N 2.92; found: C 46.73, 
H 3.43, N 2.98. 
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Chapter 6 
(R)-{(η4-1,5-cyclooctadiene)-[1-(2-tert-butyl-4,5-dihydro-oxazol-4-ylmethyl)-3-tert-butyl-
imidazolin-2-ylidene]iridium(I)}-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 90e 
N
O
N
N
BArF
Ir
 
Synthesis according to the metalation procedure 6.3.4  using imidazolium salt 89e (200 mg, 
0.177 mmol), [(η4-cod)IrCl]2 (60 mg, 0.088 mmol) and NaOtBu (17 mg, 0.177 mmol) yielded 
an orange/yellow solid (174 mg, 69%, 0.122 mmol). 
[ ]20Dα = +55 (c = 0.113, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.70 (mc, 8H; BArF ortho CH), 7.53 (mc, 4H; 
BArF para CH), 6.96 (mc, 1H; imid CH), 6.70 (mc, 1H; imid CH), 5.55 (mc, 1H; NCH2), 4.61 
(mc, 2H; oxaz CH2 + oxaz CH), 4.25 (mc, 2H; cod CH), 4.02 (mc, 1H; cod CH), 3.88 (mc, 
2H; cod CH + NCH2), 3.70 (mc, 2H; oxaz CH2), 2.38 (mc, 1H; cod CH2), 2.15 (mc, 3H; cod 
CH2), 2.03 (mc, 1H; cod CH2), 1.88 (mc, 1H; cod CH2), 1.64 (mc, 10H; 1 x cod CH2 + 9 x 
tBuimid CH3), 1.51 (mc, 1H; cod CH2), 1.21 (s, 9H; tBuoxaz CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 181.3 (OCN), 174.2 (NCN), 161.7 (q, 
1J(B,C) = 49.9 Hz, 4C; BArF quat. C ipso to B), 134.8 (br, 8C; BArF ortho CH), 128.9 (qq, 
2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 
8C; BArF CF3), 122.0 (imid CH), 119.0 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF 
para CH), 82.6 (cod CH), 77.8 (cod CH), 70.2 (oxaz CH2), 63.8 (cod CH), 63.2 (oxaz CH), 
58.9 (tBuimid C), 58.5 (cod CH), 51.5 (NCH2), 34.0 (tBuoxaz C), 34.0 (cod CH2), 32.3 (3C; 
tBuimid CH3), 30.7 (cod CH2), 30.5 (cod CH2), 28.3 (3C; tBuoxaz CH3), 28.0 (cod CH2); 
IR (KBr): ν~  = 2974w, 1611w, 1481w, 1424w, 1404w, 1356m, 1275s, 1134bs, 888w, 839w, 
713w, 682w, 671w cm-1; 
MS (FAB): m/z (%): 564 (100) [M - BArF]+; 
EA calcd (%) for C55H49BF24IrN3O (1426.97): C 46.29, H 3.46, N 2.94; found: C 45.98, 
H 3.44, N 2.80. 
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 Experimental 
(R)-{(η4-1,5-cyclooctadiene)-[1-(2-adamantan-1-yl-4,5-dihydro-oxazol-4-ylmethyl)-3-
methyl-imidazolin-2-ylidene]iridium(I)}-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 90f 
N
O
N
N
BArF
Ir
 
Synthesis according to the metalation procedure 6.3.4  using imidazolium salt 89f (250 mg, 
0.215 mmol), [(η4-cod)IrCl]2 (72 mg, 0.107 mmol) and NaOtBu (21 mg, 0.215 mmol) yielded 
an orange solid (208 mg, 66%, 0.142 mmol). 
[ ]20Dα = +61 (c = 0.174, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.71 (mc, 8H; BArF ortho CH), 7.53 (mc, 4H; 
BArF para CH), 6.65 (mc, 2H; imid CH), 5.18 (mc, 1H; NCH2), 4.58 (mc, 2H; oxaz CH2 + 
oxaz CH), 4.54 (mc, 1H; cod CH), 4.47 (mc, 1H; cod CH), 3.97 (mc, 1H; cod CH), 3.78 (mc, 
2H; NCH2 + oxaz CH2), 3.67 (s, 3H, NCH3), 2.32 (mc, 2H; cod CH2), 2.25 (mc, 5H; 2 x cod 
CH2 + 3 x adam CH), 1.93 (mc, 2H; cod CH2), 1.90-1.70 (m, 11H; 2 x cod CH2 + 9 x adam 
CH2), 1.67 (mc, 3H; adam CH2); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 180.7 (OCN), 175.4 (NCN), 161.7 (q, 
1J(B,C) = 49.9 Hz, 4C; BArF quat. C ipso to B), 134.8 (br, 8C; BArF ortho CH), 128.9 (qq, 
2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 
8C; BArF CF3), 122.4 (imid CH), 122.1 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF 
para CH), 85.9 (cod CH), 79.8 (cod CH), 70.6 (oxaz CH2), 62.2 (cod CH), 61.9 (oxaz CH), 
57.0 (cod CH), 51.7 (NCH2), 40.1 (3C; adam CH2), 37.2 (NCH3) 36.0 (adam C), 35.9 (3C; 
adam CH2), 32.9 (cod CH2), 32.5 (cod CH2), 29.8 (cod CH2), 29.1 (cod CH2), 27.5 (3C; adam 
CH); 
IR (KBr): ν~  = 2918w, 2857w, 1607m, 1457w, 1356m, 1278s, 1125bs, 887w, 838w, 714w, 
685w, 670w cm-1; 
MS (FAB): m/z (%): 600 (100) [M - BArF]+; 
EA calcd (%) for C58H49BF24IrN3O (1463.02): C 47.62, H 3.38, N 2.87; found: C 47.27, 
H 3.41, N 2.69. 
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Chapter 6 
(R)-{(η4-1,5-cyclooctadiene)-[1-(2-adamantan-1-yl-4,5-dihydro-oxazol-4-ylmethyl)-3-
isopropyl-imidazolin-2-ylidene]iridium(I)}-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 90g 
N
O
N
N
BArF
Ir
 
Synthesis according to the metalation procedure 6.3.4  using imidazolium salt 89g (200 mg, 
0.168 mmol), [(η4-cod)IrCl]2 (56 mg, 0.084 mmol) and NaOtBu (16 mg, 0.168 mmol) yielded 
an orange solid (130 mg, 52%, 0.087 mmol). 
[ ]20Dα = +65 (c = 0.141, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.71(mc, 8H; BArF ortho CH), 7.54 (mc, 4H; 
BArF para CH), 6.80 (mc, 1H; imid CH), 6.72 (mc, 1H; imid CH), 5.22 (mc, 1H; NCH2), 4.55 
(mc, 3H; oxaz CH2 + oxaz CH + iPr CH), 4.46 (mc, 1H; cod CH), 4.41 (mc, 1H; cod CH), 
3.88 (mc, 1H; cod CH), 3.83 (mc, 1H; cod CH), 3.77 (mc, 2H; NCH2 + oxaz CH2), 2.27 (mc, 
2H; cod CH2), 2.10 (mc, 2H; cod CH2), 2.06 (mc, 4H; 1 x cod CH2 + 3 x adam CH), 1.87 (mc, 
7H; 1 x cod CH2 + 6 x adam CH2), 1.79 (mc, 4H; 1 x cod CH2 + 3 x adam CH2), 1.66 (mc, 
4H; 1 x cod CH2 + 3 x adam CH2), 1.38 (d, 3J(H,H) = 7.2 Hz, 3H; iPr CH3), 1.29 (d, 3J(H,H) 
= 6.9 Hz, 3H; iPr CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 180.6 (OCN), 174.1 (NCN), 161.7 (q, 
1J(B,C) = 49.9 Hz, 4C; BArF quat. C ipso to B), 134.8 (br, 8C; BArF ortho CH), 128.9 (qq, 
2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 
8C; BArF CF3), 123.1 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para CH), 116.5 
(imid CH), 85.4 (cod CH), 79.2 (cod CH), 70.6 (oxaz CH2), 62.5 (cod CH), 62.0 (oxaz CH), 
57.3 (cod CH), 52.4 (iPr CH), 51.6 (NCH2), 40.0 (3C; adam CH2), 36.0 (adam C), 35.9 (3C; 
adam CH2), 33.4 (cod CH2), 32.0 (cod CH2), 29.9 (cod CH2), 29.1 (cod CH2), 27.5 (3C; adam 
CH), 25.2 (iPr CH3), 22.2 (iPr CH3); 
IR (KBr): ν~  = 2916w, 1608m, 1425w, 1355m, 1278s, 1126bs, 888w, 839w, 713w, 682w, 
671w cm-1; 
MS (FAB): m/z (%): 628 (100) [M - BArF]+; 
EA calcd (%) for C60H53BF24IrN3O (1491.07): C 48.33, H 3.58, N 2.82; found: C 48.06, 
H 3.55, N 2.68. 
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 Experimental 
(R)-{(η4-1,5-cyclooctadiene)-[1-(2-adamantan-1-yl-4,5-dihydro-oxazol-4-ylmethyl)-3-(2,4,6-
trimethyl-phenyl)-imidazolin-2-ylidene]iridium(I)}-tetrakis[3,5-
bis(trifluoromethyl)phenyl]borate 90h 
N
O
N
N
BArF
Ir
 
Synthesis according to the metalation procedure 6.3.4  using imidazolium salt 89h (240 mg, 
0.189 mmol), [(η4-cod)IrCl]2 (64 mg, 0.095 mmol) and NaOtBu (18 mg, 0.189 mmol) yielded 
an orange solid (187 mg, 63%, 0.119 mmol). 
[ ]20Dα = +48 (c = 0.177, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.71 (mc, 8H; BArF ortho CH), 7.52 (mc, 4H; 
BArF para CH), 7.00 (mc, 1H, arom CH), 6.95 (mc, 1H, arom CH), 6.80 (mc, 1H; imid CH), 
6.72 (mc, 1H; imid CH), 4.95 (mc, 1H; oxaz CH), 4.67 (mc, 1H; NCH2), 4.43 (mc, 1H; oxaz 
CH2), 4.29 (mc, 1H; cod CH), 3.98 (mc, 2H; oxaz CH2 + cod CH), 3.88 (mc, 1H; NCH2), 3.59 
(mc, 1H; cod CH), 3.07 (mc, 1H; cod CH), 2.34 (s, 3H; CaromCH3), 2.20-2.00 (m, 11H; 3 x 
adam CH2 + 3 x adam CH + 3 x CaromCH3 + 2 x cod CH2), 2.00-1.82 (m, 8H; 3 x adam CH2 + 
3 x CaromCH3 + 2 x cod CH2), 1.82-1.75 (m, 3H; 3 x adam CH2), 1.75-1.60 (m, 6H; 3 x adam 
CH2 +3 x cod CH2), 1.60-1.50 (m, 1H; cod CH2); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 180.1 (OCN), 170.9 (NCN), 161.7 (q, 
1J(B,C) = 49.9 Hz, 4C; BArF quat. C ipso to B), 140.3 (arom C), 134.8 (br, 8C; BArF ortho 
CH), 134.5 (arom C), 134.3 (arom C), 134.2 (arom C), 129.7 (arom CH), 129.3 (arom CH), 
128.9 (qq, 2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 
272.5 Hz, 8C; BArF CF3), 124.3 (imid CH), 122.3 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 
4C; BArF para CH), 84.5 (cod CH), 76.0 (cod CH), 69.7 (oxaz CH2), 63.6 (cod CH), 61.9 
(oxaz CH), 61.9 (cod CH), 51.0 (NCH2), 39.6 (3C; adam CH2), 36.3 (adam C), 35.9 (3C; 
adam CH2), 34.0 (cod CH2), 31.4 (cod CH2), 30.8 (cod CH2), 28.0 (cod CH2), 27.5 (3C; adam 
CH), 21.0 (CaromCH3), 18.8 (CaromCH3), 17.6 (CaromCH3); 
IR (KBr): ν~  = 2920w, 1609m, 1456w, 1356m, 1278s, 1126bs, 887w, 713w, 684w cm-1; 
MS (FAB): m/z (%): 704 (100) [M - BArF]+; 
EA calcd (%) for C66H57BF24IrN3O (1567.17): C 50.58, H 3.67, N 2.68; found: C 50.57, 
H 3.68, N 2.75. 
 181
Chapter 6 
(R)-{(η4-1,5-cyclooctadiene)-[1-(2-adamantan-1-yl-4,5-dihydro-oxazol-4-ylmethyl)-3-(2,2-
dimethyl-propyl)-imidazolin-2-ylidene]iridium(I)}-tetrakis[3,5-
bis(trifluoromethyl)phenyl]borate 90i 
N
O
N
N
BArF
Ir
 
Synthesis according to the metalation procedure 6.3.4  using imidazolium salt 89i (213 mg, 
0.175 mmol), [(η4-cod)IrCl]2 (59 mg, 0.087 mmol) and NaOtBu (17 mg, 0.175 mmol) yielded 
an orange solid (133 mg, 50%, 0.087 mmol). 
[ ]20Dα = +33 (c = 0.129, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.71 (mc, 8H; BArF ortho CH), 7.53 (mc, 4H; 
BArF para CH), 6.89 (mc, 1H; imid CH), 6.75 (mc, 1H; imid CH), 5.34 (mc, 1H; NCH2), 4.55 
(mc, 2H; oxaz CH2 + oxaz CH), 4.44 (mc, 1H; cod CH), 4.31 (mc, 1H; cod CH), 3.95 (mc, 
3H; 2 x cod CH + 1 x NCH2C(CH3)3), 3.81 (mc, 2H; NCH2 + oxaz CH2), 3.52 (mc, 1H; 
NCH2C(CH3)3), 2.27 (mc, 2H; cod CH2), 2.17 (mc, 1H; cod CH2), 2.05 (mc, 5H; 3 x adam 
CH + 2 x cod CH2), 1.94 (mc, 1H; cod CH2), 1.85 (mc, 3H; adam CH2), 1.78 (mc, 6H; adam 
CH2), 1.71 (mc, 1H; cod CH2), 1.63 (mc, 4H; 1 x cod CH2 + 3 x adam CH2), 0.95 (s, 9H, 
NCH2C(CH3)3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 181.2 (OCN), 176.4 (NCN), 161.7 (q, 
1J(B,C) = 49.9 Hz, 4C; BArF quat. C ipso to B), 134.8 (br, 8C; BArF ortho CH), 128.9 (qq, 
2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 
8C; BArF CF3), 122.9 (imid CH), 121.4 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF 
para CH), 85.2 (cod CH), 78.4 (cod CH), 70.5 (oxaz CH2), 62.5 (cod CH), 62.0 (oxaz CH), 
61.3 (NCH2C(CH3)3), 59.2 (cod CH), 52.1 (NCH2), 39.9 (3C; adam CH2), 36.3 (adam C), 
35.9 (3C; adam CH2), 33.8 (cod CH2), 32.0 (NCH2C(CH3)3), 31.7 (cod CH2), 30.0 (cod CH2), 
29.0 (cod CH2), 27.7 (3C; tBu CH3), 27.5 (NCH2C(CH3)3); 
IR (KBr): ν~  = 2917w, 1607w, 1455w, 1423w, 1400w, 1355m, 1278s, 1126bs, 887w, 839w, 
713w, 681w, 670w cm-1; 
MS (FAB): m/z (%): 656 (100) [M - BArF]+; 
EA calcd (%) for C62H57BF24IrN3O (1519.13): C 49.02, H 3.78, N 2.77; found: C 49.12, 
H 3.83, N 2.83. 
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 Experimental 
(R)-{(η4-1,5-cyclooctadiene)-[1-(2-adamantan-1-yl-4,5-dihydro-oxazol-4-ylmethyl)-3-tert-
butyl-imidazolin-2-ylidene]iridium(I)}-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 90j 
N
O
N
N
BArF
Ir
 
Synthesis according to the metalation procedure 6.3.4  using imidazolium salt 89j (200 mg, 
0.166 mmol), [(η4-cod)IrCl]2 (56 mg, 0.083 mmol) and NaOtBu (16 mg, 0.166 mmol) yielded 
an orange/yellow solid (120 mg, 48%, 0.080 mmol). 
[ ]20Dα = +39 (c = 0.128, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.70 (mc, 8H; BArF ortho CH), 7.53 (mc, 4H; 
BArF para CH), 6.96 (mc, 1H; imid CH), 6.67 (mc, 1H; imid CH), 5.51 (mc, 1H; NCH2), 4.78 
(mc, 2H; oxaz CH2 + oxaz CH), 4.42 (mc, 1H; cod CH), 4.25 (mc, 1H; cod CH), 3.99 (mc, 
1H; cod CH), 3.86 (mc, 2H; cod CH + NCH2), 3.61 (mc, 2H; oxaz CH2), 2.40-2.30 (m, 1H; 
cod CH2), 2.30-2.00 (m, 7H, 4 x cod CH2 + 3 x adam CH), 1.83 (mc, 7H; 1 x cod CH2 + 6 x 
adam CH2), 1.76 (mc, 3H; adam CH2), 1.67 (mc, 12H; 3 x adam CH2 + 9 x tBuimid CH3), 1.55 
(mc, 2H; cod CH2); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 181.7 (OCN), 174.2 (NCN), 161.7 (q, 
1J(B,C) = 49.9 Hz, 4C; BArF quat. C ipso to B), 134.8 (br, 8C; BArF ortho CH), 128.9 (qq, 
2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.5 (q, 1J(F,C) = 272.5 Hz, 
8C; BArF CF3), 122.0 (imid CH), 119.1 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF 
para CH), 82.4 (cod CH), 77.6 (cod CH), 69.6 (oxaz CH2), 63.4 (cod CH), 63.0 (oxaz CH), 
58.9 (tBuimid C), 57.6 (cod CH), 51.1 (NCH2), 39.7 (3C; adam CH2), 36.1 (adam C), 35.8 (3C; 
adam CH2), 33.8 (cod CH2), 32.4 (3C; tBuimid CH3), 30.8 (cod CH2), 30.7 (cod CH2), 28.2 
(cod CH2), 27.5 (3C; adam CH); 
IR (KBr): ν~  = 2918w, 1609w, 1455w, 1439w, 1417w, 1356m, 1278s, 1126bs, 887w, 839w, 
713w, 684w, 671w cm-1; 
MS (FAB): m/z (%): 642 (100) [M - BArF]+; 
EA calcd (%) for C61H55BF24IrN3O (1505.10): C 48.68, H 3.68, N 2.79; found: C 48.73, 
H 3.62, N 2.80. 
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(R)-{(η4-1,5-cyclooctadiene)-[1-(2-(2,6-dimethyl-phenyl)-4,5-dihydro-oxazol-4-ylmethyl)-3-
methyl-imidazolin-2-ylidene]iridium(I)}-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 90k 
N
O
N
N
BArF
Ir
 
Synthesis according to the metalation procedure 6.3.4  using imidazolium salt 89k (220 mg, 
0.187 mmol), [(η4-cod)IrCl]2 (63 mg, 0.094 mmol) and NaOtBu (18 mg, 0.187 mmol) yielded 
an orange solid (198 mg, 74%, 0.138 mmol). 
[ ]20Dα = +48 (c = 0.121, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.72 (mc, 8H; BArF ortho CH), 7.53 (mc, 4H; 
BArF para CH), 7.34 (mc, 1H; arom CH), 7.10 (mc, 2H; arom CH), 6.71 (mc, 2H; imid CH), 
5.12 (mc, 1H; NCH2), 4.88 (mc, 1H; oxaz CH2), 4.67 (mc, 1H; oxaz CH), 4.23 (mc, 1H; cod 
CH), 4.05 (mc, 1H; cod CH), 3.95 (mc, 1H; NCH2), 3.90-3.80 (m, 6H; 1 x oxaz CH2 + 2 x 
cod CH + 3 x NCH3), 2.20 (s, 3H, CaromCH3), 2.10 (mc, 1H; cod CH2), 1.97 (mc, 2H; cod 
CH2), 1.93 (s, 3H, CaromCH3), 1.82 (mc, 2H; cod CH2), 1.68 (mc, 1H; cod CH2), 1.53 (mc, 1H; 
cod CH2); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 174.6 (OCN), 171.2 (NCN), 161.7 (q, 
1J(B,C) = 49.9 Hz, 4C; BArF quat. C ipso to B), 136.4 (arom C), 135.8 (arom C), 134.8 (br, 
8C; BArF ortho CH), 131.6 (arom CH), 128.9 (qq, 2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; 
BArF C ipso to CF3), 127.8 (arom CH), 127.5 (arom CH), 125.4 (arom C), 124.5 (q, 1J(F,C) = 
272.5 Hz, 8C; BArF CF3), 123.0 (imid CH), 122.3 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 
4C; BArF para CH), 84.9 (cod CH), 83.9 (cod CH), 70.2 (oxaz CH2), 65.3 (cod CH), 62.1 
(oxaz CH), 57.6 (cod CH), 47.9 (NCH2), 37.7 (NCH3), 34.3 (cod CH2), 31.0 (cod CH2), 30.6 
(cod CH2), 28.2 (cod CH2), 19.4 (CaromCH3), 19.1 (CaromCH3); 
IR (KBr): ν~  = 2962w, 2081w, 2014w, 1610m, 1469w, 1356m, 1279s, 1125bs, 968w, 888w, 
839w, 778w, 713w, 681w, 671w cm-1; 
MS (FAB): m/z (%): 570 (100) [M - BArF]+; 
EA calcd (%) for C56H43BF24IrN3O (1432.95): C 46.94, H 3.02, N 2.93; found: C 46.62, 
H 3.15, N 3.03. 
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(R)-{(η4-1,5-cyclooctadiene)-[1-(2-(2,6-dimethyl-phenyl)-4,5-dihydro-oxazol-4-ylmethyl)-3-
isopropyl-imidazolin-2-ylidene]iridium(I)}-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 90l 
N
O
N
N
BArF
Ir
 
Synthesis according to the metalation procedure 6.3.4  using imidazolium salt 89l (285 mg, 
0.245 mmol), [(η4-cod)IrCl]2 (82 mg, 0.123 mmol) and NaOtBu (24 mg, 0.245 mmol) yielded 
an orange solid (297 mg, 83%, 0.203 mmol). 
[ ]20Dα = +46 (c = 0.150, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.70 (mc, 8H; BArF ortho CH), 7.53 (mc, 4H; 
BArF para CH), 7.36 (mc, 1H; arom CH), 7.10 (mc, 2H; arom CH), 6.87 (mc, 1H; imid CH), 
6.71 (mc, 1H; imid CH), 5.10 (mc, 1H; NCH2), 4.86 (mc, 1H; oxaz CH2), 4.78 (mc, 1H; iPr 
CH), 4.62 (mc, 1H; oxaz CH), 4.15 (mc, 1H; cod CH), 4.09 (mc, 1H; cod CH), 3.94 (mc, 1H; 
NCH2), 3.83 (mc, 1H; oxaz CH2), 3.73 (mc, 2H; cod CH), 2.20 (s, 3H, CaromCH3), 2.16 (mc, 
1H; cod CH2), 2.06 (s, 3H, CaromCH3), 1.95 (mc, 4H; cod CH2), 1.75 (mc, 1H; cod CH2), 1.42 
(d, 3J(H,H) = 6.9 Hz, 3H; iPr CH3), 1.36 (mc, 2H; cod CH2), 1.30 (d, 3J(H,H) = 6.8 Hz, 3H; 
iPr CH3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 173.0 (OCN), 171.4 (NCN), 161.7 (q, 
1J(B,C) = 49.9 Hz, 4C; BArF quat. C ipso to B), 136.5 (arom C), 135.8 (arom C), 134.8 (br, 
8C; BArF ortho CH), 131.6 (arom CH), 128.9 (qq, 2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; 
BArF C ipso to CF3), 127.8 (arom CH), 127.6 (arom CH), 125.4 (arom C), 124.5 (q, 1J(F,C) = 
272.5 Hz, 8C; BArF CF3), 122.9 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para 
CH), 117.4 (imid CH), 83.7 (cod CH), 83.5 (cod CH), 70.1 (oxaz CH2), 65.5 (cod CH), 62.3 
(oxaz CH), 57.6 (cod CH), 52.2 (iPr CH), 47.5 (NCH2), 35.3 (cod CH2), 31.7 (cod CH2), 30.1 
(cod CH2), 27.6 (cod CH2), 25.5 (iPr CH3), 22.3 (iPr CH3), 20.5 (CaromCH3), 19.5 (CaromCH3); 
IR (KBr): ν~  = 2973w, 2081w, 2015w, 1611m, 1466w, 1425w, 1356m, 1279s, 1126bs, 888w, 
839w, 713w, 681w, 671w cm-1; 
MS (FAB): m/z (%): 598 (100) [M - BArF]+; 
EA calcd (%) for C58H47BF24IrN3O (1460.99): C 47.68, H 3.24, N 2.88; found: C 47.47, 
H 3.28, N 2.82. 
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(R)-{(η4-1,5-cyclooctadiene)-[1-(2-(2,6-dimethyl-phenyl)-4,5-dihydro-oxazol-4-ylmethyl)-3-
(2,4,6-trimethyl-phenyl)-imidazolin-2-ylidene]iridium(I)}-tetrakis[3,5-
bis(trifluoromethyl)phenyl]borate 90m 
N
O
N
N
BArF
Ir
 
Synthesis according to the metalation procedure 6.3.4  using imidazolium salt 89m (220 mg, 
0.178 mmol), [(η4-cod)IrCl]2 (60 mg, 0.089 mmol) and NaOtBu (17 mg, 0.178 mmol) yielded 
an orange solid (178 mg, 65%, 0.116 mmol). 
[ ]20Dα = +12 (c = 0.110, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.72 (mc, 8H; BArF ortho CH), 7.54 (mc, 4H; 
BArF para CH), 7.35 (mc, 1H; aromoxaz CH), 7.10 (mc, 2H; aromoxaz CH), 6.97 (mc, 2H; 
aromimid CH), 6.86 (mc, 1H; imid CH), 6.77 (mc, 1H; imid CH), 4.74 (mc, 1H; oxaz CH2), 
4.61 (mc, 1H; oxaz CH), 4.41 (mc, 1H; NCH2), 4.26 (mc, 1H; NCH2), 4.20 (mc, 1H; oxaz 
CH2), 3.77 (mc, 1H; cod CH), 3.58 (mc, 1H; cod CH), 3.42 (mc, 1H; cod CH), 3.13 (mc, 1H; 
cod CH), 2.33 (s, 3H, Carom, imidCH3), 2.31 (s, 3H, Carom, oxazCH3), 2.28 (s, 3H, Carom, oxazCH3), 
2.06 (s, 3H, Carom, imidCH3), 2.02 (s, 3H, Carom, imidCH3), 1.82-1.57 (m, 6H; cod CH2), 1.40-1.20 
(m, 2H; cod CH2); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 173.8 (OCN), 169.8 (NCN), 161.7 (q, 
1J(B,C) = 49.9 Hz, 4C; BArF quat. C ipso to B), 140.2 (aromimid C), 137.6 (aromoxaz C), 137.4 
(aromoxaz C), 134.9 (aromimid C), 134.8 (br, 8C; BArF ortho CH), 134.4 (aromimid C), 134.2 
(aromimid C), 132.4 (aromoxazCH), 129.8 (aromimidCH), 129.7 (aromimidCH), 128.9 (qq, 2J(F,C) 
= 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 128.5 (aromoxazCH), 128.4 (aromoxaz 
CH), 124.8 (imid CH), 124.7 (aromoxaz C), 124.5 (q, 1J(F,C) = 272.5 Hz, 8C; BArF CF3), 
121.6 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para CH), 82.4 (cod CH), 81.9 (cod 
CH), 69.2 (oxaz CH2), 64.8 (cod CH), 62.7 (oxaz CH), 62.4 (cod CH), 51.5 (NCH2), 33.6 
(cod CH2), 31.4 (cod CH2), 30.3 (cod CH2), 28.4 (cod CH2), 21.0 (Carom imid CH3), 20.4 (Carom 
oxaz CH3), 20.3 (Carom oxaz CH3), 18.3 (Carom imid CH3), 18.1 (Carom imid CH3); 
IR (KBr): ν~  = 2927w, 1608m, 1466w, 1355m, 1278s, 1126bs, 933w, 713w, 681w, cm-1; 
MS (FAB): m/z (%): 674 (100) [M - BArF]+; 
EA calcd (%) for C64H51BF24IrN3O (1537.09): C 50.01, H 3.34, N 2.73; found: C 49.84, 
H 3.38, N 2.95. 
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(R)-{(η4-1,5-cyclooctadiene)-[1-(2-(2,6-dimethyl-phenyl)-4,5-dihydro-oxazol-4-ylmethyl)-3-
(2,2-dimethyl-propyl)-imidazolin-2-ylidene]iridium(I)}-tetrakis[3,5-
bis(trifluoromethyl)phenyl]borate 90n 
N
O
N
N
BArF
Ir
 
Synthesis according to the metalation procedure 6.3.4  using imidazolium salt 89n (244 mg, 
0.205 mmol), [(η4-cod)IrCl]2 (69 mg, 0.102 mmol) and NaOtBu (20 mg, 0.205 mmol) yielded 
an orange solid (250 mg, 82%, 0.168 mmol). 
[ ]20Dα = +51 (c = 0.110, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.72 (mc, 8H; BArF ortho CH), 7.53 (mc, 4H; 
BArF para CH), 7.34 (mc, 1H; arom CH), 7.10 (mc, 2H; arom CH), 6.95 (mc, 1H; imid CH), 
6.80 (mc, 1H; imid CH), 5.06 (mc, 1H; NCH2), 4.84 (mc, 1H; oxaz CH2), 4.55 (mc, 1H; oxaz 
CH), 4.22 (mc, 1H; CH2C(CH3)3), 4.06 (mc, 3H; 1 x NCH2+ 2 x cod CH), 3.90 (mc, 1H; oxaz 
CH2), 3.80 (mc, 1H; cod CH), 3.75 (mc, 1H; cod CH), 3.58 (mc, 1H; CH2C(CH3)3), 2.19 (mc, 
4H; 3 x CaromCH3 + 1 x cod CH2), 1.93 (mc, 6H; 3 x cod CH2 + 3 x CaromCH3), 1.83 (mc, 1H; 
cod CH2), 1.74 (mc, 1H; cod CH2), 1.43 (mc, 2H; cod CH2), 0.94 (mc, 9H; CH2C(CH3)3); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 175.4 (OCN), 172.0 (NCN), 161.7 (q, 
1J(B,C) = 49.9 Hz, 4C; BArF quat. C ipso to B), 136.5 (arom C), 136.0 (arom C), 134.8 (br, 
8C; BArF ortho CH), 131.7 (arom CH), 128.9 (qq, 2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; 
BArF C ipso to CF3), 128.0 (arom CH), 127.7 (arom CH), 125.2 (arom C), 124.5 (q, 1J(F,C) = 
272.5 Hz, 8C; BArF CF3), 122.4 (imid CH), 122.3 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 
4C; BArF para CH), 83.5 (cod CH), 82.8 (cod CH), 69.8 (oxaz CH2), 62.9 (oxaz CH), 62.0 
(cod CH), 61.2 (NCH2C(CH3)3), 60.0 (cod CH), 48.5 (NCH2), 34.6 (cod CH2), 32.8 (cod 
CH2), 31.9 (NCH2C(CH3)3), 31.0 (cod CH2), 30.6 (cod CH2), 28.1 (NCH2C(CH3)3), 19.6 
(CaromCH3), 19.3 (CaromCH3); 
IR (KBr): ν~  = 2965w, 2889w, 2016w, 1609m, 1468w, 1424w, 1356m, 1279s, 1126bs, 967w, 
934w, 888w, 839w, 713w, 681w, 670w cm-1; 
MS (FAB): m/z (%): 626 (100) [M - BArF]+; 
EA calcd (%) for C60H51BF24IrN3O (1489.06): C 48.40, H 3.45, N 2.82; found: C 48.07, 
H 3.33, N 2.94. 
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(R)-{(η4-1,5-cyclooctadiene)-[1-(2-(2,6-dimethyl-phenyl)-4,5-dihydro-oxazol-4-ylmethyl)-3-
tert-butyl-imidazolin-2-ylidene]iridium(I)}-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 90o 
N
O
N
N
BArF
Ir
 
Synthesis according to the metalation procedure 6.3.4  using imidazolium salt 89o (256 mg, 
0.217 mmol), [(η4-cod)IrCl]2 (73 mg, 0.108 mmol) and NaOtBu (21 mg, 0.217 mmol) yielded 
an orange solid (204 mg, 64%, 0.139 mmol). 
[ ]20Dα = +49 (c = 0.089, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.72 (mc, 8H; BArF ortho CH), 7.54 (mc, 4H; 
BArF para CH), 7.33 (mc, 1H; arom CH), 7.12 (mc, 1H; arom CH), 7.04 (mc, 1H; imid CH), 
7.02 (mc, 1H; arom CH), 6.76 (mc, 1H; imid CH), 5.46 (mc, 1H; NCH2), 4.85 (mc, 2H; oxaz 
CH2 + oxaz CH), 4.37 (mc, 1H; cod CH), 4.26 (mc, 1H; cod CH), 4.18 (mc, 1H; cod CH), 
4.01 (mc, 1H; NCH2), 3.88 (mc, 2H; oxaz CH2), 3.59 (mc, 1H; cod CH), 2.20 (mc, 4H, 3 x 
CaromCH3 + 1 x cod CH2), 2.10-1.80 (m, 5H; cod CH2), 1.67 (s, 9H, C(CH3)3), 1.59 (s, 3H, 
CaromCH3), 1.38 (mc, 1H; cod CH2), 1.32 (mc, 1H; cod CH2); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 175.3 (OCN), 171.3 (NCN), 161.7 (q, 
1J(B,C) = 49.9 Hz, 4C; BArF quat. C ipso to B), 136.0 (arom C), 135.5 (arom C), 134.8 (br, 
8C; BArF ortho CH), 131.8 (arom CH), 128.9 (qq, 2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; 
BArF C ipso to CF3), 127.8 (arom CH), 127.6 (arom CH), 125.2 (arom C), 124.5 (q, 1J(F,C) = 
272.5 Hz, 8C; BArF CF3), 122.0 (imid CH), 119.6 (imid CH), 117.5 (sept, 3J(F,C) = 3.8 Hz, 
4C; BArF para CH), 80.8 (cod CH), 79.9 (cod CH), 70.2 (oxaz CH2), 66.2 (cod CH), 62.9 
(oxaz CH), 59.1 (tBuimid C), 56.0 (cod CH), 49.8 (NCH2), 35.5 (cod CH2), 32.5 (cod CH2), 
32.4 (3C; tBuimid CH3), 29.3 (cod CH2), 27.1 (cod CH2), 19.7 (CaromCH3), 19.1 (CaromCH3); 
IR (KBr): ν~  = 2956w, 1630w, 1611w, 1475w, 1438w, 1416w, 1356m, 1280s, 1127bs, 964w, 
940w, 887w, 839w, 714w, 682w, 670w cm-1; 
MS (FAB): m/z (%): 612 (100) [M - BArF]+; 
EA calcd (%) for C59H49BF24IrN3O (1475.03): C 48.04, H 3.35, N 2.85; found: C 48.04, 
H 3.47, N 3.06. 
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(R)-{(η4-1,5-cyclooctadiene)-[1-(2-(phenyl)-4,5-dihydro-oxazol-4-ylmethyl)-3-(2,4,6-
trimethyl-phenyl)-imidazolin-2-ylidene]iridium(III)}-tetrakis[3,5-
bis(trifluoromethyl)phenyl]borate 90p 
N
O
N
N
BArF
Ir
H
 
Synthesis according to the metalation procedure 6.3.4  using imidazolium salt 89p (723 mg, 
0.598 mmol), [(η4-cod)IrCl]2 (200 mg, 0.299 mmol) and NaOtBu (57.5 mg, 0.598 mmol) 
yielded a colourless solid (758 mg, 84%, 0.502 mmol). 
[ ]20Dα = +18.5 (c = 0.159, CHCl3); 
1H NMR (500.1 MHz, CD2Cl2, 295 K) : δ = 7.72 (mc, 8H; BArF ortho CH), 7.56 (mc, 4H; 
BArF para CH), 7.34 (mc, 1H; aromoxaz CH), 7.13 (s, 1H; aromimid CH), 7.02 (mc, 3H; 
aromoxaz CH + aromoxaz CH + imid CH), 6.77 (mc, 1H; imid CH), 6.69 (aromoxaz CH), 6.68 (s, 
1H; aromimid CH), 5.29-5.22 (m, 2H, oxaz CH2 + oxaz CH), 5.02 (mc, 1H; cod CH), 4.89 (mc, 
1H; oxaz CH2), 4.82 (mc, 1H; cod CH), 4.68(mc, 1H; NCH2), 4.41 (mc, 1H; cod CH), 4.12 
(mc, 1H; NCH2), 3.37 (mc, 1H; cod CH), 3.19 (mc, 1H; cod CH2), 2.75 (mc, 1H; cod CH2), 
2.52 (mc, 2H; cod CH2), 2.43 (mc, 2H; cod CH2), 2.38 (s, 3H; CaromCH3), 2.15 (s, 3H; 
CaromCH3), 2.01 (mc, 1H; cod CH2), 1.91 (mc, 1H; cod CH2), 0.44 (s, 3H; CaromCH3), -14.6 (s, 
1H; Ir H ); 
13C{1H} NMR (125.7 MHz, CD2Cl2, 295 K) : δ = 182.3 (OCN), 161.7 (q, 1J(B,C) = 49.9 Hz, 
4C; BArF quat. C ipso to B), 156.4 (NCN), 154.1 (Ir Carom), 141.3 (aromoxaz CH), 139.8 
(aromimid C), 136.6 (aromimid C), 135.3 (aromimid C), 134.8 (br, 8C; BArF ortho CH), 134.1 
(aromimid C), 133.9 (aromoxaz CH), 129.3 (aromimid CH), 129.0 (aromimid CH), 128.8 (qq, 
2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 127.3 (aromoxaz CH), 124.5 
(q, 1J(F,C) = 272.5 Hz, 8C; BArF CF3), 124.4 (imid CH), 123.6 (aromoxaz CH), 123.5 (imid 
CH), 117.4 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para CH), 89.2 (cod CH), 87.2 (cod CH), 85.2 
(cod CH), 82.7 (cod CH), 77.5 (oxaz CH2), 59.8 (oxaz CH), 55.9 (NCH2), 36.9 (cod CH2), 
32.8 (cod CH2), 28.9 (cod CH2), 27.5 (cod CH2), 20.8 (CaromCH3), 17.5 (CaromCH3), 15.4 
(CaromCH3), 1 quat. C not detected; 
IR (KBr): ν~  = 2933w, 1610m, 1435w, 1354s, 1277s, 1126bs, 887m, 839w, 744w, 712w, 
682w, 671w cm-1; 
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MS (FAB): m/z (%): 646 (100) [M - BArF]+; 
EA calcd (%) for C62H47BF24IrN3O (1509.06): C 49.35, H 3.14, N 2.78, O 1.06; found: 
C 49.39, H 2.98, N 2.77, O 1.34. 
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6.4 Phosphine/phosphinite-N-heterocyclic carbene ligands 
Since a detailed description of compounds 111-115;1 110c, 117c and 118c;2 and 1373 can be 
found in the literature, their analytical data will not be presented here. 
6.4.1 Synthesis of carbamates 117a and 117b 
methyl-carbamic acid tert-butyl ester 117a 
N
H
O
O
 
A solution of Boc2(O) (24.00 g, 110 mmol) in THF (50 ml) was added to a solution of 
methylamine (2M, 50 ml, 100 mmol) in THF at 0°C over 10 minutes. DMAP (122 mg, 
1 mmol) was added to the mixture, which was then stirred at room temperature for 19 hours. 
The reaction mixture was concentrated in vacuo to remove the solvent and the residue was 
dissolved in Et2O (150 ml). The organic layer was washed with water, a saturated aqueous 
solution of NaHCO3 and brine, dried over magnesium sulfate, before being concentrated in 
vacuo to yield a colourless oil. The crude product was purified by chromatography on silica 
gel eluting with a mixture of ethyl acetate and hexane (1:9) to yield a colourless oil (7.15 g, 
54.5 mmol, 55%). 
Rf = 0.33 (EtOAc/Hexane 1:9); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 4.41 (br, 1H; NH), 2.69 (s, 3H; NCH3), 1.41 (s, 
9H; C(CH3)3) 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 157.0 (OCON), 79.5 (C(CH3)3), 28.8 (3C; 
C(CH3)3), 27.6 (NCH3); 
IR (NaCl): ν~  =  3357 mbr, 2976m, 2933m, 1696sbr, 1531m, 1456w, 1419w, 1391w, 1366m, 
1277m, 1250m, 1175s, 954w, 868w, 782 cm-1; 
MS (FAB): m/z (%): 132 (10) [M + H]+, 76 (63), 57 (100), 41 (44); 
EA calcd (%) for C6H13NO2 (131.17): C 54.94, H 9.99, N 10.68; found: C 54.92, H 9.79, 
N 7.04, O 10.51. 
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isopropyl-carbamic acid tert-butyl ester 117b 
N
H
O
O
 
Synthesis according to the previous general procedure using diethylamine 116b (1.00 g, 
16.92 mmol), Boc2(O) (4.06 g, 18.61 mmol) and DMAP (20 mg, 0.17 mmol) yielded a white 
solid (2.21 g, 13.77 mmol, 74%). 
Rf = 0.48 (EtOAc/Hexane 1:9); 
m.p. 69-71°C; 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 4.31 (br, 1H; NH), 3.71 (mc, 1H; CH(CH3)2), 
1.41 (s, 9H; C(CH3)3), 1.11 (mc, 3H; CH(CH3)2), 1.09 (mc, 3H; CH(CH3)2); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 155.6 (NCOO), 79.3 (OC(CH3)3), 43.0 
(C(CH3)2), 28.8 (C(CH3)3), 23.5 (CH(CH3)2); 
IR (KBr): ν~  = 3346m, 2978m, 2935m, 1683s, 1539m, 1459m, 1367m, 1256s, 1174s, 1078s, 
938w, 886w, 841w, 778w, 753w, 643m, 461w, 424w cm-1; 
MS (FAB): m/z (%): 160 (100) [M + H]+, volatile compound difficult to measure; 
EA calcd (%) for C8H17NO2 (159.23): C 60.35, H 10.76, N 8.80, O 20.10; found: C 60.41, 
H 10.56, N 8.64, O 20.28. 
6.4.2 Synthesis of aldehydes 110a and 110b 
methyl-(2-oxo-ethyl)-carbamic acid tert-butyl ester 110a 
N
Boc
O
 
A solution of carbamate 117a (10.05 g, 76.6 mmol) in DMF (100 ml) at 0°C was added to a 
suspension of KH (3.38 g, 84.3 mmol, free of mineral oil) in DMF at 0°C over ½ hour. The 
reaction mixture was stirred at room temperature until the gas evolution had ceased (typically 
2 hours). 3,3-Dimethylallylbromide (13.7 g, 91.9 mmol) was then added and the resultant 
mixture was stirred at room temperature for a further one hour. The solution was quenched 
with a saturated aqueous solution of NaHCO3 (100 ml) and water (100 ml), then the mixture 
extracted three times with Et2O (3 x 100 ml). The combined organic layers were dried over 
anhydrous magnesium sulfate and concentrated in vacuo to yield a colourless oil (11.56 g). 
Since 118a was not stable on silica gel, the crude product was used for the next step without 
purification. 
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Crude olefin 118a was dissolved in a mixture of CH2Cl2 and MeOH (3:1, 500 ml). The 
mixture was cooled to -78°C and a ozone was bubbled into the reaction mixture until TLC 
analysis indicated that no starting material remained (typically ½ hour). The reaction mixture 
was warmed to room temperature and reduced with dimethyl sulfide (7.21 g, 116 mmol). The 
solvent and excess dimethyl sulfide were removed under high vacuum. The crude product was 
purified by chromatography on silica gel eluting with a mixture of ethyl acetate and hexane 
(3:7) to yield a colorless oil (6.38 g, 36.8 mmol, 48% over two steps). 
Rf = 0.40 (EtOAc/Hexane 3:7); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 9.56 (s, 1H; CHO), 3.99-3.87 (m, 2H; NCH2), 
2.93-2.88 (m, 3H; NCH3), 1.44-1.38 (m, 9H; C(CH3)3); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 199.0 (CHO), 156.5 (NCOO), 155.8 
(NCOO), 81.1 (C(CH3)3), 80.9 (C(CH3)3), 59.6 (NCH2), 59.1 (NCH2), 36.2 (NCH3), 28.6 (br, 
3C; C(CH3)3), two sets of signals were observed due to amide conformers; 
IR (NaCl): ν~  =  2976m, 2933m, 1734m, 1695s, 1481m, 1456m, 1392m, 1297w, 1242m, 
1158s, 1056w, 929w, 878w, 775w cm-1; 
MS (FAB): m/z (%): 174 (37), [M + H]+, 118 (100), 57 (88); 
elemental analysis calcd (%) for C8H15NO3 (173.21): C 55.47, H 8.73, N 8.09; found: 
C 54.73, H 8.44, N 8.09. 
isopropyl-(2-oxo-ethyl)-carbamic acid tert-butyl ester 110b 
N
Boc
O
 
Synthesis according to the previous general procedure using carbamate 117b (4.83 g, 
30.4 mmol), KH (1.34 g, 33.4 mmol), 3,3-dimethylallylbromide (5.97 g, 40.1 mmol) and 
dimethyl sulfide (2.52 g, 40.6 mmol) yielded a white solid (1.790 g, 8.89 mmol, 30%). 
Rf = 0.54 (EtOAc/Hexane 3:7); 
m.p. 36-37°C; 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 9.48 (br, 1H; CHO), 4.50 (br, 0.64H; CH(CH3)2), 
4.23 (br, 0.36H; CH(CH3)2), 1.60-1.30 (m, 9H; C(CH3)3), 1.07 (mc, 6H; CH(CH3)2). 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ =  
δ = 200.2 (CHO), 155.8 (NCOO), 154.8 (NCOO), 80.8 (C(CH3)3), 80.6 (C(CH3)3), 51.4 
(NCH2), 51.1 (NCH2), 47.4 (CH(CH3)2), 46.0 (CH(CH3)2), 28.4 (br, 3C; C(CH3)3), 21.1 
(CH(CH3)2), 20.7 (CH(CH3)2), two sets of signals were observed due to amide conformers; 
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IR (KBr): ν~  = 2978m, 2805w, 2709w, 1739m, 1696s, 1437m, 1398m, 1366m, 1295m, 
1253m, 1219m, 1169s, 1108m, 1019m, 900m, 857w, 823w, 773m, 680w, 456w cm-1; 
MS (FAB): m/z (%): 202 (10) [M + H]+, 172 (39), 146 (21), 116 (34), 72 (60), 57 (100); 
EA calcd (%) for C10H19NO3 (201.26): C 59.68, H 9.51, N 6.96, O 23.85; found: C 59.61, 
H 9.37, N 7.05, O 23.96. 
6.4.3 Synthesis of phosphines 119a-c 
(S)-(2-{1-[(diphenylphosphanyl)-methyl]-2-methyl-propylamino}-ethyl)-methyl-carbamic 
acid tert-butyl ester 119a 
N
H
PPh2NBoc
 
A solution of aldehyde 110a (421 mg, 2.43 mmol) in 1,2-dichlorethane (5 ml) was added to a 
solution of amino-phosphine 111 (600 mg, 2.21 mmol) and NaHB(OAc)3 (933 mg, 
4.42 mmol) in 1,2-dichlorethane (3 ml) at room temperature. The reaction mixture was stirred 
at room temperature for four hours and quenched with a saturated aqueous solution of 
NaHCO3 (10 ml). The organic layer was separated and the aqueous layer was extracted three 
times with CH2Cl2 (3 x 10 ml). The combined organic layers were dried over magnesium 
sulfate and concentrated in vacuo to yield a yellow oil. The crude product was purified by 
chromatography on silica gel eluting with a mixture of ethyl acetate and hexane (4:6) to yield 
a colourless oil (700 mg, 1.63 mmol, 74%). 
Rf = 0.56 (EtOAc/Hexane 4:6); 
[ ]20Dα = +52.2 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.49-7.43 (m, 2H; arom CH), 7.43-7.38 (mc, 2H; 
arom CH), 7.37-7.27 (m, 6H; arom CH), 3.19 (br, 2H; NCH2), 2.82 (s, 3H; CH3), 2.71-2.58 
(br, 2H; NCH2), 2.36 (mc, 1H; PCH2CH), 2.22 (br, 1H; PCH2), 2.25-1.85 (br, 2H; 1 x PCH2 + 
1 x CCH(CH3)2), 1.44 (br, 9H; OC(CH3)3), 0.87 (d, 3J(H;H) = 6.8 Hz, 3H; NCH(CH3)2), 0.83 
(d, 3J(H;H) = 7.8 Hz, 3H; NCH(CH3)2),1 NH not detected; 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 155.9 (br, NCO), 139.6 (br, arom C), 138.4 
(br, arom C), 133.4 (arom CH), 133.2 (arom CH), 132,7 (br, arom CH), 132.6 (br, arom CH), 
129.0 (arom CH), 128.7-128.4 (5C; arom CH), 70.4 (OC(CH3)3), 60.6 (br; PCH2CH), 49.2 
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(NCH2), 45.9 (NCH2), 35.2 (NCH3), 30.8 (br, CCH(CH3)2), 30.6 (br, PCH2), 28.6 (3C; 
C(CH3)3), 18.4 (br, CCH(CH3)2), 17.5 (CCH(CH3)2); 
31P{1H} NMR (202.5 MHz, CDCl3, 295 K) : δ = -21.2 (s); 
IR (NaCl): ν~  =  3056w, 2961m, 1694s, 1478m, 1433w, 1392m, 1368w, 1247w, 1155m, 
879w, 741w, 696w cm-1; 
MS (FAB): m/z (%):429 (100) [M + H]+, 445 (18) oxidation during measurement; 
EA calcd (%) for C25H37N2O2P (428.55): C 70.07, H 8.70, N 6.54, O 7.47; found: C 69.83, 
H 8.52, N 6.60, O 7.55. 
(S)-(2-{1-[(diphenylphosphanyl)-methyl]-2-methyl-propylamino}-ethyl)-isopropyl-carbamic 
acid tert-butyl ester 119b 
N
H
PPh2NBoc
 
Synthesis according to the previous general procedure using aldehyde 110b (250 mg, 
1.24 mmol), amino-phosphine 111 (306 mg, 1.13 mmol) and NaHB(OAc)3 (526 mg, 
2.48 mmol) yielded a colourless oil which crystallised on standing (413 mg, 0.904 mmol, 
80%). 
Rf = 0.69 (EtOAc/Hexane 1:1); 
m.p. 51-52°C; 
[ ]20Dα = +60.4 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.46 (mc, 2H; arom CH), 7.40 (mc, 2H; arom 
CH), 7.36-7.27 (br, 6H; arom CH), 4.40-3.80 (br, 1H; NCH(CH3)2), 3.30-2.90 (br, 2H; 
NCH2), 2.65 (br, 2H; NCH2), 2.40 (br, 1H; PCH2CH), 2.27 (br, 1H; PCH2), 2.15-1.85 (br, 2H; 
1 x PCH2 + 1 x CCH(CH3)2), 1.42 (br, 9H; OC(CH3)3), 1.07 (br, 6H; NCH(CH3)2), 0.89 (br, 
3H; CCH(CH3)2), 0.84 (br, 3H; CCH(CH3)2), 1 NH not detected; 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 138.3 (d, 1J(P,C) = 12.6 Hz; arom C), 133.4 
(d, 2J(P,C) = 19.3 Hz, 2C; arom CH), 132.6 (d, 2J(P,C) = 17.5 Hz, 2C; arom CH), 128.8-128.3 
(5C; arom CH), 60.5 (br; PCH2CH), 47.9 (NCH2), 46.5 (br, NCH(CH3)2), 42.8 br, (NCH2), 
30.8 (d, 1J(P,C) = 7.0 Hz; PCH2), 30.5 (br, CCH(CH3)2), 28.6 (3C; C(CH3)3), 20.9 (2C; 
NCH(CH3)2), 18.6 (CCH(CH3)2), 17.5 (CCH(CH3)2), 1 arom C and 1 quat C(CH3)3 not 
detected; 
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31P{1H} NMR (202.5 MHz, CDCl3, 295 K) : δ = -21.1 (br); 
IR (KBr): ν~  = 3068w, 2967m, 2872m, 2815m, 1593s, 1472m, 1412m, 1367m, 1343m, 
1299m, 1250w, 1169m, 1122m, 1089w, 998w, 905w, 836w, 744m, 695m, 508w cm-1; 
MS (FAB): m/z (%): 457 (100) [M + H]+, 473 (17) oxidation during measurement; 
EA calcd (%) for C27H41N2O2P (456.60): C 71.02, H 9.05, N 6.14, O 7.01; found: C 70.91, 
H 8.97, N 6.22, O 7.03. 
(S)-(2-{1-[(diphenylphosphanyl)-methyl]-2-methyl-propylamino}-ethyl)-(2,4,6-trimethyl-
phenyl)-carbamic acid tert-butyl ester 119c 
N
H
PPh2NBoc
 
Synthesis according to the previous general procedure using aldehyde 110c (675 mg, 
2.43 mmol), amino-phosphine 111 (600 mg, 2.21 mmol) and NaHB(OAc)3 (937 mg, 
4.42 mmol) yielded a colourless oil (961 mg, 1.80 mmol, 82%). 
Rf = 0.43 (EtOAc/Hexane 2:8); 
[ ]20Dα = +30.5 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.47-7.24 (m, 10H; aromphenyl CH), 6.88-6.83 (m, 
2H; arommesityl CH), 3.55-3.25 (m, 2H; NCH2), 2.76-2.62 (m, 2H; NCH2), 2.35 (mc, 1H; 
PCH2CH), 2.28-2.24 (m, 3H; mesityl CH3), 2.24-2.17 (m, 1H; PCH2), 2.16-2.09 (m, 6H; 
mesityl CH3), 2.02-1.87 (m, 2H; 1 x PCH2 + 1 x CCH(CH3)2), 1.48 (s, 3H; OC(CH3)3), 1.30 
(s, 6H; OC(CH3)3), 0.84 (m, 6H; CCH(CH3)2), 1 NH not detected; 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ =  139.7 (arom), 139.6 (arom), 138.3 (arom), 
138.2 (arom), 138.0 (arom), 136.8 (arom), 136.5 (br, arom), 135.9 (arom), 135.8 (arom), 
135.3 (br, arom), 133.4 (arom), 133.29 (arom), 133.28 (arom), 133.1 (arom), 132.8 (arom), 
132.7 (arom), 132.6 (arom), 132.4 (arom), 129.4 (arom), 129.3 (arom), 129.2-128.3 (m, 
arom), 60.8 (br; PCH2CH), 60.5 (d, 2J(P,C) = 12.6 Hz; PCH2CH), 51.0 (NCH2), 49.9 (br, 
NCH2), 46.6 (br, NCH2), 30.8 (d, 1J(P,C) = 7.0 Hz; PCH2), 30.7 (d, 1J(P,C) = 7.3 Hz; PCH2), 
30.6 (br, CCH(CH3)2), 30.5 (br, CCH(CH3)2), 28.6 (3C; C(CH3)3), 28.4 (3C; C(CH3)3), 21.0 
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(mesityl CH3), 18.6 (CH3), 18.31 (CH3), 18.29 (CH3), 18.1 (CH3), 17.8 (CH3), 17.3 (CH3); 
two sets of signal corresponding to the amide rotamers, 2 quat C(CH3)3 not detected; 
31P{1H} NMR (202.5 MHz, CDCl3, 295 K) : δ = -21.2 (br), -21.3 (s); 
IR (KBr): ν~  =  3054m, 2959m, 2927m, 2867m, 1695s, 1479m, 1370m, 1310m, 1254m, 
1150m, 1030w, 994w, 855w, 741m, 696m cm-1; 
MS (FAB): m/z (%): 533 (100) [M + H]+, 549 (38) oxidation during measurement; 
EA calcd (%) for C33H45N2O2P1 (532.70): C 74.41, H 8.51, N 5.26, O 6.01; found: C 74.43, 
H 8.49, N 5.29, O 6.12. 
6.4.4 Synthesis of diamines 120a-c 
(S)-N-{1-[(diphenylphosphanyl)-methyl]-2-methyl-propyl}-N'-methyl-ethane-1,2-diamine 
120a 
N
H
PPh2NH
 
TFA (6.00 g, 53.0 mmol) was added to a solution of phosphine 119a (450 mg, 1.05 mmol) in 
CH2Cl2 (15 ml) at 0°C. The reaction mixture was stirred at room temperature for 20 hours. 
The reaction mixture was quenched with water (15 ml) and 5M NaOH until pH > 10. The 
organic layer was separated and the aqueous layer was extracted two times with CH2Cl2 
(2 x 15 ml). The combined organic extracts were dried over anhydrous magnesium sulfate and 
concentrated in vacuo to yield a yellow oil (327 mg, 0.99 mmol, 95%) of >95% purity as 
judged by 1H-NMR analysis. 
[ ]20Dα = +71.8 (c = 1.00, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 7.49-7.27 (m, 10H; arom CH), 2.78-2.54 (m, 4H; 
NCH2), 2.43 (s, 3H; CH3), 2.37 (mc, 1H; PCH2CH), 2.23 (mc, 1H; PCH2), 2.03-1.86 (m, 2H; 
PCH2 + CCH(CH3)2), 0.87 (d, 3J(H,H) = 6.8 Hz, 3H; CCH(CH3)2), 0.84 (d, 3J(H,H) = 6.9 Hz, 
3H; CCH(CH3)2), 2 NH not detected; 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 139.8 (d, 1J(P,C) = 12.0 Hz; arom C), 138.6 
(d, 1J(P,C) = 12.8 Hz; arom C), 133.6 (d, 2J(P,C) = 19.2 Hz, 2C; arom CH), 132.8 (d, 2J(P,C) 
= 18.3 Hz, 2C; arom CH), 129.3 (arom CH), 129.1-128.6 (5C; arom CH), 60.7 (d, 2J(P,C) = 
12.7 Hz; PCH2CH), 51.7 (NCH2), 46.4 (NCH2), 36.1 (NCH3), 31.2-31.0 (m, 2C; PCH2 + 
CCH(CH3)2), 19.0 (CCH(CH3)2), 17.5 (CCH(CH3)2); 
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IR (NaCl): ν~  =  3055w, 2954s, 2887m, 2792m, 1686m, 1585w, 1471m, 1435m, 1381w, 
1305w, 1271w, 1198m, 1131m, 1027w, 997w, 910w, 827w, 741s, 696s cm-1; 
MS (FAB): m/z (%):329 (100) [M + H]+, 345 (17) oxidation during measurement; 
EA (%) for C20H29N2P (328.44): C 73.14, H 8.90, N 8.53; found: C 69.56, H 8.36, N 8.17. 
(S)-N-{1-[(diphenylphosphanyl)-methyl]-2-methyl-propyl}-N'-isopropyl-ethane-1,2-diamine 
120b 
N
H
PPh2NH
 
Synthesis according to the previous general procedure using phosphine 119b (358 mg, 
0.784 mmol) and TFA (4.47 g, 39.2 mmol) yielded a yellow oil (278 mg, 0.780 mmol, 99%) 
of >95% purity as judged by 1H-NMR analysis. 
[ ]20Dα = +60.5 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.45 (mc, 2H; arom CH), 7.40 (mc, 2H; arom 
CH), 7.31 (mc, 6H; arom CH), 2.78 (mc, 1H; NCH(CH3)2), 2.69 (mc, 2H; NCH2), 2.59 (mc, 
2H; NCH2), 2.38 (mc, 1H; PCH2CH), 2.21 (mc, 1H; PCH2), 1.99 (mc, 1H; PCH2), 1.93 (mc, 
1H; CCH(CH3)2), 1.07 (mc, 6H; NCH(CH3)2), 0.87 (d, 3J(H,H) = 6.9 Hz, 3H; CCH(CH3)2), 
0.83 (d, 3J(H,H) = 6.9 Hz, 3H; CCH(CH3)2), 2 NH not detected; 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 139.6 (d, 1J(P,C) = 12.3 Hz; arom C), 138.5 
(d, 1J(P,C) = 13.1 Hz; arom C), 133.3 (d, 2J(P,C) = 18.3 Hz, 2C; arom CH), 132.6 (d, 2J(P,C) 
= 18.4 Hz, 2C; arom CH), 128.9 (arom CH), 128.7-128.2 (5C; arom CH), 60.3 (d, 2J(P,C) = 
12.9 Hz; PCH2CH), 49.0 (NCH(CH3)2), 47.2 (NCH2), 46.7 (NCH2), 30.7 (d, 1J(P,C) = 11.9 
Hz; PCH2), 30.7 (CCH(CH3)2), 22.8 (NCH(CH3)2), 22.6 (NCH(CH3)2), 18.6 (CCH(CH3)2), 
17.3 (CCH(CH3)2); 
31P{1H} NMR (202.5 MHz, CDCl3, 295 K) : δ = -20.9 (s); 
IR (NaCl): ν~  =  3056w, 2959m, 1683m, 1589w, 1469m, 1435m, 1380w, 1266w, 1178m, 
1133m, 1027w, 831w, 739m, 696m cm-1; 
MS (FAB): m/z (%): 357 (100) [M + H]+, 373 (19) oxidation during measurement; 
EA calcd (%) for C8H16ClNO2 (356.49): C 74.12, H 9.33, N 7.86; found: C 72.64, H 9.25, 
N 7.96. 
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(S)-N-{1-[(diphenylphosphanyl)-methyl]-2-methyl-propyl}-N'-(2,4,6-trimethyl-phenyl)-
ethane-1,2-diamine 120c 
N
H
PPh2NH
 
Synthesis according to the previous general procedure using phosphine 119c (184 mg, 
0.346 mmol) and TFA (1.97 g, 17.3 mmol) yielded a yellow oil (122 mg, 0.284 mmol, 82%) 
of >95% purity as judged by 1H-NMR analysis. 
[ ]20Dα = +54.7 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.48 (mc, 2H; aromphenyl CH), 7.42 (mc, 2H; 
aromphenyl CH), 7.38-7.27 (m, 6H; aromphenyl CH), 6.81 (mc, 2H; arommesityl CH), 2.99 (mc, 
1H; NCH2), 2.88 (mc, 1H; NCH2), 2.76 (mc, 1H; NCH2), 2.70 (mc, 1H; NCH2), 2.44 (mc, 
PCH2CH; 1H), 2.30-2.20 (m, 10H; 1 x PCH2 + 6 x mesitylortho CH3 + 3 x mesitylpara CH3), 
2.06 (mc, PCH2; 1H), 1.99 (mc, CH(CH3)2; 1H), 0.93 (d, 3J(H,H) = 6.8 Hz, 3H; CH(CH3)2), 
0.87 (d, 3J(H,H) = 6.9 Hz, 3H; CH(CH3)2), 2 NH not detected; 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 144.0 (arommesityl C), 139.5 (d, 1J(P,C) = 
13.8 Hz; aromphenyl C), 138.6 (d, 1J(P,C) = 14.8 Hz; aromphenyl C), 133.3 (d, 2J(P,C) = 19.3 Hz, 
2C; aromphenyl CH), 132.7 (d, 2J(P,C) = 19.7 Hz, 2C; aromphenyl CH), 130.9 (arommesityl C), 
129.6-129.4 (4C; 2 x arommesityl C + 2 x arommesityl CH), 128.9 (aromphenyl CH), 128.7-128.4 
(5C; arom CH), 60.6 (d, 2J(P,C) = 13.1 Hz; PCH2CH), 49.0 (br, NCH2), 48.1 (NCH2), 30.9 (d, 
1J(P,C) = 7.4 Hz; PCH2), 30.7 (br, CH(CH3)2), 20.7 (mesityl CH3), 18.7 (2C; mesityl CH3), 
18.3 (CH(CH3)2), 17.7 (CH(CH3)2); 
31P{1H} NMR (202.5 MHz, CDCl3, 295 K) : δ = -21.3 (s); 
IR (NaCl): ν~  =  3353w, 3056w, 2955m, 1683w, 1586w, 1482m, 1436m, 1375w, 1304w, 
1236w, 1106w, 1027w, 853w, 739m, 698m cm-1; 
MS (FAB): m/z (%):433 (100) [M + H]+, 449 (15) oxidation during measurement; 
EA calcd (%) for C28H37N2P (432.59): C 77.74, H 8.62, N 6.48; found: C 76.36, H 8.13, 
N 6.77. 
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6.4.5 Synthesis of imidazolium salts 109a-c 
(S)-1-{1-[(diphenylphosphanyl)-methyl]-2-methyl-propyl}-3-methyl-4,5-dihydro-3H-
imidazol-1-ium-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 109a 
N
PPh2N
BArF
 
A solution of diamine 120a (217 mg, 0.661 mmol) and NH4BF4 (77 mg, 0.726 mmol) in 
triethylorthoformate (4.0 ml, 26.0 mmol) was heated at 110°C for 1 hour. The crude oil was 
decanted and dissolved in CH2Cl2 (10 ml). NaBArF (586 mg, 0.661 mmol) was added to the 
mixture, which was then stirred for 15 minutes. The solution was filtered and concentrated in 
vacuo to remove the solvent. The crude product was purified by chromatography on silica gel 
under inert atmosphere eluting with CH2Cl2 to yield a white solid (409 mg, 0.340 mmol, 
51%). 
m.p. 97-98°C; 
[ ]20Dα = +26.5 (c = 1.00, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 7.69 (mc, 8H; BArF ortho CH), 7.53 (mc, 4H; 
BArF para CH), 7.45-7.25 (m, 10H; arom CH), 7.05 (s, 1H; NCHN), 3.65-3.43 (m, 3H; 
NCH2), 3.43-3.15 (m, 2H; 1 x NCH2 + 1 x PCH2CH), 2.87 (s, 3H; NCH3), 2.57 (mc, 1H; 
PCH2), 2.27 (mc, 1H; PCH2), 1.78 (mc, 1H; CHCH(CH3)2), 0.99 (d, 3J(H,H) = 6.6 Hz, 3H; 
CH2CH(CH3)2), 0.79 (d, 3J(H,H) = 6.6 Hz, 3H; CH2CH(CH3)2); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 162.0 (q, 1J(B,C) = 49.9 Hz, 4C; BArF quat. 
C ipso to B), 156.0 (NCHN), 136.2 (d, 1J(P,C) = 10.2 Hz, 1C; arom C), 135.2 (br, 8C; BArF 
ortho CH), 134.4 (d, 1J(P,C) = 9.8 Hz, 1C; arom C), 133.3 (d, J(P,C) = 20.2 Hz, 2C; arom 
CH), 132.8 (d, J(P,C) = 19.5 Hz, 2C; arom CH), 130.59 (arom CH), 130.57 (arom CH), 129.7 
(d, J(P,C) = 7.4 Hz, 2C; arom CH), 129.6 (d, J(P,C) = 7.7 Hz, 2C; arom CH), 129.3 (qq, 
2J(F,C) = 31.1 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.9 (q, 1J(F,C) = 272.5 Hz, 
8C; BArF CF3), 117.9 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para CH), 65.8 (d, 2J(P,C) = 14.8 Hz, 
1C; PCH2CH), 50.0 (NCH2), 46.0 (d, 4J(P,C) = 3.5 Hz, 1C; NCH2), 35.2 (NCH3), 32.2 (d, 
3J(P,C) = 6.7 Hz, 1C; CH2CH(CH3)2), 29.3 (d, 1J(P,C) = 15.2 Hz, 1C; PCH2), 19.6 
(CH2CH(CH3)2), 19.4 (CH2CH(CH3)2); 
31P{1H} NMR (202.5 MHz, CDCl3, 295 K) : δ = -25.4 (s); 
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IR (KBr): ν~  =  3076w, 2975w, 1659m, 1612w, 1526w, 1467w, 1435w, 1358s, 1280s, 1123s, 
930w, 889m, 838w, 748w, 711w, 674m, 501w, 450w cm-1; 
MS (FAB): m/z (%): 339 (100) [M - BArF]+, 355 (29) oxidation during measurement; 
EA calcd (%) for C53H40BF24N2P (1202.64): C 52.93, H 3.35, N 2.33; found: C 53.14, H 3.34, 
N 2.36. 
 
(S)-1-{1-[(diphenylphosphanyl)-methyl]-2-methyl-propyl}-3-isopropyl-4,5-dihydro-3H-
imidazol-1-ium-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 109b 
N
PPh2N
BArF
 
Synthesis according to the previous general procedure using diamine 120b (167 mg, 
0.468 mmol), NH4BF4 (49 mg, 0.468 mmol), triethylorthoformate (2.0 ml, 13.0 mmol) and 
NaBArF (414 mg, 0.468 mmol) yielded a white solid (460 mg, 0.373 mmol, 80%). 
m.p. 98-99°C; 
[ ]20Dα = +25.1 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.70 (mc, 8H; BArF ortho CH), 7.53 (mc, 4H; 
BArF para CH), 7.44-7.35 (m, 10H; arom CH), 7.13 (s, 1H; NCHN), 3.70-3.55 (m, 4H; 3 x 
NCH2 + 1 x NCH(CH3)2), 3.43 (mc, 1H; NCH(CH3)2), 3.24 (mc, 1H; PCH2CH), 2.62 (mc, 
1H; PCH2), 2.26 (mc, 1H; PCH2), 1.79 (mc, 1H; CHCH(CH3)2), 1.21 (m, 6H; NCH(CH3)2), 
0.98 (d, 3J(H,H) = 6.6 Hz, 3H; CH2CH(CH3)2), 0.79 (d, 3J(H,H) = 6.4 Hz, 3H; 
CH2CH(CH3)2); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 161.8 (q, 1J(B,C) = 49.9 Hz, 4C; BArF quat. 
C ipso to B), 153.8 (NCHN), 135.9 (d, 1J(P,C) = 9.8 Hz, 1C; arom C), 134.9 (br, 8C; BArF 
ortho CH), 135.0 (d, 1J(P,C) = 9.3 Hz, 1C; arom C), 132.8 (d, J(P,C) = 11.4 Hz, 2C; arom 
CH), 132.7 (d, J(P,C) = 11.2 Hz, 2C; arom CH), 130.5 (arom CH), 130.2 (arom CH), 129.6 
(d, J(P,C) = 7.4 Hz, 2C; arom CH), 129.4 (d, J(P,C) = 7.5 Hz, 2C; arom CH), 129.0 (qq, 
2J(F,C) = 31.1 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.7 (q, 1J(F,C) = 272.5 Hz, 
8C; BArF CF3), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para CH), 65.3 (d, 2J(P,C) = 11.9 Hz, 
1C; PCH2CH), 51.4 (NCH(CH3)2), 45.8 (NCH2), 44.8 (d, 4J(P,C) = 4.1 Hz, 1C; NCH2), 31.8 
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(d, 3J(P,C) = 6.1 Hz, 1C; CH2CH(CH3)2), 28.9 (d, 1J(P,C) = 13.9 Hz, 1C; PCH2), 20.57 
(NCH(CH3)2), 20.47 (NCH(CH3)2), 19.4 (CH2CH(CH3)2), 19.0 (CH2CH(CH3)2); 
31P{1H} NMR (202.5 MHz, CDCl3, 295 K) : δ = -22.6 (s); 
IR (KBr): ν~  = 3072w, 2978w, 1643m,1470w, 1434w, 1358s, 1279s, 1128s, 930w, 890w, 
838w, 744w, 708m, 674m, 506w, 450w cm-1; 
MS (FAB): m/z (%): 367 (100) [M - BArF]+, 383 (37) oxidation during measurement; 
EA calcd (%) for C55H44BF24N2P (1230.70): C 53.68, H 3.60, N 2.28; found: C 53.49, H 3.64, 
N 2.36. 
(S)-1-{1-[(diphenylphosphanyl)-methyl]-2-methyl-propyl}-3-(2,4,6-trimethyl-phenyl)-4,5-
dihydro-3H-imidazol-1-ium-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 109c 
N
PPh2N
BArF
 
Synthesis according to the previous general procedure using diamine 120c (150 mg, 
0.347 mmol), NH4BF4 (36 mg, 0.347 mmol), triethylorthoformate (4.0 ml, 26.0 mmol) and 
NaBArF (307 mg, 0.347 mmol) yielded a colourless oil (218 mg, 0.166 mmol, 48%). 
[ ]20Dα = +63.2 (c = 1.00, CHCl3); 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.70 (mc, 8H; BArF ortho CH), 7.50 (mc, 4H; 
BArF para CH), 7.48-7.39 (m, 5H; 3 x aromphenyl CH + 2 x arommesityl CH), 7.38-7.30 (m, 6H; 
1 x NCHN + 5 x aromphenyl CH), 6.98 (br, 2H; aromphenyl CH), 4.25-4.06 (m, 3H; 3 x NCH2), 
3.96 (mc, 1H; NCH2), 3.18 (mc, 1H; PCH2CH), 2.78 (mc, 1H; PCH2), 2.40-2.25 (br, 6H; 2 x 
CH3), 2.15 (m, 2H; 1 x CH3 + 1 x PCH2), 1.93 (mc, 1H; NCH(CH3)2), 1.00 (d, 3J(H,H) = 6.6 
Hz, 3H; NCH(CH3)2), 0.91 (d, 3J(H,H) = 6.4 Hz, 3H; NCH(CH3)2); 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 161.8 (q, 1J(B,C) = 49.9 Hz, 4C; BArF quat. 
C ipso to B), 156.9 (NCHN), 142.1 (arommesityl C) 135.7 (d, 1J(P,C) = 7.9 Hz, 1C; aromphenyl 
C), 134.9 (br, 8C; BArF ortho CH), 133.6 (d, 1J(P,C) = 10.6 Hz, 1C; aromphenyl C), 133.3 (d, 
J(P,C) = 10.5 Hz, 2C; aromphenyl CH), 131.9 (d, J(P,C) = 18.7 Hz, 2C; aromphenyl CH), 131.0 
(2C; arommesityl CH), 130.6 (aromphenyl CH), 129.8 (aromphenyl CH), 129.8 (d, J(P,C) = 7.4 Hz, 
2C; aromphenyl CH), 129.2 (d, J(P,C) = 7.2 Hz, 2C; aromphenyl CH), 129.1 (arommesityl C), 129.0 
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(qq, 2J(F,C) = 31.1 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to CF3), 124.7 (q, 1J(F,C) = 
272.5 Hz, 8C; BArF CF3), 117.5 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para CH), 64.7 (d, 2J(P,C) 
= 11.1 Hz, 1C; PCH2CH), 50.6 (NCH2), 45.9 (d, 4J(P,C) = 5.8 Hz, 1C; NCH2), 31.9 (d, 
3J(P,C) = 5.1 Hz, 1C; NCH(CH3)2), 28.8 (d, 1J(P,C) = 13.9 Hz, 1C; PCH2), 21.1 (mesityl 
CH3), 19.5 (NCH(CH3)2), 18.9 (NCH(CH3)2), 18.5 (br, 2C; mesityl CH3), 2 arommesityl C not 
observed; 
31P{1H} NMR (202.5 MHz, CDCl3, 295 K) : δ = -26.0 (s); 
IR (NaCl): ν~  = 3067w, 2970w, 2939w, 1639m, 1357m, 1279s, 1126sbr, 998w, 934w, 889m, 
839m, 744w, 710m, 675m, 577w, 504w cm-1; 
MS (FAB): m/z (%): 443 (100) [M - BArF]+, 459 (32) oxidation during measurement; 
EA calcd (%) for C61H48BF24N2P (1306.80): C 56.07, H 3.70, N 2.14; found: C 55.95, H 3.70, 
N 2.12. 
6.4.6 Synthesis of iridium complexes 121a-c 
(S)-[(η4-1,5-cyclooctadiene)-(1-{1-[(diphenylphosphanyl)-methyl]-2-methyl-propyl}-3-
methyl-imidazolin-2-ylidene)iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 121a 
N
PPh2N
BArF
Ir
 
Freshly sublimed NaOtBu (18 mg, 0.192 mmol) was added to a solution of imidazolium salt 
109a (231 mg, 0.192 mmol) and [(η4-cod)IrCl]2 (64 mg, 0.096 mmol) in THF (10 ml). The 
reaction mixture was stirred at room temperature for 2 hours then concentrated in vacuo to 
remove the solvent. The crude product was purified by chromatography on silica gel eluting 
with CH2Cl2 to yield a red solid (210 mg, 0.140 mmol, 73%). 
[ ]20Dα = -17 (c = 0.15, CHCl3); 
31P{1H} NMR (202.5 MHz, CD2Cl2, 295 K) : δ = 17.05 (s, 0.75; minor), 16.44 (s, major); 
IR (KBr): ν~  = 3076w, 2968w, 2887w, 2840w, 1612w, 1526m, 1440m, 1357s, 1279s, 1127s, 
998w, 934w, 889m, 838w, 744w, 711m, 674m, 579w, 518w, 479w, 448w cm-1; 
MS (FAB): m/z (%):639 (100) [M - BArF]+; 
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EA calcd (%) for C61H51BF24IrN2P (1502.02): C 48.78, H 3.42, N 1.87; found: C 48.81, 
H 3.45, N 1.84. 
(S)-[(η4-1,5-cyclooctadiene)-(1-{1-[(diphenylphosphanyl)-methyl]-2-methyl-propyl}-3-
isopropyl-imidazolin-2-ylidene)iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 
121b 
N
PPh2N
BArF
Ir
 
Synthesis according to the previous general procedure using imidazolium salt 109b (291 mg, 
0.237 mmol), [(η4-cod)IrCl]2 (79 mg, 0.118 mmol) and NaOtBu (23 mg, 0.237 mmol) yielded 
a red solid (250 mg, 0.163 mmol, 69%); 
[ ]20Dα = -5 (c = 0.10, CHCl3); 
31P{1H} NMR (202.5 MHz, CD2Cl2, 295 K) : δ = 15.13 (s, 1.00; major), 14.34 (s, 0.70, 
minor); 
IR (KBr): ν~  = 3065w, 2977w, 2886w, 2839w, 1611w, 1491m, 1453m, 1357s, 1279s, 1127s, 
999w, 933w, 889m, 839w, 743w, 711m, 675m, 585w, 535w, 524w, 447w cm-1; 
MS (FAB): m/z (%):667 (100) [M - BArF]+; 
EA calcd (%) for C63H55BF24IrN2P (1530.08): C 49.45, H 3.62, N 1.83; found: C 49.45, 
H 3.76, N 1.94. 
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(S)-[(η4-1,5-cyclooctadiene)-(1-{1-[(diphenylphosphanyl)-methyl]-2-methyl-propyl}-3-
methyl-imidazolin-2-ylidene)iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 121c 
N
PPh2N
BArF
Ir
 
Synthesis according to the previous general procedure using imidazolium salt 109b (150 mg, 
0.115 mmol), [(η4-cod)IrCl]2 (39 mg, 0.057 mmol) and NaOtBu (11 mg, 0.115 mmol) yielded 
a red solid (138 mg, 0.086 mmol, 75%); 
[ ]20Dα = -6 (c = 0.1, CHCl3); 
1H NMR and 13C{1H} NMR see Figure 6.1 
31P{1H} NMR (202.5 MHz, CDCl3, 246 K) : δ = 9.91 (s, minor), 6.96 (s, major); 
IR (KBr): ν~  = 2971w, 2928w, 2888w, 2840w, 1611w, 1486w, 1435w, 1356s, 1278s, 1127s, 
1000w, 968w, 935w, 889w, 839w, 744w, 711w, 676m, 580w, 513w, 448w cm-1; 
MS (FAB): m/z (%): 743 (100) [M - BArF]+; 
EA analysis calcd (%) for C69H59BF24IrN2P (1606.18): C 51.60, H 3.70, N 1.74; found: 
C 51.57, H 3.60, N 1.81. 
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N
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5.11 dP
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N
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N
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7.47
7.55
7.55
132.5
130.9
7.18
7.38
7.38
36.5
2.17
2.01
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1.57
1.31
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35.71
1.87
2.36
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5.36 dP
83.6
3.38 dP
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3.18
Minor conformer
 
Figure 6.1 1H-NMR(500.1 MHz, CDCl3, 246 K) and 13C-NMR(125.7 MHz, CDCl3, 246 K) 
partial assignment of both conformers of complex 121c. One NOE observed in the major 
conformer spectrum is crucial for determining the geometry. 
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6.4.7 Synthesis of imidazolium salt 129 
(R)-1-(2-hydroxy-2-phenyl-ethyl)-3-isopropyl-3H-imidazol-1-ium 129 
N
OHN
BArF  
A mixture of 1H-imidazole (960 mg, 14.1 mmol) and commercially available epoxide 126 
(1.693 mg, 14.1 mmol) was heated at 50°C for 12 hours. Degassed CH3CN (5 ml) and 
isopropyl iodide (2.39 g, 14.1 mmol) were added to the reaction mixture at room temperature. 
The solution was heated at 80°C for a further 3 hours. Upon cooling, a solid precipitated from 
the reaction mixture, was filtered and carefully washed once with CH3CN (5 ml). Purification 
by crystallisation from CH3CN yielded a white solid (1.51 g, 4.23 mmol, 30%). 
NaBArF (252 mg, 0.285 mmol) was added to a solution of iodide imidazolium salt (102 mg, 
0.285 mmol) in CH2Cl2 (8 ml). The mixture was filtered and concentrated in vacuo to remove 
the solvent. The crude product was purified by chromatography on silica gel eluting with 5% 
MeOH in CH2Cl2 to yield a colourless oil (260 mg, 0.237, 83%). 
[ ]20Dα = +23.7 (c = 1.00, CHCl3); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 7.89 (mc, 1H; arom CH), 7.72 (mc, 8H; BArF 
ortho CH), 7.54 (mc, 4H; BArF para CH), 7.32 (m, 2H; arom CH), 7.11 (m, 2H; arom CH), 
7.03 (mc, 1H; imid CH), 7.01 (mc, 1H; imid CH), 5.05 (mc, 1H; CHOH), 4.31 (mc, 2H;1 x 
NCH2 + 1 x CH(CH3)2), 4.15 (mc, 1H; NCH2), 2.32 (br, 1H; OH), 1.39 (mc, 6H; CH(CH3)2), 
1H NCHN not observed; 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ =  162.0 (q, 1J(B,C) = 49.9 Hz, 4C; BArF quat. 
C ipso to B), 138.1 (arom C), 135.2 (br, 8C; BArF ortho CH), 133.1 (NCHN), 130.5 (arom 
CH), 130.1 (2C; arom CH), 129.4 (qq, 2J(F,C) = 31.1 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso 
to CF3), 125.4 (2C; arom CH), 124.9 (q, 1J(F,C) = 272.5 Hz, 8C; BArF CF3), 124.4 (imid CH), 
120.1 (imid CH), 117.9 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para CH), 72.0 (CHOH), 57.3 
(NCH2), 54.5 (CH(CH3)2), 22.82 (CH(CH3)2), 22.78 (CH(CH3)2); 
IR (NaCl): ν~  = 3645w, 3171w, 3083w, 2992w, 1611w, 1555w, 1461m, 1359s, 1280s, 1120s, 
927w, 889m, 834w, 762w, 738w, 710m, 673m, 579w, 528w, 446w cm-1; 
MS (FAB): m/z (%): 231 (100) [M - BArF]+; 
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EA calcd (%) for C46H31BF24N2O (1094.52): C 50.48, H 2.85, N 2.56, O 1.46; found: 
C 50.56, H 2.89, N 2.63, O 1.64. 
6.4.8 Synthesis of iridium complex 131 
(R)-{(η4-1,5-cyclooctadiene)-[1-(2-diphenylphosphinite-2-phenyl-ethyl)-3-isopropyl-
imidazol-2-ylidene]iridium(I)}-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 131 
BArFN
Ir PPh2
O
N
 
Phosphamide 130 (80 mg, 0.312 mmol) was added to a homogeneous solution of imidazolium 
salt 129 (228 mg, 0.208 mmol), 4,5-dichloroimidazole (43 mg, 0.312 mmol) and NEt3 
(32 mg, 0.312 mmol) in CH2Cl2 (3 ml) at 0°C. The reaction mixture was stirred at room 
temperature for 48h. If needed, the reaction can be monitored by 31P-NMR (101.2 MHz, 
CD2Cl2, 300 K) analysis: δ = 115.8 ppm: phosphinite 124, δ = 58.2 ppm: phosphamide 130 
and δ = 17.9 ppm oxidised phosphinite. The solution was concentrated in vacuo to remove the 
solvent and the residue was purified by chromatography on alox (Fluka adjusted to grade III) 
under inert atmosphere eluting with CH2Cl2 to yield an oil (160 mg, 0.124 mmol, 60%). 
NaOtBu (12 mg, 0.124 mmol) and [(η4-cod)IrCl]2 (41.6 mg, 0.062 mmol) were added to a 
solution of phosphinite 124 (160 mg, 0.124 mmol) in THF (5 ml). The reaction mixture was 
stirred at room temperature for 2 hours. The solution was concentrated in vacuo to yield a red 
solid. The crude product was purified by chromatography on silica gel eluting with CH2Cl2 to 
yield a red product (135 mg, 0.086 mmol, 69%). 
[ ]20Dα = +33 (c = 0.10, CHCl3); 
1H NMR and 13C{1H} NMR see Figure 6.2 
31P{1H} NMR (162.0 MHz, CDCl3, 300 K) : δ = 96.5 (s, major), 86.8 (s, major); 
IR (KBr): ν~  = 2955w, 2924w, 2894w, 2848w, 1611w, 1453m, 1358s, 1280s, 1114s, 933w, 
887m, 837w, 756w, 709m, 675m, 581w, 491w, 447w cm-1; 
MS (FAB): m/z (%):715 (100) [M - BArF]+; 
EA calcd (%) for C61H51BF24IrN2PO (1578.08): C 50.23, H 3.26, N 1.78; found: C 50.22, 
H 3.45,N 1.82. 
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13C NMR
1H NMR
89.9
4.65 dP
95.7
5.22 dP
Minor conformer
Ir
ON
N
P
123.1
6.98
119.4
6.96
57.5
5.67 / 4.25 82.1
5.23
171.1
53.2
4.96
25.2
1.48
23.5
1.25
126.0
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79.2
4.14
80.7
3.47
 
Figure 6.1 1H-NMR(500.1 MHz, CDCl3, 246 K) and 13C-NMR(125.7 MHz, CDCl3, 246 K) 
partial assignment of both conformers of complex 131. 
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6.4.9 Synthesis of aldehyde 139 
2,3-diphenyl-3H-imidazole-4-carbaldehyde 139 
N
N
O
 
K2CO3 (2.11 g, 15.3 mmol) was added to a solution of N-phenylbenzamidine 138 (2.00 g, 
10.2 mmol) and bromoaldehyde 137 (2.95 g, 15.3 mmol) in a mixture of CH3Cl and H2O (8:1, 
22.5 ml) at room temperature. The reaction mixture was stirred at room temperature for 10 
hours. Water (100 ml) and CH2Cl2 (100 ml) were added to the mixture. The organic layer was 
separated and the aqueous layer was extracted two times with CH2Cl2 (2 x 100 ml). The 
combined organic extracts were dried over anhydrous magnesium sulfate and concentrated in 
vacuo to remove the solvent. The residue was purified by chromatography on silica gel 
eluting with 5% CH3CN in CH2Cl2 to yield a white solid (1.96 g, 7.89 mmol, 77%). 
Rf = 0.28 (CH3CN /CH2Cl2 5:95); 
1H NMR (400.1 MHz, CDCl3, 300 K) : δ = 9.64 (s, 1H; CHO), 8.02 (s, 1H; NCCHN), 7.54-
7.43 (m, 3H; arom CH), 7.42-7.37 (m, 2H; arom CH), 7.37-7.22 (m, 5H; arom CH); 
13C{1H} NMR (100.6 MHz, CDCl3, 300 K) : δ = 178.8 (CHO), 152.9 (C), 141.3 (CH), 136.5 
(C), 134.1 (C), 130.2 (CH), 130.0 (2C; arom CH), 129.9 (CH), 129.5 (2C; arom CH), 128.9 
(C), 128.0 (2C; arom CH), 128.1 (2C; arom CH); 
IR (KBr): ν~  = 3058w, 2924w, 2846w, 1677s, 1525m, 1496m, 1458m, 1438m, 1421m, 
1339m, 1289m, 1267m, 1170m, 1074w, 1027w, 954w, 926w, 887w 815m, 780m, 722m, 
696m, 558m cm-1; 
MS (FAB): m/z (%): 249(100) [M + H]+; 
EA calcd (%) for C16H12N2O (248.28): C 77.40, H 4.87, N 11.28, O 6.44; found: C 77.42, 
H 4.79, N 11.43, O 6.48. 
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6.4.10 Synthesis of alcohol 140 
1-(2,3-diphenyl-3H-imidazol-4-yl)-ethanol 140 
N
N
OH
 
A 3M solution of MeMgCl (2.82 ml, 8.46 mmol) in THF was added to a solution of aldehyde 
139 (1.40 g, 5.63 mmol) in THF (50 ml) at -78°C. The reaction was stirred for ½ hour and 
warmed to room temperature. After stirring for 12 hours, a saturated aqueous solution of 
NH4Cl was added until the formation of two phases. The organic layer was separated and the 
aqueous layer was extracted three times with Et2O (3 x 50 ml). The combined organic extracts 
were dried over anhydrous magnesium sulfate and concentrated in vacuo to remove the 
solvent. The residue was purified by crystallisation from hot AcOEt to yield white crystals 
(1.25 g, 4.73 mmol, 83%). 
Rf = 0.39 (EtOAc); 
m.p. 167-168°C; 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.41 (mc, 3H; phenyl CH), 7.32-7.15 (m, 6H; 7 x 
phenyl CH + 1 x imid CH), 4.59 (q, 3J(H,H) = 6.6 Hz, 1H; CHOH), 3.08 (br, 1H; OH), 1.50 
(d, 3J(H,H) = 6.6 Hz, 3H; CH3), 2 arom. H have very broad signal in the aromatic region and 
are not assigned; 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 148.0 (C), 138.3 (CH3CHC), 137.1 (C), 
130.2 (C), 129.6 (2C; phenyl CH), 129.0 (phenyl CH), 128.5 (2C; phenyl CH), 128.4 (phenyl 
CH), 128.3 (br, 2C; phenyl CH), 128.2 (2C; phenyl CH), 125.6 (imid CH), 60.8 (CHOH), 
22.3 (CH3); 
IR (KBr): ν~  = 3226mbr, 3061m, 2977m, 2884w, 2364w, 1597w, 1499m, 1462m, 1403m, 
1362w, 1282w, 1158w, 1118m, 1072m, 957w, 896w, 829w, 776m, 698m cm-1; 
MS (FAB): m/z (%): 265 (100) [M + H]+; 
EA calcd (%) for C17H16N2O (264.32): C 77.25, H 6.10, N 10.60, O 6.05; found: C 76.99, 
H 6.08, N 10.59, O 6.16. 
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6.4.11 Synthesis of imidazolium salt 141 
4-(1-hydroxy-ethyl)-1-isopropyl-2,3-diphenyl-3H-imidazol-1-ium-tetrakis[3,5-
bis(trifluoromethyl)phenyl]borate 141 
N
N
OH
BArF
 
iPrI (322 mg, 1.89 mmol) was added to a solution of alcohol 140 (500 mg, 1.89 mmol) in 
DMF (1.5 ml). The reaction mixture was heated at 95°C for 18 hours and then concentrated in 
vacuo at 80°C. The residue was purified by chromatography on silica gel eluting first with 
CH2Cl2 and then with 5% MeOH in CH2Cl2 to yield an oil. NaBArF was added to a solution 
of the oil in CH2Cl2 (5 ml). The solution was stirred at room temperature for 15 minutes, was 
filtered and concentrated in vacuo to remove the solvent. The crude product was purified by 
chromatography on silica gel eluting with CH2Cl2 to yield a white solid (420 mg, 0.360 mmol, 
19%). 
Rf = 0.47 (CH2Cl2/MeOH 100:5); 
m.p. 147-148°C; 
1H NMR (500.1 MHz, CDCl3, 295 K) : δ = 7.70 (mc, 8H; BArF ortho CH), 7.53 (mc, 5H; 4 x 
BArF para CH + 1 x phenyl CH), 7.46 (mc, 1H; phenyl CH), 7.43-7.36 (m, 5H; 4 x phenyl 
CH)+ 1 x imid CH), 7.16 (mc, 2H; phenyl CH), 4.72 (q, 3J(H,H) = 6.5 Hz, 1H; CHOH), 4.47 
(mc, 1H; CH(CH3)2), 1.77 (br, 1H; OH), 1.46 (mc, 6H; CH(CH3)2), 1.43 (d, 3J(H,H) = 6.5 Hz, 
1H; CH3), 2 arom. H have very broad signal in the aromatic region and are not assigned; 
13C{1H} NMR (125.7 MHz, CDCl3, 295 K) : δ = 161.8 (q, 1J(B,C) = 49.9 Hz, 4C; BArF quat. 
C ipso to B), 145.5 (NCN), 140.2 (CH3CHC), 134.9 (br, 8C; BArF ortho CH), 133.4 (phenyl 
CH), 131.9 (phenyl C), 131.8 (phenyl CH), 130.5 (2C; phenyl CH), 130.2 (2C; phenyl CH), 
129.7 (2C; phenyl CH), 129.0 (qq, 2J(F,C) = 31.12 Hz, 3J(B,C) = 2.9 Hz, 8C; BArF C ipso to 
CF3), 127.2 (br, 2C; phenyl CH), 124.7 (q, 1J(F,C) = 272.5 Hz, 8C; BArF CF3), 120.1 (phenyl 
C), 117.53 (sept, 3J(F,C) = 3.8 Hz, 4C; BArF para CH), 60.8 (CHOH), 52.6 (CH(CH3)2), 22.9 
(3C; CH(CH3)2), 22.8 (3C; CH(CH3)2), 22.0 (CH3); 
IR (KBr): ν~  = 3593w, 3592wbr, 3165w, 3002w, 1611m, 1501m, 1471m, 1357s, 1279s, 
1125s, 890m, 838w, 796w, 747w, 712m, 675m, 580w, 448w cm-1; 
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MS (FAB): m/z (%): 307 (100) [M]+; 
EA calcd (%) for C52H35BF24N2O (1170.62): C 53.35, H 3.01, N 2.39, O 1.37; found: 
C 53.29, H 3.03, N 2.40, O 1.45. 
6.4.12 Synthesis of phosphinite-imidazolium salt 135 
Phosphamide 130 (66 mg, 0.256mmol) was added to a homogeneous solution of imidazolium 
salt 141 (200 mg, 0.171 mmol), 4,5-dichloroimidazole (35 mg, 0.256 mmol) and NEt3 
(26 mg, 0.256 mmol) in CH2Cl2 (3 ml) at 0°C. The reaction mixture was stirred at room 
temperature for 48h. If needed, the reaction can be monitored by 31P-NMR (101.2 MHz, 
CD2Cl2, 300 K) analysis: δ = 111.3 ppm: phosphinite 135 and δ = 58.2 ppm: phosphamide 
130. The solution was concentrated in vacuo to remove the solvent and the residue was 
purified by chromatography on alox (Fluka adjusted to grade III) under inert atmosphere 
eluting with a mixture of pentane and CH2Cl2 (6:4) to yield a colourless oil (210 mg, 
0.155 mmol, 91%). 
Since phosphinite 135 is an air-sensitive compounds, every attempts to synthesise C(5) 
activated NHC iridium complex was performed with freshly prepared phosphinite 
imidazolium salt 135. 
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6.5 X-ray data analyses 
X-ray data analyses were carried out by Mr Markus Neuburger at the Departement of 
Chemistry at the University of Basel. The crystal structures were solved by Mr Markus 
Neuburger, Dr Sylvia Schaffner and Dr Stefan Kaiser. 
Single crystals suitable for X-ray analysis were obtained for compounds 62, 65, 67, 81b, 90p, 
90q, 122b and 122c. Data collection was performed with a Kappa CCD diffractometer. The 
structures were solved with SIR924 or SIR97 and refined with CRYSTALS.5 A Chebychev 
polynomial was applied as a weighting scheme.6 Hydrogen atoms were calculated and refined 
as riding atoms. 
Despite of unsatisfactorily refinements, structure 62 and 67 were used in this work. 
It is out of doubt that the postulated carbene-complex is present in structure 62. However 
refinement presented problems and the R-value remained at 6.4%. Difference Fourier maps 
still show quite high maxima, most of them near the cod-ligand, which could not be explained 
and modelled using a disorder model. It is therefore possible that the crystal was a twin or that 
it contains crystalline impurities causing errors in the data. The structure is good enough to 
show clearly the coordination geometry and the connectivity of the synthesised compound, 
but crystallographic data such as bond lengths and angles can not be used. 
The asymmetric unit of the structure of 67 contains two cations and two anions. Both iridium 
complexes show the same configuration, but fitting one model on top of the other shows 
differences in conformation. If the arrangement is pseudo-centrosymmetric, all non-chiral 
parts would fit the higher symmetry in such a way that the structure solves (to some extent) in 
the controsymmetric spacegroup P 21/n. Reflections measured at low Theta angles had to be 
omitted in order to refine successfully (errors due to the effects of the beam stop). Otherwise 
the pseudo-symmetric arrangement caused some temperature parameters of the carbon atoms 
of the cod ligand to refine to values that were not physically sensible. The following 
difference Fourier map showed rather high residual electron density, most maxima were 
found near the iridium atoms. Carrying out absorption correction using DIFABS reduced the 
maxima, but the electron density that could not be modelled is still too high to get a good 
R-value. The refinement converged at about 6.9%. The structure gives clear answers to 
questions about connectivity and conformation of the compound, but crystallographic data 
such as bond lengths and angles can not be used. 
The crystallographic data of complexes 65, 81b, 90p, 90q, 122b and 122c are depicted in 
Tables 6.1, 6.2 and 6.3. 
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Table 6.1 Crystallographic data of 65 and 81b. 
Complex 65 81b 
Molecular Formula C27H34Cl1Ir1N2 C54H47BB1F24Ir1N3O1
Formula Weight 614.25 1412.97 
Colour orange orange 
Temperature (K) 293 173 
Crystal size (mm3) 0.23 x 0.28 x 0.32 0.30 x 0.30 x 0.38 
Crystal system orthorhombic monoclinic 
Space group P 21 21 21 P 21
a (Å) 11.7124(2) 10.8046(2) 
b (Å) 12.4049(3) 19.6132(5) 
c (Å) 16.6848(3) 13.9118(3) 
α (Å) 90 90 
β (Å) 90 111.2951(19) 
γ (Å) 90 90 
Volume (Å3) 2424.15(8) 2746.8 
Z 4 2 
Density (calc.)(Mg m-3) 1.683 1.708 
μ (Mo Kα) (mm-1) 5.636 2.555 
Θmax (°) 30.029 32.51 
Reflections measured 38620 75698 
Reflections independent 7071 19214 
Reflection used 3993(>4.00σ(I)) 14183 (>3.00σ(I)) 
Number of parameters 335 859 
R (observed data) 0.0265 0.0313 
wR (all data) 0.0342 0.0302 
Goodness of fit on F 1.0974 1.0147 
Residual density (e Å-3) -1.14/0.77 -1.15/1.76 
CCDC deposition code  288265 
 215
Chapter 6 
Table 6.2 Crystallographic data of 90p and 90q. 
Complex 90p 90q 
Molecular Formula C62H48BB1F24Ir1N3O2 C22H35F6Ir1N3O1P1
Formula Weight 1527.06 694.72 
Colour orange red 
Temperature (K) 173 173 
Crystal size (mm3) 0.11 x 0.16 x 0.19 0.24 x 0.30 x 0.33 
Crystal system orthorhombic orthorhombic 
Space group P 2 21 21 P 21 21 21
a (Å) 12.5922(15) 11.903(1) 
b (Å) 18.6153(14) 14.1273(15) 
c (Å) 26.563(3) 14.8258(11) 
α (Å) 90 90 
β (Å) 90 90 
γ (Å) 90 90 
Volume (Å3) 6226.6(11) 2493.1 
Z 4 4 
Density (calc.)(Mg m-3) 1.709 1.851 
μ (Mo Kα) (mm-1) 2.268 5.485 
Θmax (°) 27.501 35.00 
Reflections measured 188493 46765 
Reflections independent 14273 10907 
Reflection used 10804 (>2.00σ(I)) 9941(>2.00σ(I)) 
Number of parameters 1056 309 
R (observed data) 0.0432 0.0278 
wR (all data) 0.0401 0.0266 
Goodness of fit on F 1.0496 1.0348 
Residual density (e Å-3) -1.60/2.96 -2.90/1.56 
CCDC deposition code 288266 288267 
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Table 6.3 Crystallographic data of 122b and 122c. 
Complex 122b 122c 
Molecular Formula C31H43BB1F4Ir1N2P1 C37H47BB1F4Ir1N2P1
Formula Weight 753.29 829.72 
Colour orange orange 
Temperature (K) 173 173 
Crystal size (mm3) 0.20 x 0.22 x 0.24 0.16 x 0.20 x0.22 
Crystal system monoclinic monoclinic 
Space group P 1 21 1 P 1 21 1 
a (Å) 9.61460(10) 10.16900 
b (Å) 15.13960(10) 10.97560(10) 
c (Å) 11.07970(10) 15.4379(2) 
α (Å) 90 90 
β (Å) 110.3712(5) 91.4016(4) 
γ (Å) 90 90 
Volume (Å3) 1511.91(2) 1722.52(3) 
Z 2 2 
Density (calc.)(Mg m-3) 1.655 1.600 
μ (Mo Kα) (mm-1) 4.517 3.973 
Θmax (°) 32.600 32.545 
Reflections measured 21652 84111 
Reflections independent 10991 12477 
Reflection used 10142(>3.00σ(I)) 11463(>3.00σ(I)) 
Number of parameters 362 417 
R (observed data) 0.0202 0.0212 
wR (all data) 0.0238 0.0257 
Goodness of fit on F 1.0632 0.8594 
Residual density (e Å-3) -2.85/2.24 -2.40/2.41 
CCDC deposition code   
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